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There is an increasing need to understand how inflammation is initiated by endogenous factors in 
the absence of infection. Various diseases such as atherosclerosis and arthritis are shaped by 
endogenous mediators. In situations such as transplant or trauma where there is extensive amount 
of tissue damage, endogenous factors can be released to influence inflammation. The modes of 
activation in which immune cells liberate endogenous factors for incurring immune responses 
remain elusive. 
Adenosine triphosphate (ATP) activation of the puringeric receptor P2X7 has been 
implicated in several immune responses. P2X7 promotes the shedding of microvesicles (MV) and 
the secretion of inflammatory mediators. I hypothesized that P2X7-induced MV containing some 
of these inflammatory mediators would promote the activation of innate immune cells such as 
macrophages. 
Using murine bone marrow derived macrophages as a model for macrophage function, I 
describe that harvested P2X7-induced MV from myeloid cells promote macrophage activation 
including pro-inflammatory cytokine secretion and co-stimulatory ligand upregulation. 
Phospholipids from P2X7-induced MV are partially responsible for the observed macrophage 
activation. Isolated phospholipids from P2X7-induced MV activate TLR4.  
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Secondly, I describe mature cathepsin D release into P2X7-induced MV from myeloid 
cells. P2X7-induced MV from myeloid cells contain both intermediate and mature forms of 
cathepsin D. Furthermore, P2X7 stimulation of myeloid cells promotes the peripheral 
displacement of cathepsin D and dynamin. Dynasore, a selective and potent dynamin inhibitor, 
significantly reduced the secretion of mature but not intermediate cathepsin D. 
Lastly, I describe a novel morphological alteration following P2X7 activation of myeloid 
cells. ATP stimulates de novo filopodia production. These filopodia are the result of actin 
polymerization, Rho kinases, and phospholipases. Furthermore, P2X7 promotes the re-
localization of lipids and actin-based machinery to the periphery of ATP treated cells. 
Collectively, these results demonstrate that P2X7-induced MV possess stimulatory cargo 
including phospholipids that can activate macrophages and cathepsins that are potentially 
capable of degrading extracellular matrix components. This data would suggest a provocative 
role for P2X7-induced MV and actin-based processes in promoting sterile disease. 
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1.0 INTRODUCTION 
 
Inflammation is highly relevant in the study of life and disease. It has been described since the 
start of recorded history and it is reported in the earliest of scientific publications. Our definition 
of inflammation has expanded beyond the cardinal features of redness and swelling as 
inflammation is now understood to be indicative for how efficient immune responses are 
mounted. Furthermore, this has led to a vast and complex understanding of cells and their 
interplay with various molecules. There is increasing awareness that inflammation is not just 
initiated by foreign materials but it can also be initiated by endogenously derived materials. 
“Sterile inflammation” results from endogenous materials acting on immune cells in the absence 
of infection; these endogenous materials are called “endogenous danger signals”. An objective 
for our lab is to establish how endogenous danger signals are generated, how they are 
disseminated, and how they act to promote inflammation. The following sections aim to provide 
the background of what is currently known and being hypothesized for inflammation. In 
particular, the following sections will discuss how various endogenous danger signals promote 
sterile inflammation or how endogenous danger signals act in complex with foreign materials to 
promote pathogenesis and ultimately disease. 
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1.1 INNATE IMMUNE RESPONSES 
 
Immunity is a unifying term used to describe a physiological response that is engaged at least in 
part by immune cells (e.g., T cells, B cells, macrophages, etc.) to elicit inflammation or 
immunosuppression. Immune cells are the primary mediators for immunity but there is an 
increasing understanding that they are not the only mediators, as epithelial and fibroblasts, 
among other non-immune cells, can influence inflammation or immunosuppression (1). Secreted 
soluble factors such as cytokines or membrane-bound materials such as integrins can dictate 
immune responses.   
Inflammation is described by a variety of phenotypes on several levels. On a larger scale, 
an inflammatory response results in increased swelling, heat, pain, and redness; this process was 
detailed by Celsus, a physician from the first century (2). This is in part due to an influx of 
immune cells such as monocytes and neutrophils from blood to sites of inflammation. These 
immune cells, among several other immune cells, employ secreted and membrane-bound factors 
that alter cellular and tissue composition. This alteration may be beneficial when dealing with 
situations such as infections, whereby this influx of immune cells controls pathogen load, while 
also promoting the development of subsequent immune responses. 
In contrast to inflammation is immunosuppression whereby there is a calming down 
response to negate inflammation. Immunosuppression is recognized through several 
mechanisms. Once thought to be passive, it is actually a very active process by cells (e.g., T 
regulatory cells) that recognizes normal/healthy self versus compromised self (3).  
Immunosuppression in this manner can also be programmed subsequent to inflammation to 
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promote activities such as wound healing (4). Explanations of innate immune mechanisms that 
modulate inflammation will be discussed at length throughout this introduction. 
 
1.1.1  Innate versus adaptive immunity 
 
Innate and adaptive immune cells respond to stimuli in different ways (5). Thus the ways that 
they affect immunity are different. Adaptive immunity is an immunological response against 
very specific recognizable molecular epitopes (e.g., major histocompatibility complex plus 
peptide on antigen presenting cells) and the initial response promotes the development of a 
“memory” response whereby subsequent encounter(s) with the same specific recognized epitope 
typically results in faster and stronger immunity. Usually it is thought that adaptive immune 
responses are developed slowly over time (e.g., on the order of several days to months). In 
contrast to adaptive immunity, innate immunity is an immunological response against conserved 
recognizable molecular patterns (e.g., pathogen associated molecular patterns) and it does not 
maintain a “memory” response for subsequent encounters with the same specific recognized 
pattern. Innate immune responses develop faster than adaptive responses (e.g., on the order of 
minutes to hours). 
Innate immune cells can “prime” and coordinate the type of adaptive immune response 
that occurs in a given situation. This coordination is in part due to specific intrinsic abilities that 
various immune cells have and where they are located at various times during the injury or 
insult. The following introduction will elaborate on the types of immune cells, how immune cell 
function, and some of the stimuli that alter their function. 
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1.1.2  Innate immune cells 
 
Innate immune cells comprise of a diverse group of cells originating from hematopoietic stem 
cell precursors (5). Some members of the innate immune cell family includes mononuclear 
myeloid precursor derived cells such as subsets of monocytes, macrophages and dendritic cells, 
mononuclear lymphoid precursor derived cells such as subsets of NK cells, and 
polymorphonuclear cells such as neutrophils. Their functions can be quite different but together 
they can help promote a quicker response in situations of insult or injury. 
 One function following injury or infection is for these innate immune cells to produce 
cytokines and chemokines. Tissue resident macrophages are usually thought of as the first and 
largest producers of these inflammatory mediators (6). The most common mediators include 
cytokines such IL-1β, IL-6, TNF-α, which promote inflammation through the ligation of 
receptors on a variety of cell types; thus in this way they are described as inflammatory 
cytokines. For instance, TNF-α can ligate TNF receptor inducing the recipient cell’s apoptotic 
death; this may be beneficial for the control of pathogen load in the case of an infected cell. 
Depending on the stimuli found at the site of insult, specific cytokines can influence the ensuing 
immune response(s). Secreted chemokines are important for the recruitment of other types of 
immune cells – both of the innate and adaptive arms. For instance, CCL3 and CCL4 are potent in 
recruiting primed T cells from lymph nodes (described below) whereas IL-8 is very potent for 
circulating neutrophil and monocyte recruitment from the blood (7). Once these cells are 
recruited, they can also respond to inflammatory cytokines and release inflammatory content 
including other inflammatory cytokines or materials that result in inflammation. Chemokines can 
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also result in signal transduction for the release of these materials such as inflammatory granules 
(including secretory lysosomes) from neutrophils. 
Several innate immune cells function as phagocytic cells – in other words, they are 
endowed with intrinsic capabilities to engulf and internalize relatively larger sized materials 
(e.g., materials that are one micron or larger in diameter) (6). Phagocytes include cell types such 
as macrophages, dendritic cells and neutrophils. Their specific functions, localizations, and 
responses to stimuli may vary but as phagocytes, these cells are able to engulf and internalize 
materials such as bacteria for their clearance. In addition to phagocytic activities during 
infection, innate immune cells can produce factors that promote the innate immune response or 
the development of adaptive immune responses.  
 Antigen presentation allows innate immune cells to promote adaptive immune response 
development. Some phagocytic cells can also act as professional antigen presenting cells (APC) 
(6). In the process of infection macrophages and in particular dendritic cells process proteins and 
lipids in unique compartmentalized ways such that they can engage the adaptive immune 
response; this process is called antigen presentation. Antigen presentation can occur in a variety 
of ways and the compartmentalization of proteins and lipids processing can vary. Most notably, 
antigen presentation occurs with specifically sized peptides associated within proteins called 
major histocompatibility complexes (MHC). MHC come in different types – most notably class I 
and class II for the presentation of peptides. The types of peptides, as well as where and how 
they are modified, are different between MHC class I and MHC class II. Typically, endogenous 
proteins/peptides found within cells are targeted for degradation within proteasomes then 
trafficked to the endoplasmic retriculum for processing and loading onto MHC class I molecules 
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(8). Exogenous proteins/peptides or self proteins that are endocytosed are typically targeted for 
degradation within acidified late endosomes to be loaded onto MHC class II molecules (9). The 
loading of these peptides onto MHC enable the stable expression of these MHC on the plasma 
membrane. Once there, MHC in context of peptides can initiate signal transduction pathways 
through specific T cell receptors expressed by T cells. 
 Dendritic cells are thought to be the primary cell type for effective antigen presentation to 
initiate primary immune responses (10). Dendritic cells can not only efficiently handle peptides 
for antigen presentation but they are also more likely than macrophages to migrate from sites of 
insult towards lymph nodes. Lymph nodes provide an environment conducive for activating 
naïve T cells, which have not previously encountered presented antigen outside of the thymus. 
Dendritic cells are matured by stimuli such as pathogen associated molecular patterns (PAMPs), 
which activate pattern recognition receptors (PRRs) expressed by dendritic cells. Following their 
maturation, dendritic cells migrate towards increasing concentration gradients of CCL19, a 
chemokine secreted within lymph nodes (11). CCL19 binds to CCR7 found on mature dendritic 
cells, which initiates signal transduction pathways that enables this specific migration. Dendritic 
cells approach lymph nodes from peripheral tissues and engage with various cell types, including 
lymph node-resident dendritic cells and naïve T cells. Migratory dendritic cells can transfer 
intact protein antigens (cross-presentation) (12) or MHC plus peptides (semi-direct presentation) 
(13) to lymph node resident dendritic cells. In this manner, the lymph node resident dendritic 
cells can engage naïve T cells in the lymph node and result in their induction of signal 
transduction pathways for activation (i.e., priming). Migratory dendritic cells are also able to 
prime naïve T cells (14). Primed T cells initially proliferate then migrate away from lymph nodes 
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to peripheral sites of insult. For instance, expression of CCR5 sensitizes certain subsets of T cells 
to high concentrations of CCL3 and CCL4 secreted by innate immune cells at sites of insult (15). 
 
1.1.3  Pathogen Associated Molecular Patterns versus Damage Associated Molecular Patterns 
 
For the initial recognition response to mount immunity, immune cells need to be properly 
licensed. The specific mechanisms in which this coordination occurs is still a work in progress 
but there are two main hypotheses put forward. These two hypotheses include:  
1) the recognition of self versus non-self (16) and  
2) the recognition of healthy self versus non-healthy self (17) 
While these two hypotheses are generally put forward, they do not fully answer how 
innate immune cells are engaged. There are different types of mounted immune responses to 
infection versus endogenous materials that promote diseases in the absence of infection (18). For 
the recognition of dying cells, there are “find me” or “eat me” signals that have completely 
different roles than what the two hypotheses provide (19, 20). Instead of promoting pro-
inflammatory situations, endogenous factors released during cell death can also dampen immune 
responses to allow the repair of tissue (21). Furthermore, it is increasingly understood that certain 
endogenous factors may synergize with foreign materials to induce immune responses (22).  
 The self versus non-self hypothesis is supported by observations that immune cells 
become activated in response to infection whereas immune cells can be quiescent in the absence 
of infection. Pathogens such as bacteria or viruses contain novel repeating molecular patterns or 
foreign materials that are not normally found within the host organism (5). Most innate immune 
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cells possess a battery of receptors and ways of recognizing the presence of pathogen originated 
materials. Together these pathogen originated materials are called Pathogen Associated 
Molecular Patterns (PAMPs). The receptors that can be ligated by these PAMPs and elicit 
downstream signal transduction are called Pattern Recognition Receptors (PRRs). PRRs are 
expressed by many types of innate immune cells. An example of PAMPs and PRRs would be 
flagellin activation of Toll-Like Receptor 5 (TLR5) (23). Flagellin is a protein found on bacterial 
flagella and TLR5 is expressed by CD11c+ intestinal lamina propria dendritic cells (24). TLRs 
can be differentially expressed among several types of cells; for instance, TLR5 is not expressed 
by conventional mouse dendritic cells or bone marrow derived macrophages (25). In the context 
of infection, flagellin proteins ligate TLR5 expressed on dendritic cells to activate transcription 
factors such as nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) (26). These 
transcription factors result in the transcription of novel response elements and the eventual 
translation of inflammatory mediators such as pro-inflammatory cytokines and chemokines. 
 There are many different PAMPs, and the recognition of PAMPs is achieved through a 
diversity of plasma membrane-bound and intracellular PRRs (5). Toll-like receptors (TLRs) can 
be found on the plasma membrane or within endosomes (27). A listing of TLRs and their 
respective PAMPs are provided in Table 1. In addition to TLRs, there are other types of PRRs. 
These include the nucleotide-binding oligomerization domain-containing protein (NOD)-like 
receptors (NLRs) (28) and retinoic acid-inducible gene 1 protein (RIG)-I-like receptors (RLRs) 
(29), which are included in Table 2 with their respective PAMPs. 
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Table 1: Toll-like receptors (TLRs), ligands, cellular expression and localization. DC, dendritic cell; DN, 
double negative for CD4+ and CD8+; pDC, plasmacytoid dendritic cell; mΦ, macrophage; nΦ, neutrophil; NK, 
natural killer; T reg, T regulatory cell. Data compiled from (23, 27, 30, 31) 
TLR Primary Physiological 
Ligand 
Generalized Immune Cell Type Expression Cellular 
Localization 
TLR1/2 Triacylated lipoproteins 
from Gram-negative 
bacteria & mycoplasma 
Mouse: CD4+ DC, CD8+ DC, DN DC, pDC, monocyte, 
mΦ, nΦ 
 
Human: monocyte, mDC, pDC, T cells, B cells, mΦ, nΦ 
Plasma 
membrane 
TLR2/6 Diacylated lipopeptides 
from Gram-positive 
bacteria & mycoplasma 
Mouse: CD4+ DC, CD8+ DC, DN DC, pDC, T cells, T 
reg, B cells, monocyte, mΦ, nΦ, NK cells 
 
Human: monocyte, mDC, T cells, mΦ, nΦ, NK cells 
Plasma 
membrane 
TLR3 Double-stranded RNA Mouse: CD8+ DC, DN DC, T cells 
 
Human: mDC, NK cells 
Endosomes 
TLR4 Lipopolysaccharide Mouse: CD4+ DC, CD8+ DC, DN DC, pDC, T reg, 
mΦ, monocytes, nΦ, NK cells 
 
Human: monocytes, T cells, mΦ, nΦ, NK cells 
Plasma 
membrane & 
endosomes 
TLR5 Flagellin Mouse: CD4+ DC, DN DC, pDC, T reg, nΦ 
 
Human: monocytes, mDC, nΦ, NK cells 
Plasma 
membrane 
TLR7 Single-stranded RNA Mouse: CD4+ DC, DN DC, pDC, B cells, mΦ 
 
Human: monocytes, mDC, pDC, B cells, mΦ 
Endosomes 
TLR8 Single-stranded RNA Mouse: CD4+ DC, CD8+ DC, DN DC, pDC, T reg 
 
Human: monocytes, mDC 
Endosomes 
TLR9 Unmethylated 
2’deoxyribo(cytidine-
phosphate-guanosine) 
Mouse: CD4+ DC, CD8+ DC, DN DC, pDC, T cells, 
mΦ, B cells 
 
Human: pDC, T cells, B cells 
Endosomes 
TLR10 Unknown; involved in 
recognition of TLR2 
ligands? 
Human: mDC, pDC, B cells Plasma 
membrane 
TLR11 Uropathogenic bacterial 
components; profilin-like 
molecule derived T. gondii 
None reported Endosomes 
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Table 2: Cytosolic pattern recognition receptors (PRRs), ligands and cellular expression. DC, dendritic cell; 
mΦ, macrophage; nΦ, neutrophil; NK, natural killer. Data compiled from (23, 27, 30, 31) 
PRR Primary Physiological Ligand Generalized Immune Cell Type 
Expression 
NOD1 Diaminopimelic acid-containing muropeptide from Gram-
negative bacteria 
Broad expression across immune cells 
NOD2 Muramyl dipeptide Monocytes, DC, nΦ 
NLRP1 Muramyl dipeptide Monocytes, mΦ, DC 
NLRP3 Various stimuli Monocytes, mΦ, DC, nΦ 
NLRC4 Flagellin Monocytes, mΦ, DC 
NAIP5 Flagellin MΦ, DC 
AIM2 Double-stranded DNA MΦ, DC 
MDA5 Double-stranded RNA Monocytes, mΦ, nΦ, NK cells 
RIG-I Double-stranded RNA Monocytes, mΦ, DC, nΦ, NK cells 
 
The type of signal transduction that occurs downstream from PRRs can also greatly vary 
between PRRs to elicit different responses. Some TLRs require adaptor molecules such as 
MyD88 or TRIF to elicit signal transduction (27); the type of accessory molecule required is 
different for specific TLRs. Some TLRs modulate transcription factors more effectively than 
others such as by modulating the function of NF-κB, activator protein-1 (AP-1), or interferon 
regulatory factors (IRF) (e.g., IRF-3) (32). These transcription factors influence the type of 
cytokines that will be produced. For instance, IRF-3 is a prominent transcription factor for Type 
I interferon transcription rather than NF-κB (32). Many of these induced pathways are elicited 
with specificity for the type of insult. For instance, double stranded RNA, a product of many 
viruses, is found within endosomes during certain viral infections, and can activate TLR3 for 
IRF-3 activity (32). Type I interferons directly interfere with virus propagation through ligation 
of receptors to elicit signal transduction for viral clearance (33). 
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Some PRRs do not directly induce the production and secretion of pro-inflammatory 
cytokines. In some instances, they promote the conversion of an inactive cytokine to become an 
inflammatory cytokine. This is the case for certain NLRs (e.g., NLRP1 and NLRP3), whereby 
the product of another PRR, such as IL-1β and IL-18, is actually sequestered in a zymogen state 
within cells (28). In this case, pro-IL-1β and pro-IL-18 are inactive and are not secreted from 
these non-NLR (but PAMP-activated) innate immune cells. Pro-IL-1β and pro-IL-18 (among 
other substrates) can be cleaved through the activity of caspase-1, which is activated through a 
multi-protein platform called the inflammasome (34). This complex includes a specific NLR 
protein (e.g., NLRP3) and linker domains (CARD domains found on the NLR protein or ASC 
that bind in pyrin domains found on some NLRs like NLRP3) to caspase-1. Multiple molecules 
of caspase-1 then oligomerize, which promotes the cleavage of various substrates, including pro-
IL-1β and pro-IL-18, to mature IL-1β and IL-18, respectively. Through pathways that are not 
fully understood, mature IL-1β and IL-18 are rapidly released as soluble mediators of 
inflammation.  
In addition to PAMPs, there are Damage Associated Molecular Patterns (DAMPs) (35). 
At sites of injury or infection, normally sequestered cellular content is either passively or 
actively released from cells that have compromised plasma membrane. In order for the released 
cellular content to be classified as a DAMP, the extracellular expression of these released 
materials should be minor in non-compromised individuals and the released material should 
modulate inflammation. For instance, intracellular adenosine triphosphate (ATP) is held within 
cells at a high concentration (>3 mM) ATP but upon cellular damage, ATP is lost out to the 
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extracellular space resulting in a gradient of ATP surrounding damaged cells (36). The danger 
hypothesis is strengthened through observations that inflammation can occur in the absence of 
infection such as situations of trauma or diseases such as arthritis or atherosclerosis; instead of 
foreign materials, it is appreciated that several endogenous factors promote inflammation in 
these instances (18). 
Innate immune cells possess a variety of receptors that can recognize various DAMPs 
(32). In the case of ATP, these receptors are called purinergic receptors (37), ATP binding 
receptors that will be discussed at length in the following section. Many DAMPs are reported to 
act through PRRs that can also be activated by PAMPs. For instance, High Mobility Group Box 
1 (HMGB1) is reported to activate TLR2 and TLR4 (38), in addition to activating TLR9 through 
endocytosis into endosomes by the non-PRR Receptor for Advanced Glycosylation End products 
(RAGE) (39). A list of known DAMPs with their receptors is shown in Table 3. 
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Table 3: DAMPs and their activating receptors. ECM, extracellular matrix. Data compiled from (22, 32) unless 
indicated. 
DAMP Physiological Source/Description Reported 
Receptor(s) 
Biglycan ECM proteoglycan found in bone, cartilage, and tendons TLR2, TLR4 
Extra domain A of fibronectin Cellular fibronectin produced in response to tissue injury TLR4 
Heparan sulfates ECM proteoglycan layered over endothelial cells; 
released upon tissue damage 
TLR4 
Hyaluronic acid Glycosaminoglycan that is a primary component of ECM TLR2, TLR4 
Surfactant protein A Protein component of pulmonary surfactant TLR4 
Tenascin-C ECM glycoprotein upregulated in inflammation TLR4 
Versican ECM proteoglycan upregulated in tumors TLR2 
Fibrinogen Soluble plasma glycoprotein TLR4 
Heat shock proteins Intracellular compartments TLR2, TLR4 
(Disputed) 
Formyl-peptides From mitochondria of necrotic cells FPR1 (40) 
S100A8 and S100A9 Abundant cytoplasmic proteins of phagocytes TLR4, RAGE 
HMGB1 alone or in complex 
with self DNA or RNA 
Non-histone DNA-binding protein from nuclei of 
necrotic cells 
TLR2, TLR4, TLR7, 
TLR9, RAGE 
Chromatin-DNA/RNA & 
ribonucleoprotein complexes 
Nuclei of necrotic cells TLR7, TLR9 
Oxidized low-density 
lipoprotein (OxLDL) 
Atherosclerotic lesions TLR4/6 heterodimer 
(41) 
Advanced glycation end-
product of low density 
lipoprotein (AGE-LDL) 
Derived from oxidized low-density lipoprotein TLR4, RAGE 
Oxidized palmitoyl-
arachidonyl-phosphatidyl-
choline (OxPAPC) 
Derived from oxidized low-density lipoprotein TLR4 
Serum amyloid A Apolipoproteins associated with high-density lipoprotein TLR2, TLR4 
β-amyloid Alzheimer’s disease TLR4/6 heterodimer 
Cardiac myosin Abundant protein in the heart TLR2, TLR8 
Angiotensin II Oligopeptide found in blood TLR4 
β-defensin 2 Secreted from neutrophils TLR4 
LL37 + self DNA or RNA Secreted from neutrophils TLR7, TLR9 
ATP Sequestered purine within cells NLRP3 (via P2X7) 
Self double-stranded DNA Released from nuclei of necrotic cells AIM2 
Uric acid crystals; cholesterol 
crystals 
Breakdown of purine nucleotides formed during gout 
disease; developed during atherogenesis 
NLRP3 (via 
phagocytosis) 
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In addition to the promiscuity of PRR for PAMPs and DAMPs, DAMPs can coordinate 
with PAMPs to elicit inflammation. This is especially evident with the inflammasome whereby 
PAMP induced activation (e.g., TLR activity) results in pro-IL-1β and inflammasome expression 
then DAMP induced activation (e.g., ATP ligation of the P2X7 purinergic receptor) results in 
pro-IL-1β cleavage through inflammasome assembly (42). It is becoming more apparent that 
DAMPs may serve as an adjuvant to PAMPs in eliciting more efficient innate immune responses 
(22). 
Although not often described as being DAMPs, various host-derived materials such as 
certain types of lipids can modulate immunity (6). Prominent among lipid ligands are 
eicosanoids such as prostaglandin E2, which can enhance inflammation among other activities 
(43). Oxidized low density lipoprotein built up in atherosclerotic lesions during the progression 
of atherosclerosis has agonistic activities through TLR4/6 heterodimer (41). Phospholipids such 
as phosphatidylinositols and sphingomylein also have demonstrated NF-κB activity although 
their route of activation is not revealed (44). The primary stimulatory and immunosuppressive 
lipids are included in Table 4. 
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Table 4: Lipids in immunological responses. Data compiled from (45-47). 
Lipids/fatty acids Synthesizing Enzyme(s) Activating 
Receptor(s) 
Activities 
Arachidonic acid 
(AA) 
Phospholipase C (PLC) or 
phospholipase A2 (PLA2) 
NA Precursor fatty acid in eicosanoid 
synthesis 
Prostaglandins  Cyclooxygenase pathways from 
arachidonic acid 
DP1-2, EP1-4, FP, 
IP1-2, TP 
PGE2 and PGI2 are pro-
inflammatory; PGJ2 and PGA1/2 
are anti-inflammatory 
Leukotrienes  5-lipoxygenase activity from 
arachidonic acid for LTA4; LTA4 
is converted by other enzymes to 
the other forms 
GPCR and PPAR 
groups 
Histamine production; LTB4 and 
LTC4 are pro-inflammatory 
Lipoxins  15-lipoxygenase from arachidonic 
acid 
Cysteinyl 
leukotriene 
receptor type 1 
Antagonist to several 
leukotrienes 
Phosphatidic acid 
(PA) 
Phospholipase D (PLD) activity 
from phosphatidylcholine or 
diacylglycerol kinase 
phosphorylation of diacylglycerol 
NA Precursor lipid for conversion to 
other forms; incorporates into 
membranes for curvature 
Lysophos-phatidic 
acid (LPA) 
Phospholipase A2 (PLA2) from 
phosphatidic acid 
Lysophosphatidic 
acid receptor 1, 3 
G protein-coupled receptor 
activity for proliferation, 
migration, and survival 
Diacylglycerol 
(DAG) 
Lipid phosphate phosphohydrolase 
activity from phosphatidic acid; 
cleavage product from 
phospholipase C 
Transient Receptor 
Potential Canonical 
cation channel 
(TRPC3/6/7) 
Precursor lipid for conversion to 
other forms; activates protein 
kinase C, TRPC3/6/7 cation 
channels 
Lysophos-
phatidylcholine 
(LPC) 
Phospholipase A2 from 
phosphatidylcholine 
G2A G protein-coupled receptor 
activity to downregulate T cell 
responsiveness 
Ceramide Ceramide is produced by 
dihydroceramide desaturase. 
NA Precursor lipid for conversion to 
other forms; stabilizes lipid rafts 
for signal transduction; pro-
apoptotic 
Sphingomyelin Sphingomyelinase activity from 
ceramide 
NA Precursor lipid for conversion to 
other forms – primarily ceramide 
and sphingosine 1-phosphate 
Sphingosine 1-
phosphate (S1P) 
Ceramidase conversion from 
ceramide to sphingosine then 
sphingosine kinase to S1P  
S1P1-S1P5 G protein-coupled receptor 
activity to promote survival 
Sphingosyl-
phosphoryl-choline 
(SPC) 
Sphingomyelinase conversion from 
ceramide to sphingomyelin then 
sphingomyelin deacylase to SPC 
OGR1 G protein-coupled receptor 
activity for immunosuppression 
Oxidized 
phospholipids with 
sn-2 acyl group 
Oxidation processes of 
phospholipids; found in oxidized 
low density lipoprotein (LDL) or 
minimally modified LDL 
CD36, PPAR-γ, or 
TLR4/6 hetrodimer 
Phagocytosis; macrophage 
activation; immunosuppression 
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1.1.4  Toll-Like Receptor signaling pathways 
 
TLRs are a set of receptors that can differentially respond to specific PAMPs and DAMPs via 
signal transduction pathways to activate gene transcription (32). Typical transcription factors 
include NF-κB, mitogen-activated protein kinase (MAPK)-induced AP-1, and IRFs (e.g., IRF-3, 
IRF-5 IRF-7). These transcription factors can be fine-tuned to transcribe different gene response 
elements. NF-κB can homodimerize or heterodimerize between 5 different subunits. The type of 
NF-κB dimerization dictates which gene response elements are activated for the expression of 
co-stimulatory ligands, cytokines, pro-survival factors, among other materials (26).  
TLR signaling pathways are modulated in several ways. The basic signal transduction 
elicited by a ligand involves cross-linking of a given TLR with the same TLR (homodimer) or 
with another TLR (heterodimer) (48). Sometimes the interaction of a PAMP with its respective 
TLR is mediated through accessory proteins. For TLR4 signaling, the ligand lipopolysaccharide 
(LPS) binds to the accessory molecules CD14 and LPS binding protein (49). The sensitivity of 
TLR4 is modulated by MD2, which enables enhanced cross-linking. Most PAMP ligand 
recognition is mediated by the leucine-rich repeat domains of TLRs. 
 The localization of a TLR can affect the type of accessory molecules that it encounters 
and the resulting downstream signal transduction (50). As mentioned, some TLRs are expressed 
at the plasma membrane whereas others are contained within endosomes. Sometimes the location 
places the TLR within reach of other essential macromolecules that enable its activity. For 
instance, once TLR9 is ligated by unmethylated CpG DNA (commonly derived from certain 
bacteria and viruses) within endolysosomes its activation occurs after cleavage by 
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endolysosomal proteases (51). TLR7 activity often requires autophagic processes to deliver its 
ligand of ssRNA (commonly associated with certain viruses that replicate in cytosol) to 
endolysosomes as well (52). TLR4 is also differentially modulated by its localization (32). At the 
plasma membrane, TLR4 interacts through its intracellular TIR domain with accessory signaling 
molecules MyD88 and TIRAP, which signal an early phase activation of NF-κB for pro-
inflammatory cytokine production. After clathrin/dynamin-dependent endocytosis into 
endosomes, the TIR domain of TLR4 then interacts with the accessory molecules TRIF and 
TRAM, where they signal a late phase activation of NF-κB and IRF3 for pro-inflammatory 
cytokines and type I interferons, respectively. 
 The specific accessory molecules that associate with the TIR domains of various TLRs 
dictate the type of downstream cytokines that are produced (32). Most TLRs employ MyD88 as 
an accessory molecule, which recruits other molecules called IL-1 receptor associated kinases 
(IRAK-1, -2, -4, and –M). IRAK-4 initiates downstream activity for NF-κB and MAPK-
mediated transcription pathways whereas IRAK-1 and IRAK-2 sustain signaling for robust 
transcription. IRAK activates the E3 ligase TRAF6, which mediates polyubiquitination and 
binding and activation of TAK1 and NEMO. TAK1 then phosphorylates IKKαβ, which 
phosphorylates IκB for proteasome-mediated degradation to activate NF-κB. Additionally, 
TAK1 initiates MAPK pathways Erk1/2, p38, and Jnk for AP-1 activity. There is also a MyD88-
independent activation pathway that is dependent upon TRIF, which can activate TAK1 through 
different accessory proteins but yet activate the same downstream signaling pathways – NF-κB 
and MAPK. Unlike MyD88, TRIF can also activate IRF3 activity for Type I Interferon-β 
transcription, through TRAF3 activation of TBK1-IKKi phosphorylation. These pathways are 
illustrated in Figure 1-1. 
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Figure 1-1: TLR induced signaling pathways. 
TLR are found on the plasma membrane or within endosomes. Upon engagement with specific ligands, a given TLR 
can interact with adaptor proteins such as TIRAP/MyD88, TRIF/TRAM, or MyD88 alone. These adaptor proteins 
connect with signal transduction pathways for protein phosphorylation or ubiquitination. Ultimately, these signals 
converge for transcription factor activation (e.g., AP-1 or NF-κB) for pro-inflammatory cytokine production and 
upregulation of co-stimulatory ligands or for the production of type I interferons (e.g., IRF3 or IRF7). 
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 MAPK signaling can be activated through a variety of upstream pathways (53), for 
example through the activities of protein kinase A (PKA) and protein kinase C (PKC). PKA is 
activated through elevated intracellular levels of cyclic adenosine monophosphate (cAMP), 
generated by adenylate cyclase (54). PKC is activated by at least two different stimuli, depending 
on the specific PKC isoform (55). Conventional PKC isoforms are activated by elevated 
intracellular levels of calcium and diacylglycerol (DAG), whereas novel PKC isoforms are 
activated by DAG, but not calcium. As kinases, PKA and PKC can lead to the phosphorylation 
of several signaling intermediate pathways that tie into MAPK pathways among other signaling 
pathways to elicit biological responses. For instance, PKC can influence guanine exchange 
factors (GEFs) (e.g., RasGEF SOS) to activate small G proteins (e.g., Ras) to lead to its 
downstream activities with MEK1/2, which can modulate activities for p38, Erk1/2, and Jnk 
MAPK pathways. PKA can be activated by various G proteins (especially Gs-mediated cAMP 
generation) but they can also activate 14-3-3, which can then associate with c-Raf family 
members to engage MAPK pathways.  
There is an established connection between TLRs and other various stimuli that regulate 
NF-κB and MAPK pathways. For instance, TNF-α is a cytokine that is commonly added as a 
reagent to dendritic cell maturation cocktails in addition to Poly I:C, a TLR3 agonist, for better 
dendritic cell maturation (56). Direct PKA activation of dendritic cells alone, however, can also 
elicit ample levels of maturation (57). Various isoforms of PKC have been demonstrated to 
modulate TLR function. PKCδ binds to TLR2 and TLR4 adaptors TIRAP/Mal (co-factors of 
MyD88) to influence p38 MAPK and NF-κB (58). PKCα/β enhances nuclear translocation of 
NF-κB in TLR2 and TLR4 stimulated neutrophils, and also enhances IKKα/β activation as well 
as phosphorylation of the p65 subunit of NF-κB (59). PKCϵ phosphorylates TRIF following 
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TLR4-induced activation of macrophages (60). In some instances, LPS-induced NF-κB requires 
PKCζ (61, 62). Hyaluronan signaling through TLR2 with macrophages also requires PKCζ (63). 
Finally, PKCα modulate NF-κB activation in several immune cell types including T cells (64), 
monocytes (65), and neutrophils (66). 
 Deficiencies in TLR signaling can seriously impact the clearance of pathogens and 
protection from their subsequent pathogenesis; however, at the same time, TLR recognition of 
DAMPs can have also pathological consequences. DNA-chromatin complexes and 
ribonucleoprotein complexes released from dying cells mediate TLR7- and TLR9-dependent 
development of systemic autoimmune diseases such as systemic lupus erythematosus (67). 
HMGB1 acts in a similar capacity, where it is thought that HMGB1 or other DNA binding 
proteins may protect released self DNA and allow its entry to endocytic compartments (68). 
HMGB1 itself can bind to TLR4 for its activation (69). HMGB1 is acknowledged to promote 
septic shock and ischemic reperfusion through TLR2, TLR3, TLR4, and TLR9 (70). Host 
derived β-amyloid and oxidized phospholipids act in a TLR4/TLR6 heterodimeric dependent 
manner for the potential of non-pathogenic disease progression of Alzheimer’s disease and 
atherosclerosis respectively; it is thought that TLR4 and TLR6 heterodimerize through 
cooperative activities of the scavenger receptor CD36 (41). Injury and cellular damage to the 
lungs liberate hyaluronic acid cleavage products that promote inflammation for eventual wound 
healing through TLR2 and TLR4 dependent mechanisms (71). 
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1.1.5  NOD-Like Receptor signaling pathways 
 
In contrast to TLRs, NLRs are strictly intracellular cytosolic receptors (28). NLRs function as 
oligomerization platforms for the recruitment and coupling of several proteins through common 
binding domains such as caspase activation and recruitment domains (CARD). This recruitment 
can result in several different activities, depending on the NLR and its binding partners. NOD1 
and NOD2 recognize various bacterial cell wall components, leading to RIP2 activation of the 
IKK complex and NF-κB transcription. 
In contrast to NOD1 and NOD2, most of the other NLRs activate caspase-1 (42). NLRP1 
is activated by muramyl dipeptide (72) or anthrax lethal toxin in collaboration with NOD2 (73). 
NLRC4 and NAIP5 are activated by the specific flagellin of Salmonella typhimurium (74) and 
Shigella flexneri (75), and Legionella pneumophila (76), respectively. AIM2 is activated by 
double stranded DNA (77). NLRP3 is activated by several stimuli without apparent molecular 
specificity; it appears to occur downstream of materials that inflict membrane damage. Examples 
include pore forming agents like certain bacterial toxins or ATP activation of large-pore 
formation by P2X7 (78), materials that are hard to phagocytose such as uric acid crystals (79) or 
cholesterol crystals (80), or materials that promote potassium efflux such as the potassium 
ionophore nigericin or maitotoxin (78). Stability of lysosomes (81), activation of cathepsin B 
(81, 82), and reactive oxygen species (83-85) can also contribute to NLRP3 activation. 
Regardless of the initial stimuli and the ensuing pathways, the hallmark of these particular NLRs 
is the activation of caspase-1 through their respective inflammasome platforms for the processing 
of pro-IL-1β and pro-IL-18 to their biologically active, mature, forms. These pathways are 
depicted in Figure 1-2. 
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Figure 1-2: Inflammasome activation pathways. 
Activation of the inflammasome requires two distinct and sequential signals: a “signal 1” prerequisite of NF-κB 
induction (e.g., by TLR ligands) and a “signal 2”, which is promoted by a variety of stimuli depending on the type of 
NLR-inflammasome protein (i.e., NLRP3, AIM2, NLRP1, or NLRC4). NLRP3 is activated by several materials 
including ATP activation of P2X7/Pannexin-1, pore-forming toxins, and the “frustrated phagocytosis” of various 
crystals. NLRP3 activation can also require potassium efflux, cathepsin B activity, reactive oxygen species (ROS), 
or lysosomal damage. AIM2 is activated by cytosolic recognition of double-stranded DNA. NLRP1 is activated by 
muramyl-dipeptide. NLRC4 is activated by certain types of flagellin and/or Type III or Type IV secretion 
components. NLRP3, AIM2, and NLRP1 act with ASC to activate caspase-1 for caspase-1 cleavage. NLRC4 is 
ASC-independent. Ultimately, these inflammasome platforms result in the caspase-1 dependent cleavage of 
immature zymogen forms of IL-1β and IL-18 to their mature biologically active forms. 
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NLRP3 contributes to both infectious and non-infectious disease. Even though TLRs 
such as TLR7 and various RLRs recognize viral components, they are dispensable in terms of 
promoting CD8+ T cell cytolytic responses against influenza A viruses, whereas NLRP3 is 
indispensable; this is in large part due to its capacities to promote IL-1β (83, 86, 87). Mutations 
in NLRP3 promote familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and 
chronic infantile neurological, cutaneous and articular syndrome (88); these autosomal diseases 
are the result in overactive NLRP3 and IL-1β production (89). Other activators of NLRP3 
include silica crystals and asbestos (90), which can promote silicosis- and asbestosis-induced 
pulmonary fibrosis, respectively, in a NLRP3-dependent manner. 
 
1.1.6  Macrophage activation 
 
Macrophages and dendritic cells, among other cell types, can be stimulated by various PAMPs 
and DAMPs. The responses to these stimuli are often called activation or maturation for 
macrophages and dendritic cells respectively. Macrophage activation is characterized in a few 
distinctive ways (91). Often the types of activation are loosely correlated to polarized CD4+ T 
cell helper subtypes including Th1, Th2, and T regulatory polarized T helper cells. Without 
extensive elaboration that is beyond the scope of this dissertation, CD4+ T cells can be polarized 
to become cytolytic-assisting Th1 T cells, promoters of antibody class-switching (Th2 T cells), 
pro-inflammatory Th17 T cells, or immunosuppressive T regulatory cells (Treg). This list now 
includes even more than these four helper subtypes. Macrophage activation was previously 
divided into two groups – classically activated macrophages (M1), which helps to promote the 
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cytolytic response by Th1 T  cells, and alternatively activated macrophages (M2), which promote 
the class-switching capabilities of Th2 T cells (92). This area is still in a state of flux, given the 
ongoing developments in the T cell polarization field; thus macrophage activation was recently 
reclassified to include the following subtypes (91): 
1) Classically activated macrophages 
2) Regulatory macrophages 
3) Wound-healing macrophages 
These different macrophage activation states and some key polarizing molecules are diagramed 
in Figure 1-3. 
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Figure 1-3: Macrophage activation. 
Macrophages can differentiate into several types. PAMPs, IFN-γ, type I interferons, and/or TNF-α can act together 
or alone to polarize macrophages to the classical phenotype. Classically activated macrophages secrete several pro-
inflammatory cytokines and perform bactericidal activities and antigen presentation. IL-4 or IL-13 can promote 
wound healing macrophage polarization. Wound healing macrophages promote arginase activity for generating 
tissue repair molecules while decreasing cytokines secretion and antigen presentation. PAMPs plus immune 
complexes (e.g., antibodies bound to their specific epitopes), immunosuppressive stimuli (e.g., TGF-β, IL-10, 
apoptotic cells), or other stimuli for GPCR activation can promote regulatory macrophage polarization. Regulatory 
macrophages secrete a higher ratio of IL-10 to IL-12 while still exhibiting capable antigen presentation abilities 
including the upregulation of co-stimulatory ligands. These polarized forms can be very plastic, especially in the 
context of disease development. For instance regulatory macrophages can be diverted from regulatory macrophages 
to wound healing macrophages by activities or factors produced by Th2 polarized helper T cells. 
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Classically activated macrophages promote cytolytic activities. At first, it was found that 
IFN-γ and TNF-α promote macrophage activity for pro-inflammatory cytokines secretion (e.g., 
IL-6 and IL-1) (93) and polarizing cytokine secretion (e.g., IL-12p70 and IL-23) (94, 95); 
however, it is now appreciated that Type I interferons and/or certain PAMPs, through TLRs, can 
perform some of the same activities (96). PAMPs alone can induce classical activation especially 
when their ligation results in Type I intereferon and TNF-α production; this could most readily 
come about if the PAMP activates NF-κB and IRF3, such as for TLR3 and TLR4 agonists. 
Classically activated macrophages also secrete chemokines such as CXCL10 and CXCL11 that 
attract NK and T cells to sites of insult (97). In addition to cytokines or chemokines, classically 
activated macrophages can induce superoxide anion production and iNOS for pro-inflammatory 
NO (98) which, together with other processes induced by Type I and Type II interferons, can 
generate efficient microbicidal and anti-viral activities.  
Several cell types can promote the generation of classically activated macrophages. Early 
responders to infection, such as NK cells and NKT cells, can secrete prodigious amounts of IFN-
γ (99). This can additionally be aided and sustained at later times by recruited Th1 T cells, which 
can release IFN-γ at sites of insult. In the absence of being directly activated by PAMPs, tissue 
resident macrophages can receive TNF-α from PAMP-activated APC. Together IFN-γ and TNF-
α greatly promote classical activation (93). Classically activated macrophages can further 
promote Th1 polarization of CD4+ T cells and cytolytic activities of CD8+ T cells, through the 
production of IL-12 (95).  
It is also possible that classically activated macrophages could help promote Th17 
polarization of naïve CD4+ T cells, since these macrophages produce large amounts of IL-1, IL-
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6, and IL-23, which can promote Th17 polarization (94). Additionally, whereas classically 
activated macrophages are important mediators of host defense, they can also elicit 
immunopathologies such as rheumatoid arthritis (100) and inflammatory bowel disease (101), 
which have been described as Th17-mediated pathologies (102, 103). 
In addition to the secretion of polarizing cytokines, classically activated macrophages are 
also capable of antigen presentation to T cells. Classically activated macrophages exhibit 
enhanced antigen processing and antigen presentation machinery for both MHC class I and MHC 
class II antigen pathways (104). For MHC class I presentation, proteasome activity is enhanced, 
transporter associated with antigen processing (TAP, a molecule used for the transport of antigen 
from the proteasome to the ER) is upregulated, and various MHC class I chaperone molecules 
(such as calnexin and calreticulin) among others are also upregulated. For MHC class II, the 
over-all level of expressed MHC class II at the cell surface is enhanced, in part due to IFN-γ-
inducible activation of MHC class II transactivator (CIITA), a transcriptional co-activator of 
MHC class II expression. For both presentation pathways, classically activated macrophages also 
display elevated levels of co-stimulatory ligands, such as CD80 and CD86, that aid to enhance 
and sustain MHC/peptide mediated signaling through antigen cognate T cell receptors found on 
T cells.  
Regulatory macrophages and wound-healing macrophages are more recently identified 
macrophage subsets (91). Before regulatory and wound-healing macrophages were identified, 
activated macrophages without classical activation phenotype were classified as alternatively 
activated macrophages (92). We now know that wound-healing macrophages display different 
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phenotypes than regulatory macrophages; however they can share similar phenotypes and these 
subsets of macrophages are very plastic from one type of differentiation to another (105). 
Regulatory macrophages are mostly defined by their ability to promote 
immunosuppression. Regulatory macrophages display elevated production of IL-10 and reduced 
production of IL-12, although there can still be some production of pro-inflammatory cytokines 
(106). Even in the presence of pro-inflammatory cytokines, IL-10 is very immunosuppressive 
and is sufficient to decrease both the secretion of IL-12 and the efficacy of pro-inflammatory 
cytokines (107). Phagocytosis of apoptotic cells/bodies helps to promote TGF-β secretion and is 
thought to aid in regulatory macrophage differentiation (108). Prostaglandins (109), adenosine 
(110), dopamine (111), histamine (112), and sphingosine-1-phosphate (113), among several 
other host derived materials that deviate T helper responses away from Th1 polarization, can also 
promote different forms of regulatory macrophages. Tumor-associated macrophages display 
similar characteristics to regulatory macrophages, suggesting that tumor microenvironments may 
also promote regulatory macrophage differentiation (114). 
TLR activation of regulatory macrophages can elicit responses that are different from 
wound-healing macrophages or classically activated macrophages. In addition to increasing IL-
10 secretion, TLR ligation of regulatory macrophages can result in efficient naïve T cell 
activation. Regulatory macrophages can display high levels of co-stimulatory ligands including 
CD80, CD86, and LIGHT, which can enhance T cell receptor stimulation (115). Thus, in this 
manner, regulatory macrophages may serve as efficient APC – perhaps mostly for the induction 
of T regulatory cells. 
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Wound-healing macrophages are typically generated with the help of Th2 T cells with the 
purpose to act in tissue repair (115). A major factor for their differentiation is IL-4 (116), which 
is produced in large part by granulocytes (polymorphonuclear innate immune cells, including 
basophils and mast cells, which are involved in type I hypersensitivity immune responses) and 
Th2 T helper cells (117). IL-4 promotes activity of arginase, which converts arginine to 
ornithine, a precursor of the extracellular matrix components collagen and polyamines (118). 
Wound-healing macrophages appear to be dispensable for host-defense, as they are unable to 
clear various infections and do not control pathologies generated by several types of organisms 
including parasites (119). Wound-healing macrophages are also poor APCs, as they fail to 
upregulate co-stimulatory ligands or antigen presentation machinery (115). In terms of 
phenotype, wound-healing macrophages are most readily identified and separated from other 
types of macrophages by their expression of molecules involved in tissue repair, such as YM-1, 
RELM-α, and Factor XIII-A (120). The markers for and functions of wound-healing 
macrophages, classically activated macrophages, and regulatory macrophages are listed in Table 
5. 
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Table 5: Types of polarized macrophages. PAMPs: pathogen associated molecular patterns. GPCR: G-protein 
coupled receptors. Data taken from (91). 
Type of Macrophage Inducers Markers Functions/Characteristics 
Classical Macrophage PAMPs, IFN-γ, Type I 
interferons, TNF-α 
IL-12p70, nitric oxide, CCL15, 
CCL20, CXCL9, CXCL10, 
CXCL11 
Bactericidal activities, 
enhanced antigen 
presentation 
Wound-healing 
Macrophage 
IL-4, IL-13 Arginase, tissue repair 
molecules, CCL18, YM1, 
RELMα, CCL17, IL-27Rα, 
IGF1, CCL22, DCIR, stabilin 
1, Factor XIII-A 
Wound-healing activities, 
lack of cytokines and 
antigen presentation 
Regulatory Macrophage PAMPs + Immune 
complexes, TGF-β, 
IL-10, GPCR agonists, 
apoptotic cells 
IL-10, SPHK1, LIGHT, CCL1 Immunosuppression 
 
The type of macrophage activation state can be fairly plastic, especially between 
regulatory macrophages and wound-healing macrophages. This is very apparent given that 
regulatory macrophages secrete large amounts of IL-10 (115). Secreted IL-10 can induce Th2 
CD4+ T helper cells to produce IL-4 and IL-13 (121), which can act back on macrophages to 
promote their differentiation to wound-healing macrophages. 
The plasticity between wound-healing or regulatory macrophages and classical 
macrophages can result in various immunopathologies. The exact role of macrophages 
throughout tumor progression is a bit ambiguous (i.e., whether they promote or help to resolve 
cancer), but it is clear that the macrophage resident populations display more of a classically 
activated phenotype during early settings of neoplasia whereas over time macrophages switch to 
a more regulatory phenotype (122). Regulatory macrophages are thought to play a role in 
inhibiting adaptive immune responses to neo-antigens and to promote angiogenesis.  
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There is some evidence that the switch from wound-healing/regulatory macrophages to 
classically activated macrophages can promote diseases such as atherosclerosis and diabetes. 
Normally within healthy individuals, macrophages associated with adipose tissue are generally 
anti-inflammatory (123). This immunosuppression is mediated by PPAR-γ, a transcriptional 
regulator of several different factors including arginase and a factor found in wound-healing 
macrophages (124). In contrast, macrophages within adipose tissue of obese individuals are 
highly inflammatory and produce pro-inflammatory cytokines, similar to those made by 
classically activated macrophages, that interfere with insulin signaling in adipocytes for type-2 
diabetes progression (125). It is generally thought that the elevated amount of necrotic cell death 
found in adipose tissue of obese individuals dictates whether factors are released to promote 
classically activated macrophages versus wound-healing activated macrophages (126). In general 
it is acknowledged that necrotic cell death can be inflammatory, whereas apoptotic cell death is 
neutral or in some circumstances is immunosuppressive (127).  
In the case of atherosclerosis, atherosclerotic lesions can develop along blood vessels that 
are susceptible to lipid accumulation (128). Macrophages are gradually attracted to these lipid 
accumulations and form necrotic cell cores that are sites of inflammation including the presence 
of pro-inflammatory cytokines characteristic of classically activated macrophages (129). The 
exact mechanism for how this progression from wound-healing/regulatory macrophages to 
classically activated macrophages is initiated is a bit unclear, although various factors such as 
oxidized phospholipids, extracellular matrix fragments, and cellular debris found within 
atherosclerotic plagues have an ability to promote this turnover (101). 
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1.2  PURINERGIC RECEPTORS AND THEIR SIGNAL TRANSDUCTION PATHWAYS 
 
A variety of purines, including ATP, adenosine disphosphate (ADP), adenosine, and uridine 
triphosphate (UTP) can activate a set of receptors that are expressed at the plasma membrane of 
several types of cells (130). Purinergic receptors contain extracellular binding pockets for 
purines. Once engaged extracellularly with their specific purine ligand (some purinergic 
receptors display greater affinity for certain purines), purinergic receptors undergo 
conformational change to elicit specific signal transduction pathways. 
 Purinergic receptors are divided into two subtypes – P1 and P2 receptors (130). P1 
receptors have greater specificity for adenosine and inosine and do not bind ATP, ADP, or UTP. 
P1 receptors are G protein coupled receptors (GPCRs); thus when bound by their ligand, they 
induce the activation of various G proteins including differential activation of Gs, Gq, or Gi 
depending on the type of P1 receptor. P2 receptors have greater specificity for binding ATP, 
ADP, UTP, uridine-diphosphate (UDP), and UDP-glucose. P2 receptors are further divided into 
P2X and P2Y receptors. P2X receptors act as ligand-gated ion channels that allow for the influx 
and efflux of different ions. P2X receptors often act as homotrimers and heterotrimers. ATP is 
the primary physiological ligand for P2X receptors. P2Y receptors act as GPCRs for the 
activation of Gs, Gq, or Gi. A full listing of all of the known purinergic receptors, their primary 
physiological ligands and their respective EC50 values, and their immunological functions are 
within Table 6. 
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Table 6: Purinergic receptors, ligands, and functions. DC, dendritic cell; mΦ, macrophage; nΦ, neutrophil; NK, 
natural killer; PGE2, prostaglandin E2; ROS, reactive oxygen species; RNS, reactive nitrogen species; VEGF, 
vascular endothelial growth factor. Unless otherwise mentioned, data is taken from (37).    
Purinergic 
Receptor 
Physiological Ligand & 
Immune Cell Expression 
Immunological Function 
A1 Adenosine (EC50: 0.18-0.53 µM) 
Inosine (EC50: 290 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, NK cells 
NΦ: Enhances adherence to endothelium; induces chemotaxis; 
 enhances phagocytosis; enhances ROS 
MΦ: Enhances phagocytosis; enhances ROS 
NK cells: Enhances cell-mediated cytotoxicity 
A2A Adenosine (EC50: 0.56-0.95 µM 
Inosine (EC50: 50 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells, B cells 
NΦ: Inhibits adherence to endothelium; inhibits ROS; may be 
 involved in adenosine-mediated inhibition of 
 degranulation; enhances COX-2 and prostaglandin E2 
 expression; delays onset of apoptosis 
Monocytes: Inhibits adherence to endothelium 
MΦ: Inhibits NF-κB binding to DNA; increases IL-10 secretion; 
 syngerize with TLR ligands to enhance VEGF 
 expression  but inhibits TNF-α and IL-12; promotes 
 wound-healing and angiogenesis; decreases ROS 
DC: Inhibits TNF-α and IL-12 following maturation 
T cells: Attenuates activation and cytotoxicity 
A2B Adenosine (EC50: 16.2-64.1 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells 
NΦ: Inhibits adherence to endothelium; inhibits the release of 
 VEGF 
Monocytes: Inhibits adherence to endothelium; enhances IL-10 
MΦ: Enhances IL-10; decreases NOS 
T cells: Attenuates activation; inhibit NF-κB signaling 
A3 Adenosine (EC50: 0.18-0.53 µM) 
Inosine (EC50: 0.03-2.5 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells 
NΦ: Inhibits degranulation; promotes chemotaxis (131) 
MΦ: Inhibits LPS-induced CCL3 and NF-κB; decreases RNS 
T cells: Attenuates adherence of cytolytic T cells to tumor 
 targets and cytolytic functions 
P2X1 ATP (EC50: 0.05-1 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells, NK cells 
NΦ: Promotes chemotaxis (132) 
T cells: Promotes activation (133) 
P2X2 ATP (EC50: 1-30 µM) 
 
No reported expression 
No reported function 
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Table 6 (continued) 
P2X3 ATP (EC50: 0.3-1 µM) 
No reported expression 
No reported function 
P2X4 ATP (EC50: 1-10 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells, NK cells 
MΦ: Promotes PGE2 (134) and IL-1β secretion (135) 
Microglial cells: Promotes chemotaxis (136) 
T cells: Promotes activation (133) 
P2X5 ATP (EC50: 1-10 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells 
No reported function 
P2X6 ATP (EC50: 1-12 µM) 
No reported expression 
No reported function 
P2X7 ATP (EC50: 100-780 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells, B cells, NK 
cells 
NΦ: Enhance adherence to endothelium; promote priming for  ROS 
Monocytes: Promote NF-κB; induce shedding of L-selectin; 
 promotes IL-1β, IL-18, IL-1α, and arachidonic acid 
 secretion; upregulates COX-2; induces cell death 
MΦ: Promotes NF-κB; promotes IL-1β, IL-18, IL-1α, and 
 arachidonic acid secretion; upregulates COX-2; 
 regulates phagocytosis; enhances lysosomal enzyme 
 secretion enhances RNS and ROS; induces cell death 
DC: Induces maturation; promotes IL-1β, IL-18, IL-1α 
 secretion; induces cell death 
T cells: Induces shedding of L-selection; induces proliferation; 
 induces cell death of regulatory T cells; enhances 
 activity of AP-1 and NF-κB 
B cells: Induces proliferation 
P2Y1 ADP (EC50: 8 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells 
No reported function 
P2Y2 UTP (EC50: 0.14 µM) = ATP 
(EC50: 0.23 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells, eosinophils 
NΦ: Promotes chemotaxis (131); enhances degranulation; 
 promotes priming for ROS 
Monocytes: Enhances adherence to endothelium; promotes 
 CCL20 (137) and IL-8 (138) secretion; promotes 
 apoptotic cell clearance (139) 
MΦ: Enhances IL-6 and CCL2 (140) secretion; increases 
 phagocytosis; promotes chemotaxis (141); promotes 
 apoptotic cell clearance (139) 
DC: Promotes CCL20 secretion (137); promotes chemotaxis (142) 
Eosinophils: Promotes chemotaxis (142); promotes accumulation in 
lungs (143); promotes cytokine release (144) 
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Table 6 (continued) 
P2Y4 UTP (EC50: 2.5-2.6 µM) >> 
ATP, UDP 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells  
No reported function 
P2Y6 UDP (EC50: 0.3 µM) >> UTP 
(EC50: 6 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells, microglial 
cells 
Monocytes: Enhances CXCL8, IL-8 (138) and TNF-α secretion 
MΦ: Enhances NF-κB; enhances PGE2 secretion 
Dendritic cells: Enhances CXCL8 secretion 
Microglial cells: Enhances phagocytosis (145) 
P2Y11 ATP (EC50: 17 µM) 
 
Expressed by nΦ, monocytes, 
mΦ, DC, T cells, B cells 
DC: Induces maturation; enhances chemotaxis; inhibits IL-12 and 
IL-27 secretion; induces IL-23, thrombospondin-1 (146) 
and indoleamine 2, 3-dioxygenase (146) secretion 
B cells: Promotes activation 
P2Y12 ADP (EC50: 0.07 µM) 
 
Expressed by monocytes, mΦ, 
T cells, microglial cells, mast 
cells  
MΦ: Promotes chemotaxis 
Microglial cells: Promotes chemotaxis (136) 
Mast cells: Promotes chemokine and prostaglandin D2 secretion 
P2Y13 ADP (EC50: 0.06 µM) > ATP 
(EC50: 0.26 µM) 
 
Expressed by monocytes, DC, 
T cells 
No reported function 
P2Y14 UDP-glucose (EC50: 0.1-0.5 
µM) 
 
Expressed by nΦ, DC, T cells 
No reported function 
 
Purinergic receptors are expressed by virtually every cell type, including immune cells 
(37), although the subset of receptors expressed can be different between various cells. Thus 
purines can differentially regulate cellular function. Varying the concentration of particular 
extracellular purines can also differentially regulate cellular function, as each purinergic receptor 
has its own EC50 and preferred purinergic ligand. Many cell types also express plasma 
membrane-localized ectoapyrases such as CD39 and CD73; ectoapyrases can decrease the local 
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concentration of purines such as ATP by hydrolyzing ATP to adenosine monophosphate and 
adenosine, thus regulating purinergic receptor activation. 
 Purines can be released from cells passively (147). Cellular damage can result in 
compromised plasma membranes, which can allow for the passive release of intracellular content 
including purines. Purines such as ATP are normally harbored within cells at high 
concentrations, and once released can act in high local concentrations close to cells (148).  
Purine release can also be actively induced. For instance, the activation of TLRs on 
myeloid cells can result in ATP release (149, 150). The activation of certain purinergic receptors 
such as P2X7 or associated hemichannels such as pannexin 1 can result in ATP release as well 
(151). It is recently appreciated that upon cell death induced by UV light or Fas ligation, 
pannexin-1, an ion hemichannel capable of promoting large pore formation (i.e., promote 
membrane break-down to allow the entry of dyes such propidium iodide), is responsible for 
appreciable amounts of ATP and UTP release (152). From this study, UV or Fas activated 
caspase-3 and caspase-7 cleaved pannexin-1 to make it functional, to induce large pore formation 
that resulted in the release of purines. 
 Proteins and lipids are modified through purinergic signaling. In particular, P2X7 initiates 
several of these modifications. Following PAMP stimulation of macrophages, activation of P2X7 
results in caspase-1 through the NLRP3 inflammasome (78). Cleavage by caspase-1 results in the 
non-conventional secretion of several proteins including pro-inflammatory cytokines IL-1β, IL-
1α, IL-18, and fibroblast growth factor-2 (153). P2X7 activation can also result in the release of 
other proteins such as HMGB1 (154), which may involve the inflammasome. P2X7 activation 
can also stimulate various phospholipases (calcium dependent phospholipase A2 [cPLA2] (155), 
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calcium independent phospholipase A2 [iPLA2] (155), phospholipase D [PLD] (156)) that result 
in the cleavage of different lipid substrates such as phosphoinositols (PI) and 
phosphatidylcholine (PC). P2X7 also promotes “phosphatidylserine (PS)-flip” (157) whereby the 
topology of PS is switched from associating with the cytosolic side of the plasma membrane to 
being exposed extracellularly by plasma membrane associated floppases. 
Purinergic signaling has been studied in a variety of fields including neurology, 
hematology, osteology, and immunology (130). Purinergic receptors greatly influence 
neuropathic and inflammatory pain, platelet aggregation, bone generation, among several other 
functions. Several of the cells involved in these processes express multiple purinergic receptors.  
 Purinergic signaling can greatly modulate immune responses (37). In the context of ATP, 
there is a generalized spectrum of responses, where lower doses of ATP promote 
immunosuppression, and higher doses of ATP can promote inflammation (158). In this manner, 
the dose of ATP determines which purinergic receptor gets activated and thus which differential 
signal transduction pathways are initiated for various functions. It is also appreciated that ATP 
and UTP can serve as chemotactic agents to recruit myeloid-derived cells (139). The diversity 
and distribution of all of the known purinergic receptors in immune cells is listed in Table 6. 
 
1.2.1  P2X7-induced inflammation 
 
Compared to the other purinergic receptors, P2X7 could be argued to be the greatest inducer of 
inflammation. P2X7 can promote pro-inflammatory cytokine and protease release from cells, and 
promote inflammatory forms of cell death, among several other inflammatory activities. P2X7 is 
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expressed by several types of immune cells (37) (as noted in Table 6), and thus has global 
impacts on immunity. Additionally, P2X7 expression is upregulated on classically activated 
macrophages, compared with other types of activated macrophages (159). 
P2X7 initiates NLRP3 inflammasome activity of PAMP activated macrophages and 
monocytes, which results in the generation and release of biologically active forms of the 
inflammatory cytokines IL-1β and IL-18 (78). The NLRP3 inflammasome is physiologically 
relevant given its role in protection against infections such as influenza A (83), and its 
hyperactivation in autoinflammatory diseases such as familial cold autoinflammatory syndrome 
and Muckle-Wells syndrome (89). ATP and P2X7 themselves are highly physiologically relevant 
in terms of the inflammasome. Mutations of P2X7 that decrease its function or P2X7-deficient 
mice display decreased levels of IL-1β (160). Release of IL-1β is a crucial determining factor for 
neutrophil adherence at, and eventual recruitment to, sites of necrotic cell damage (40) and for 
the development of type IV hypersensitivity immune responses (161), both of which require 
ATP, P2X7, NLRP3, and IL-1β. In the context of cancer, ATP released during chemotherapy can 
activate NLRP3 in a P2X7-dependent manner in dendritic cells and the resulting IL-1β is 
required for the development of cytolytic CD8+ T cell cellular immunity (162). In the absence of 
chemotherapy induced ATP release, NLRP3 promotes tumor development through myeloid 
derived suppressor cell recruitment to tumors (163).  
As a consequence of P2X7 over-stimulation, cells can succumb to cell death. The context 
of P2X7 engagement often dictates which form of cell death occurs; however, the form of cell 
death can be ambiguous. For instance, in the case of PAMP primed and inflammasome activated 
macrophages, it has been proposed that P2X7 induces a caspase-1 mediated cell death called 
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pyroptosis (164). Alternatively, without the need for PAMP priming, T regulatory cells, which 
highly express P2X7, readily undergo cell death in the presence of P2X7 ligands (165); while not 
highly characterized in the aforementioned study, a closer look at P2X7-induced lymphocyte cell 
death concluded that it was neither apoptosis nor necrosis, but rather a type of cell death that 
displays phenotypes of both (166). In the context of a live mycobacterial infection, THP-1 
monocyte cell line undergoes autophagy in response to P2X7 to induce bactericidal activities 
(167); while not discussed in this study, autophagy can disallow cell death or it can induce type 
II/autophagic cell death (168). 
 P2X7 activation of macrophages promotes bactericidal activities. Most studies have dealt 
with mycobacteria as their bacterial load is readily controlled by P2X7-activated macrophages 
(169). Mycobacteria normally reside within endosomes of phagocytes. Upon P2X7 stimulation, 
macrophages undergo a process of endosome fusion with lysosomes, which then allows for the 
clearance of internalized mycobacteria (170). This process is mediated by phospholipase D 
(PLD) as P2X7 induces PLD-mediated phagosome-lysosome fusion (170, 171). P2X7-induced 
apoptosis of macrophages that had taken up mycobacteria has also been suggested as a 
mechanism for P2X7-related bactericidal activities (172). Additionally, individuals carrying 
deleterious polymorphisms of P2X7 are more susceptible to mycobacterial infection as their 
macrophages display decreased killing capacities (173). Furthermore, P2X7 regulates 
phagocytosis (174).  
P2X7 promotes PLD to act as a strong regulator of lipid signaling that can exacerbate 
inflammation (as mentioned above). PLD exists in two isoforms: PLD1 and PLD2. The exact 
localization of these isoforms is disputed, but it is largely reported that PLD1 is found in the 
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Golgi apparatus, whereas PLD2 is localized at the plasma membrane (175). However, in 
response to stimuli, PLD1 can be active at the plasma membrane. For instance, PLD1 
remobilizes to the plasma membrane to promote secretory granule exocytosis (176), which is a 
potential outcome of P2X7 stimulation (177). PLD hydrolyzes PC to choline and phosphatidic 
acid (PA) (178), which directly contribute to cell signaling or be converted to other lipids. PA is 
localized at the plasma membrane and due to its ability to apply negative curvature of the plasma 
membrane, PA can promote differential recruitment of materials to the plasma membrane (178). 
Additionally, PA can directly bind to proteins such as phosphatidylinositol 4-phosphate 5-kinase, 
PKCε, and PLCβ (179). As a signaling intermediate, PA can be converted through further 
hydrolysis by cPLA2 or iPLA2 to lysophosphatidic acid (LPA) or to diacylglycerol (DAG) by 
lipid phosphate phosphohydrolases (180). LPA is cleaved off into the extracellular space, where 
it can bind to receptors found on the cell surface on numerous cell types. The hydrophobicity of 
DAG keeps it at the plasma membrane where it can promote the recruitment and activation of 
molecules like PKC (181). DAG can be converted to PC, PS, phosphatidylglycerol (PG), 
phosphatidylethanolamine (PE), and phosphatidylinositol (PI). Additionally, DAG can also be 
converted to arachidonic acid (AA), which serves a substrate for generation of eicosanoids 
(including prostaglandins and leukotrienes). Notably, LPA, AA, prostaglandins, and leukotrienes 
promote inflammation (182) and are products of ATP ligation of P2X7 (183). P2X7-induced 
alterations of lipids are illustrated in Figure 1-4. 
  
41 
 
Figure 1-4: P2X7 lipid signaling pathways. 
ATP engagement of P2X7 initiates the generation and modification of lipids. The carboxy-terminus of P2X7 has 
several protein domains including a poly-proline-rich sequence that can recruit proteins with SH3 domains such as 
ADP-ribosylation factor 6 (ARF6), Rho family GTPases, and phosphatidylinositol 4-kinase (PI4K). PI4K generates 
phosphatidylinositol 4-phosphate (PI4P) from phosphatidylinositol (PI). ARF6 and Rho may activate phospholipase 
D (PLD) to produce phosphatidic acid (PA) from phosphatidylcholine (PC). PA can activate phosphatidylinositol 4-
phosphate 5-kinase (PIP5K) to make phosphatidylinositol 4, 5-bisphosphate (PIP2) from PI4P. Ion fluxes induce 
phospholipase A2 (PLA2) to produce lysophosphatidic acid (LPA) from PA, lysophosphatidylcholine (LPC) from 
phosphatidylcholine (PC), or aracidonic acid (AA). P2X7 can also activate phospholipase C (PLC) via LPA 
activation of the GPCR receptor LPA receptor (LPAR); PLC induced cleavage of PIP2 or lipid phosphate 
phosphohydrolase (LPP) conversion of PA can generate diacylglycerol (DAG). PLC also produces inositol 
trisphosphate (IP3) and AA. P2X7 can also activate neutral sphingomyelinase (N-SMase) for ceramide (CM) 
generation from sphingomyelin (SM). Solid red lines indicate activation. Dashed red lines indicate cleavage. Solid 
orange lines indicate lipid conversion. Question marks (?) indicate unknown causes. 
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P2X7 biology has relevance for several inflammatory diseases. Arthritis is an 
inflammatory disease of the joint. Macrophages from rheumatoid arthritis patients display 
elevated inflammatory responses to ATP (perhaps due to hyperactive P2X7 polymorphisms) 
compared to healthy individuals (184). Additionally, collagen-induced arthritis is significantly 
decreased in P2X7 knock-out mice (185). Independent of the inflammasome and pro-
inflammatory cytokines like IL-1β, P2X7 activation results in the release of several proteases 
called cathepsins from macrophages (186); in an in vitro model of the extracellular matrix, these 
cathepsins were able to degrade collagen, an activity relevant to arthritis. ATP acting on P2X7 on 
APCs can initiate the priming of naïve T cells for graft versus host disease (187). Alzheimer’s 
disease is a neurological inflammatory disease potentiated by β-amyloid, which is able to induce 
ATP release from microglial cells (188). Alzheimer’s progression is dependent upon P2X7 (189). 
Atherosclerosis is another relevant P2X7 influenced disease, as P2X7 promotes the shedding of 
small lipid bilayer microparticles from dendritic cells that have coagulation properties (190); 
coagulation is one of the early steps towards generating the thrombogenicity of atherosclerotic 
plaques. Lastly, among several other examples of P2X7 involvement in inflammatory diseases, 
abrogation of P2X7 and ATP ameliorates the experimental autoimmune encephalomyelitis model 
of multiple sclerosis (191), a chronic degenerative disease of the central nervous system. 
 
  
43 
1.3  SECRETED LYSOSOME-RELATED ORGANELLES 
 
The intracellular trafficking of cells dictates cellular survival and their potential to function in 
unique roles. Intracellular trafficking is also tightly linked to organelle biogenesis and the 
exocytosis of materials from cells. This section aims to detail the calcium-induced secretory 
granule (SG) activities of immune cells, highlighting the unique activity of secreting lysosome-
related organelles (LRO) (i.e., secretory lysosomes). 
 Certain immune cells can traffic proteins within SG to several unique compartments and 
have various modes for their secretion from the trans-Golgi network (TGN) (192). SG are 
secreted through regulated pathways. The biogenesis of SG start from the TGN as immature 
granules (IG), following a specific initiating stimulus. The mechanism by which certain proteins 
are retained in IG is unclear (193). Sorting signals may direct proteins whereas IG form from the 
TGN. Alternatively, proteins that are not ultimately retained for matured SG may be lost from IG 
following IG formation from the TGN. SG are then able to be secreted to the plasma membrane, 
where their contents are released to the extracellular environment. 
 LRO are an unique type of SG for immune cells including cytolytic lymphocytes, antigen 
presenting cells, mast cells, and neutrophils (194). LRO are different from conventional SG in 
terms of biogenesis. The biogenesis of LRO involves a constitutive secretion step from the TGN 
to the plasma membrane. From the plasma membrane, immature LRO are recycled from the 
plasma membrane to early endosomes and eventually to multi-vesicular bodies (MVB). Unlike 
conventional lysosomes, which primarily serve for the degradation of macromolecules, LRO 
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fuse with the plasma membrane, allowing for the dispersion of their contents into the localized 
extracellular space.  
The contents of LRO are similar to conventional lysosomes in their expression of 
hydrolases, cathepsins, and lysosome markers (e.g., Lamp-2) (194). Conventional lysosomes and 
LRO recruit similar proteins through shared lysosomal sorting signals (195). Some of these 
materials localize due to common dileucine (e.g., tyrosinase) or tyrosine-based signals on these 
sorted proteins but there are some non-common motifs. For instance, FasL, a common factor 
found within LRO generated from NK cells and cytolytic T cells to induce cell death of targeted 
cells, is instead localized to LRO due to polyproline-rich domains sandwiched between di-
arginine and di-lysine residues (196). The non-conventional localization is not only amino acid-
based; N-linked and O-linked glycosylation regulate LRO localization of TNF-α (197) and Syt I 
(198) respectively.  
Conventional SG and LRO traffic to the plasma membrane in some conserved ways. 
Upon stimulation, microtubule based processes promote the migration of SG to the plasma 
membrane (194). This initial phase of migration through microtubules is calcium-independent 
but it can depend on protein tyrosine kinases Syk and Fyn (199) or the coat-adaptor complex AP-
3 (200); Syk and Fyn may modulate microtubule nucleation, whereas the exact mechanism for 
AP-3 is a bit unclear. Rab GTPases, including Rab27a and Rab27b, connect with cell-type 
specific adaptors to transition SG from microtubules to the plasma membrane (201); this may 
occur by aiding in the tethering of SG to the plasma membrane to actin nucleation processes. 
The fusion of SG to the plasma membrane involves SNAREs and synaptotagmins (Syts) 
(194). SNAREs include vesicle SNAREs (v-SNAREs) and target membrane SNAREs (t-
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SNAREs). V-SNAREs include VAMP proteins. V-SNAREs are found on SG and they “zipper” 
into t-SNAREs at the plasma membrane to form trans-membrane complexes. T-SNAREs include 
syntaxins and SNAP-25 proteins, and the type of SNARE used for a given cell’s LRO exocytosis 
is cell-type specific. There are several different subsets of SG that possess different combinations 
of SNAREs (202); for example, one such combination commonly found in mast cells is VAMP-
8 (v-SNARE) and SNAP-23 (t-SNARE) (203). Syts are also involved in efficient fusion of SG to 
the plasma membrane (194). Syts have an N-terminal domain, an intermediate transmembrane 
domain, and cytosolic tails that include C2 domains. C2A and C2B domains act via calcium-
dependent and calcium-independent mechanisms to promote protein-protein interactions 
involved in membrane fusion. C2A enables Syt binding to phospholipids and syntaxins. C2B 
enables Syt binding to inositol polyphosphates and phosphoinositide polyphosphates ligands. 
Some common Syts are Syt I, Syt II, and Syt IV. Syt I potentiates LRO exocytosis in a calcium-
dependent manner whereas Syt II retards its exocytosis. Syt II also in effect negatively regulates 
MHC class II surface expression. Syt VII is described as a calcium regulatory protein for 
promoting LRO exocytosis. Following fusion, NSF allows the disassocation of the SNAREs for 
efficient exocytosis. 
There are numerous triggers for LRO exocytosis, but all are regulated through common 
mechanisms. For cytolytic lymphocytes, this would include calcium-driven pathways resulting 
from receptor engagement (194). For instance, TCR stimulation of cytolytic T cells with 
sufficient co-stimulation results in remobilization of their microtubule organizing centers 
(MTOC) and provides recruitment of their lytic granules towards a target cell. NK cells engage 
in strong LRO exocytosis upon antibody Fc-portion recognition by CD16. In a general sense for 
macrophages, LRO exocytosis is potentiated by stimuli that promote PKC and elevate lysosomal 
  
46 
pH (204). Such stimuli include zymosan, monensin, methylamine, and nigericin among others. 
ATP ligation of P2X7 provokes LRO exocytosis from myeloid cells (177), mast cells (205), and 
rat submandibular glands (206).  
LRO exocytosis is highly relevant in the field of immunology. Cytolytic responses are 
dependent upon LRO exocytosis for their function. Genetic diseases that display characteristic 
defects in LRO exocytosis include Chediak-Higashi syndrome, Hermansky-Pudlak syndrome 1, 
2, and 3, and Griscelli’s syndrome (207); individuals with these diseases display defects in cell-
mediated immune responses. Cathepsins released from LRO also have significant roles in 
promoting inflammation (208). Cathepsins are a family of proteases including cysteine proteases 
(cathepsins B, C, F, H, K, L1, L2, O, S, W, and Z), serine proteases (cathepsins A and G), and 
aspartyl proteases (cathepsins D and E). Released cathepsins have notable roles in cancer, 
especially in context of substrate cleavage in the extracellular matrix (e.g., laminin and 
fibronectin), which promotes tumor metastasis (209). Extracellular cathepsins also have roles in 
exacerbating other inflammatory diseases such as arthritis, Alzheimer’s, and stroke. 
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1.4  MICROVESICLES 
 
Many cell types release to the extracellular space small membraneous vesicles called 
microvesicles (MV) (210). MV comprise membrane vesicles that are typically sized between 
either 100-1000 nm or 30-150 nm in diameter. MV are also derived from a variety of cellular 
sources including from the plasma membrane or from internal compartments. The material that 
MV contain depends on the cell of origin, the cellular compartment that they originate, and the 
stimuli that promotes their generation. 
Among the best described MV are exosomes (210). Exosomes are 30-150 nm diameter in 
size lipid bilayer vesicles derived from MVB. Exosomes are thus among the types of MV that 
are derived from internal cellular sources. MVB are a class of organelles involved in endosome 
maturation that typically results in the transport of materials to lysosomes; however, some cell 
types can instead deliver these materials at times to the plasma membrane. Often, exosomes are 
generated constitutively from healthy cells; however, exosomes can be released by stimuli such 
as ATP, via P2X7 expressed on myeloid cells (211). Some of the cell types that are efficient 
producers of exosomes include B cells and dendritic cells, although the spectrum ranges to non-
immune cells such as platelets, tumor cells, and epithelial cells among several others. Markers of 
exosomes can vary depending on the cell type of origin, but exosomes can be identified with 
expression of ESCRT machinery proteins (e.g., Alix and TSG101) and tetraspanin proteins (e.g., 
CD81 and CD9) (212). Classical markers also include MHC class II and Lamp-2, although these 
are not uniquely expressed by exosomes. The materials within exosomes (i.e., their cargo) 
include several different types of proteins, lipids, DNA, and RNA (including microRNA). 
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 Exosomes originate from MVB (212), which consist of several intraluminal invaginations 
that eventually bud off to form intraluminal vesicles (ILV). These invaginations have been 
shown to contain non-specific cytoplasmic proteins (through passive engulfment), ESCRT 
(endosomal sorting complexes required for transport) machinery and related proteins, co-sorting 
lipids (often through GPI [glycosylphosphatidylinositol] anchors) and protein (often through 
tetraspanins or other chaperones). Since they are unique exosome markers, it is generally thought 
that Alix and TSG101 serve significant roles in preferentially loading materials into these ILV 
(213). GPI anchors have been implicated in part because exosomes are enriched with dense lipid-
raft microdomains and associated proteins such as tetraspanins (214). 
Exosomes are generated and eventually secreted from MVB that deviate away from 
fusing with lysosomes (212). MVB can be trafficked to fuse with lysosomes (for cargo 
degradation), recycle their material back to the cytosol, or fuse with the plasma membrane for 
exosome release.  How MVB engage in directed migration to the plasma membrane is not fully 
understood. Several analogies have been made to secretory lysosomes. Rab11 has been 
implicated in efficient exosome secretion (215); however, it is not fully understood whether it 
acts primarily in the exosome biogenesis phase to generate ILVs or to differentially present 
cargo, such as lipids, that better facilitate membrane fusion events. Once at the plasma 
membrane though, it is believed that MVB fuse with the plasma membrane, similar to secretory 
lysosomes, through the activities of SNARE proteins and synaptotagmins (216). At present time, 
the most convincing evidence for SNARE involvement is indirect; exosome secretion is sensitive 
to inhibition of calcium-driven pathways and it is known that SNARE proteins and 
synaptotagmin family membranes are modulated in part by calcium.  
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 There are a variety of non-exosome MV. Several of these MV are derived from the 
plasma membrane but some types are derived from intracellular compartments that are not MVB 
(210). MV derived from the plasma membrane include “plasma-membrane derived MV”, which 
are typically 100-1000 nm in diameter, and microparticles (aka ectosomes), which are typically 
30-150 nm in diameter. Smaller sized (30-150 nm in diameter) MV can also be shed from non-
MVB compartments such as endosomes that are released through the plasma membrane to the 
extracellular space. The phenotypic markers for different types of MV are mostly revealed 
according to their origin (e.g., plasma derived MV express plasma membrane markers); however, 
there are not uniquely identified markers that are only expressed by these MV as is the case with 
exosomes. 
 Plasma-membrane derived MV are often induced through stimuli that promote calcium-
driven pathways (210). Notable examples include P2X7 stimulation of myeloid cells and 
neutrophils (217), thrombin-receptor activation of platelets (218), and TLR4 ligation on dendritic 
cells (219). The lipid topology at the plasma membrane is primarily governed by membrane 
pumps called flippase (cytofacial-directed), floppase (exofacial-directed), and scramblase (bi-
directional), which are localized within lipid rafts domains in the plasma membrane (220). 
Heightened levels of intracellular calcium can result in the inhibition of flippase, which results in 
phosphatidylserine exposure on the outer-leaflet of the plasma membrane. Calcium promotes 
floppase and scramblase. While floppase and scramblase are not specific for particular lipids, 
they randomize lipid distribution and promote membrane asymmetry. It is speculated that this 
loss of membrane asymmetry is required for the shedding plasma membrane-derived MV (221). 
It is observed downstream of P2X7 stimulation (157). Additional calcium-dependent effectors 
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reported to be required for plasma membrane-derived MV include calpain (222), calcium-
dependent and potassium channels (for potassium efflux) (223).  
MV can interact with various cell types through a variety of mechanisms.  Due to the 
presence of adhesion molecules including tetraspanins, exosomes can directly bind to surface 
receptors found on several cells (212). For instance, exosomes expressing ICAM-1 can engage 
LFA-1 expressing CD8+ DC and activated T cells (224). Phosphatidylserine found on both 
exosomes and plasma-membrane derived MV is recognized by TIM1 and TIM4 found on Th2 
skewed T cells and phagocytes, respectively (225). Following this receptor engagement, the 
exact following mechanisms are a bit unclear.  Some suggest that MV may fuse with the plasma 
membrane of the recipient cell (219). There is also evidence of receptor mediated endocytosis, 
where MV are trafficked into endosomes or, in the case of larger MV, the uptake can be 
mediated by phagocytosis (212). Regardless of how the MV are handled after initial receptor 
interactions, MV materials can remain on the plasma membrane, enter into the cytosol, or reach 
late endosomes where they can affect the recipient cell’s behavior. 
 MV have several mechanisms to initiate immune responses (212). Most are related to the 
type of cargo that they carry or express outwardly from their membrane. These mechanisms can 
also either be direct (i.e., the MV can express materials that directly bind to target cells to initiate 
a response) or indirect (i.e., MV-contained cargo is further manipulated by some cell type that 
takes up the MV and in turn that cell initiates a target cells for a response). For instance, MV can 
outwardly express NK cell activating and inhibitory receptor ligands that can modulate NK cell 
function (226, 227). Myeloid cell activation (228), myeloid cell immunosuppression (229), and 
myeloid cell activation indifference (230) are also possible from various MV settings. Cellular 
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modulation may be imparted not only through outwardly expressed ligands or receptors but also 
possibly through other proteins, lipids, and nucleic acids including microRNAs (210). Various 
mechanisms for MV-induced immune cell modulation are detailed in Table 7. 
 
Table 7: MV-induced modulation of immune cells. Data are compiled from (210) unless indicated. 
MV Type and 
Source 
Inducer Cargo or Induced 
Modulating 
Factor 
Modulated Immune 
Cell 
Immunological 
Function 
Tumor-derived MV Constitutive Tumor-derived 
antigens 
Professional antigen 
presenting cells, 
antigen-specific T 
cells 
Adaptive immune 
responses against tumors 
 Constitutive CD95L and 
galectin-9 
T cells Apoptosis 
 Constitutive TGF-β Regulatory T cells Activation for 
immunosuppression 
 Constitutive TGF-β Cytolytic T cells and 
NK cells 
Impaired activation 
(decreased cytotoxicity) 
 Constitutive TGF-β Myeloid cells Generation of myeloid-
derived suppressor cells 
 Constitutive Phosphatidylserine Macrophages Immunosuppression via 
TGF-β secretion (231) 
 Heat shock 
stress response 
HSP70 NK cells NK cell activation 
 Heat shock 
stress response 
HSP70 Macrophages TNF-α secretion 
 Constitutive HSP72 Myeloid-derived 
suppressor cells 
Activation for 
immunosuppression (232) 
 Constitutive NKG2D NK cells NK cell inhibition 
 Constitutive Surface 
determinants, 
mRNA 
Monocytes Release of cytokines 
Dendritic cell-
derived MV 
Constitutive Peptides + MHC Antigen specific 
CD8+ or CD4+ T 
cells 
T cell activation 
 Heat shock 
stress response 
BAT3 NK cells NK cell activation 
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Table 7 (continued) 
 Constitutive UL16, MICA, 
MICB 
NK cells NK cell activation 
 Constitutive IL-15Rα NK cells NK cell activation 
 Constitutive TNF-α Epithelial cells Release of pro-
inflammatory factors 
(233) 
T cell derived MV Activation CD95L T cells Apoptosis (activation 
induced cell death) 
 Constitutive CD95L DC Apoptosis (234) 
 HIV infection Nef CD4+ T cells Apoptosis (235) 
Neutrophil derived 
MV 
Activation Phosphatidylserine Macrophages, DC Immunosuppression 
(reduced cytokines) 
Macrophage derived 
MV 
P2X7 
activation 
Phospholipids Macrophages Induction of pro-
inflammatory cytokines 
& co-stimulatory markers 
(236) 
 P2X7 
activation and 
mycobacterial 
infection 
MHC class II + 
mycobacterium 
peptide antigen 
epitope 
Antigen-specific 
CD4+ T cells 
T cell activation (237) 
Platelet-derived MV Thrombin-
induced 
activation 
CD154 B cells B cell activation 
 Thrombin-
induced 
activation 
CD154 Monocytes Release of cytokines 
 Thrombin-
induced 
activation 
Phosphatidylserine Phagocytes Induction of phagocytosis 
Reticulocyte-derived 
MV 
Maturation to 
erythrocytes 
Galectin-5 Macrophages Induction of phagocytosis 
(238) 
Fibroblast-derived 
MV 
Constitutive Membrane-bound 
TNF 
T cells Resistance to apoptosis 
by activation induced cell 
death 
Placenta-derived MV Constitutive NKG2D NK cells  Inhibition of NK cell 
activation 
Leishmania-derived 
MV 
“Infection-like 
stressors” 
Leishmania 
components 
Macrophages Release of IL-8 (239) 
 
The activities of MV-derived materials can promote either inflammation or 
immunosuppression (210). As mentioned, MV can promote immune cell activation or 
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inactivation, but some of these measures are achieved less directly. For instance, MV can 
regulate the survival of cells that they engage – either promoting survival or more often inducing 
apoptosis. FasL can be expressed on MV shed from dendritic cells, which could engage Fas on T 
cells to induce their apoptosis (240). Conversely, TNF-α on MV from fibroblasts of rheumatoid 
arthritis individuals interferes with activated T cell-induced apoptosis (241). 
 MV notably promote antigen-specific responses in both direct and indirect manners. For 
the direct response, MV have been shown to outwardly express MHC class I and II plus 
antigenic peptides to activate CD8+ and CD4+ T cells, respectively (242). In addition to MV 
alone activating T cells for an antigen-specific response, antigen presenting cells such as 
dendritic cells can capture MHC+peptide containing MV such that the MHC+peptide from the 
MV is transferred onto the plasma membrane of the recipient dendritic cell; these transferred 
intact MHC+peptides can then engage T cells for their activation (12). As MV can be derived 
from MVB (e.g., exosomes), which contain a large supply of MHC class II (212), MV can 
increase the recipient dendritic cells antigenic machinery for increased levels of MHC. 
Exosomes may also increase dendritic cell plasma membrane levels of co-stimulatory ligands to 
enhance antigen-specific responses from T cells (12). This process of receiving transferred 
MHC+peptides has been termed semi-direct presentation or “cross-dressing” (243). For the 
indirect response, dendritic cells can endocytose/phagocytose exosomes. In this manner, 
dendritic cells can process antigens from exosomes and place them within the dendritic cell’s 
endogenous MHC molecules to activate both CD8+ and CD4+ T cells through antigen cross-
presentation and antigen presentation, respectively (244). 
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 1.4.1  P2X7 as an instigator of shed microvesicles from myeloid cells 
 
 P2X7 has been reported to promote the shedding of plasma membrane derived MV and 
exosomes from myeloid cells (211, 217, 245). P2X7 directly binds to several components of 
actin-related machinery, which can result in topological and compositional changes of the 
plasma membrane (246). Though the mechanism has yet to be elucidated, P2X7-driven calcium 
pathways rapidly promote MV shedding from the plasma membrane (217). The mechanisms of 
MV induced shedding is unclear, given that P2X7 also promotes membrane blebbing, which 
some have suggested to be the source of shed MV (217), whereas others have refuted the notion 
(211, 247). 
P2X7-induced MV from TLR-primed myeloid cells contain mature IL-1β (211, 217, 245, 
247); however, the exact type, source, and content of these MV are disputed (248). It was 
originally reported that mature IL-1β is secreted within larger 1 μm diameter MV shed from the 
plasma membrane (217). The Dubyak group noted that larger sized plasma membrane MV, 
derived in response to P2X7 stimulation of TLR-primed macrophages, do not require NLRP3 
inflammasome activation, and likely do not contain IL-1β (211, 246). Instead, IL-1β is released 
in exosomes. For exosome exocytosis, NLRP3, but not caspase-1, is required. P2X7-induced MV 
are shed from both TLR-primed and non-primed cells (246, 249); however, the biological 
activities of these MV have not been evaluated. It is speculated though that P2X7-induced MV 
released from dendritic cells may have thrombotic activities (regardless of initial PAMP-
priming), as these MV contain membrane-bound tissue factor, a blood coagulant factor relevant 
for diseases such as atherosclerosis (250).  
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1.5 MISSION STATEMENT FOR THESIS WORK 
 
Inflammation is a complex biological process. Inflammation occurs not just through the 
recognition of foreign particles but it is also can occur in response to endogenously derived 
materials. In addition, inflammation is not strictly driven by soluble mediators. While significant 
progress has been made towards identifying several inflammatory mediators and their activating 
receptors, there are details left unresolved. Sterile inflammation is an emerging area in 
immunology and its interplay with chronic diseases such as atherosclerosis and arthritis is 
becoming increasingly important as disease incidence is rising. 
Damaged cells promote high local concentrations of ATP that can activate purinergic 
receptors for modulating inflammation. At higher concentrations, ATP promotes inflammation. 
From PAMP-activated or pro-inflammatory cytokine stimulated myeloid cells, ATP ligation of 
P2X7 engages NLRP3 inflammation for IL-1β and IL-18 release. IL-1β in particular has 
immense activities for inflammation from a vast diversity of cells (due to wide-spread expression 
of IL-1 receptor). Thus ATP, NLRP3, and P2X7 have several roles in promoting inflammatory 
diseases. P2X7 also has inflammatory roles outside of the NLRP3 inflammasome including the 
release of stimulatory lipids and the extracellular matrix-degrading cathepsins. 
Because of the relevance of P2X7 in inflammation, our lab has sought to further 
understand its mechanisms including potential inflammasome independent activities that might 
promote inflammation. It has been noted for several years that P2X7 promotes MV shedding; in 
most studies, it is suggested that MV shedding serves as a mechanism for IL-1β secretion from 
inflammasome-activated myeloid cells. At the same time, PAMP or pro-inflammatory cytokine 
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priming of myeloid cells is not a necessary component for efficient MV shedding, prompting me 
to hypothesize that MV, in the absence of cytokine cargo, have the capability to activate 
macrophages for pro-inflammatory cytokine release and upregulation of antigenic machinery 
(e.g., upregulation of surface expression of co-stimulatory markers and MHC class II). To test 
this hypothesis, I generated P2X7-induced MV and evaluated macrophage activation (as 
described above) paying close attention to uncovering activation signal transduction pathways 
and potential novel stimulatory materials from harvested MV. I also hypothesized that P2X7 
promotes the redistribution stimulatory materials, including cathepsins, through actin-dependent 
mechanisms, including possibly tying into how MV are shed from cells. To test this hypothesis, I 
characterized various MV populations and visually assessed global cytoskeletal alterations in 
response to P2X7 stimulation for the ability to stimulate macrophage activation and/or to 
remobilize stimulatory materials.  
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2.0  ACTIVATION OF MACROPHAGE BY P2X7-INDUCED MICROVESICLES FROM 
MYELOID CELLS IS MEDIATED BY PHOSPHOLIPIDS AND IS PARTIALLY 
DEPENDENT ON TLR4 
 
2.1 AUTHORS AND THEIR CONTRIBUTIONS 
 
This study was published in the Journal of Immunology in the September 15th issue, vol. 185, pp. 
3740-3749. Copyright permission to reprint the published study was obtained from the Journal 
of Immunology. Copyright 2010. The American Association of Immunologists, Inc. Some 
additional unpublished data was added for Figure 2-6, Figure 2-12, and Figure 2-13; there is an 
expanded Materials and Methods to explain the procedures for these experiments. L. Michael 
Thomas (Graduate Program in Immunology, University of Pittsburgh School of Medicine, 
Pittsburgh, PA) designed and performed the experiments and prepared the manuscript; his 
funding was supported by an NIH training grant T32CA082084. Russell D. Salter (Department 
of Immunology, University of Pittsburgh School of Medicine) designed the scope of the study 
and prepared and edited the manuscript; his funding was supported by NIH funds R01AI072083 
and P01CA073743. Dewayne H. Falkner received acknowledgement for his assistance in using 
the BD Biosciences FACSAria. Judong Lee and Sudesh Pawaria assisted in using a luminometer. 
Michelle E. Heid, Jessica Chu, Peter A. Keyel, and Chengqun Sun provided helpful discussions 
and cell culture assistance. Judson M. Englert provided helpful discussions and reagents. Laura 
E. Kropp provided critical reading of the manuscript. Lastly, various contributors provided 
reagents including murine bone marrow and cell lines, which are discussed and acknowledged 
within the Materials and Methods. 
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2.2 ABSTRACT 
 
ATP-mediated activation of the purinergic receptor P2X7 elicits morphological changes and pro-
inflammatory responses in macrophages. These changes include rapid shedding of microvesicles 
(MV), and the non-conventional secretion of cytokines, such as IL-1β and IL-18 following 
priming. In this study, I demonstrate the activation potential of P2X7-induced MV isolated from 
non-primed murine macrophages. Co-treatment of non-primed macrophages with ATP and 
calcium ionophore induced a rapid release of MV that were predominantly 0.5-1 µm in size. 
Exposure of primary murine bone marrow-derived macrophages to these MV resulted in co-
stimulatory ligand upregulation and TNF-α secretion. Cell homogenates or supernatants cleared 
of MV did not activate macrophages. MV-mediated activation was p38 MAPK and NF-κB-
dependent, and partially dependent on TLR4 activity, but was high-mobility group box 1 
independent. Biochemical fractionation of the MV demonstrated that the phospholipid fraction, 
not the protein fraction, mediated macrophage activation through a TLR4 dependent process. 
P2X7 activation is known to induce calcium independent phospholipase A2, calcium dependent 
phospholipase A2, and phospholipase D activities, but inhibition of these enzymes did not inhibit 
MV generation or shedding. However, blocking phospholipase D activity resulted in release of 
MV incapable of activating recipient macrophages. These data demonstrate a novel mechanism 
of macrophage activation resulting from exposure to MV from non-primed macrophages, and 
identifies phospholipids in these MV as the biologically active component. I suggest that 
phospholipids delivered by MV may be mediators of sterile inflammation in a number of 
diseases. 
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2.3 INTRODUCTION 
 
Released microvesicles (MV) mediate intercellular communication between multiple cell types, 
and affect cytokine secretion, inflammatory processes, and tumor progression (251). MV can be 
released from intracellular storage sites or shed directly from the cell surface. Release of plasma 
membrane-derived MV is typically regulated by intracellular Ca2+ mediated processes (245, 
252), or by protein kinase B (253) or protein kinase C (254, 255), and may involve engagement 
of a number of cell type specific receptors. Shedding typically involves a budding process, in 
which surface blebs selectively accumulate cellular constituents that are then packaged into MV. 
In contrast, MV derived from inside cells include secretory lysosomes (256-258), characterized 
by expression of lysosomal proteases, and exosomes (210, 251), which are stored in 
multivesicular bodies before being released by an active exocytic process.  
In macrophages and other myeloid cells, engagement of P2X7 purinergic receptors 
triggers the release of MV derived from both inside the cell (211, 257, 259) and from the plasma 
membrane (190, 217, 245, 252, 260). Secretion of IL-1β mediated by P2X7 was suggested to 
occur through the release of cell surface derived MV many years ago (217), but the content of 
these MV is still unclear. A more recent study suggests that the majority of IL-1β containing MV 
may be exosomes, as opposed to larger shedding vesicles (211). Members of the IL-1 family (IL-
1α, IL-1β, and IL-18) are stored as inactive precursors and their release after processing can be 
MV-mediated (211, 217, 245, 252), but this does not exclude other mechanisms of secretion 
(164, 261, 262). In any case, rapid secretion of mature IL-1β requires the Nod-like receptor 
family, pyrin domain containing 3 (NLRP3) inflammasome, which recruits caspase-1, allowing 
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cleavage of the pro-form of the cytokine to its bioactive form (34). Some exosomes from 
macrophages contain MHC class II and their exocytosis requires the NLRP3 inflammasome 
despite being caspase-1 independent (259). Less clear is the requirement for NLRP3 in 
controlling the P2X7-dependent release of secretory lysosomes (257) although their exocytosis 
from human monocytes is caspase-1 independent. 
Macrophages and other cells of the phagocytic lineage bind and internalize MV from 
various sources, with diverse effects on their function (210). Human monocytes binding tumor-
derived MV become activated, expressing increased HLA-DR, reactive oxygen species, and 
TNF-α through a CD44-dependent mechanism (263). In another study, human tumor-derived 
MV promoted differentiation of CD14+ myeloid cells, resulting in an HLA-DRlow phenotype. 
These cells also lacked CD80 and CD86 expression, and secreted TNF-β, TGF-β, and IL-6, with 
suppressive effects on T cell proliferation (264). Less is known about the potential immune 
stimulatory effects that macrophage-derived P2X7-induced MV may exert, which could involve 
IL-1β. 
To address this question, I induced MV shedding from non-primed mouse primary 
macrophages or cell lines through P2X7 activation, and tested purified MV for their ability to 
activate bone marrow derived macrophages (BMDM). I found that MV were able to activate 
BMDM in a partially TLR4-dependent manner and that the stimulatory component within the 
MV was found within phospholipid fractions. MV derived phospholipids activated macrophage 
through TLR4. Furthermore, MV induced activation is independent of observed loaded cargo 
such as IL-1β, TNF-α, and high-mobility group box 1 (HMGB1). 
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2.4 MATERIALS AND METHODS 
 
Cell culture and reagents - J774A.1 (TIB-67™; American Type Culture Collection, Manassas, 
VA), a murine macrophage-like cell line, and D2SC-1, a murine splenic derived immature 
dendritic cell (DC) line (a gift from L. Kane, University of Pittsburgh) were maintained in 
DMEM (Mediatech, Manassas, VA) supplemented with 10% FBS (Gemini Bio-Products; West 
Sacramento, CA), 1% additional L-glutamine (Lonza, Basel, Switzerland), and 1% penicillin and 
streptomycin (Lonza) (hereafter called DMEM complete). FSDC, a murine fetal skin derived 
immature DC line (a gift from Paula Ricciardi-Castagnoli, Singapore Immunology Network, 
Singapore), and THP-1, a human monocyte cell line (American Type Culture Collection), were 
maintained in IMDM (Lonza) supplemented with 10% FBS, 1% additional L-glutamine, and 1% 
penicillin and streptomycin (hereafter called IMDM complete). For experiments, THP-1 cells 
were treated with 20 µM PMA for 2 d to differentiate them to become more macrophage-like. 
RAW264.7 murine macrophage cell line transfected with NF-κB reporter plasmid pNF-κB-
MetLuc Vector (BD Clontech, Mountain View, CA) encoding inducible Metridia luciferase 
protein expression and secretion was a gift from R. Binder (University of Pittsburgh) and was 
maintained in DMEM complete supplemented with 500 µg/ml G418. Murine bone marrow 
derived macrophages (BMDM) were derived from C57BL/6 bone marrow (gift from L. 
Borghesi, University of Pittsburgh) and were differentiated with L-cell supplemented media as 
described previously (265). TLR4-/- mouse bone marrow (266) was a gift from R. O’Doherty 
(University of Pittsburgh). RAGE-/- mouse bone marrow (267) was a gift from T. Oury 
(University of Pittsburgh). All knock-out mouse bone marrow described were of the C57BL/6 
background.  
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Other reagents include AACOCF3 (Cayman Chemical, Ann Arbor, MI), ATP (Thermo 
Fisher Scientific; Waltham, MA), A23187 (Sigma-Aldrich, St. Louis, MO), A 438079 (Tocris 
Bioscience, Ellisville, MO), A 740003 (Tocris Bioscience), brefeldin A (Sigma-Aldrich), 
SB203580 (EMD Chemicals, Gibbstown, NJ), BATPA/AM (EMD Chemicals), bromoenol 
lactone (BEL; Enzo Life Sciences, Farmingdale, NY), bisindolylmaleimide I HCl (BIM; EMD 
Chemicals), Ki16425 (Cayman Chemical), MDL-12330A (Enzo Life Sciences), H-89 2HCl 
(EMD Chemicals), CAY10593 (Enzo Life Sciences), CAY10594 (Enzo Life Sciences), 
bromoenol lactone (BEL; Enzo Life Sciences), LPS from Escherichia coli 026:B6 (Sigma-
Aldrich), poly(I:C) (Sigma-Aldrich), synthetic monophosphoryl lipid A (MPLA; InvivoGen, San 
Diego, CA), Pam3CSK4 (InvivoGen), Limulus amebocyte lysate QCL-1000 (Lonza; used 
according to manufacturer’s protocol to assess endotoxin levels), and soluble RAGE (267) was a 
gift from T. Oury.  
Yo-Pro-1 uptake by cells - To measure P2X7-induced large pore formation, 1 x 106 
J774A.1 were treated with or without 100 µM A 740003 for 15 min before exposure to ATP and 
were then stained with 5 µM Yo-Pro-1 (Invitrogen, Carlsbad, CA) on ice. Cells were kept on ice 
until flow cytometric analysis using FITC settings, which are similar to manufacturer’s protocols 
for the dye. Flow cytometry was performed with a BD Biosciences LSR II and results were 
analyzed using FlowJo software (Tree Star, Inc., Ashland, OR). 
  MV generation and harvest - J774A.1 and other myeloid cell types were plated in T225 
cm2 flasks in duplicate per treatment. Where indicated cells were labeled with biotin using EZ-
Link Sulfo-NHS-SS-Biotin reagent (Thermo Scientific) for 30 min using the protocols supplied 
by the manufacturers. Cells were washed twice with PBS before adding inhibitors in serum-free 
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DMEM with no additions. Cells were then treated with 3 mM ATP and 10 µM A23187 in a final 
volume of 20 ml serum-free DMEM with no additions for 30 min at 37°C. Supernatant was 
harvested and centrifuged at 309.1 x g for 10 min at 4°C to remove cells and larger debris. MV 
were collected by centrifugation at 100,000 x g ultracentrifugation for 1 h at 4°C. The pellet 
material from the 100,000 x g ultracentrifugation was resuspended in 500 μl of PBS. MV were 
disrupted with 10 passes through a 27 gauge needle. Bradford assay (Thermo Fisher Scientific) 
was used to determine the protein concentration with each MV fraction according to 
manufacturer’s specifications. MV were either used immediately or stored at -20°C for later use. 
For biochemical fractionation of MV, proteins and lipids were separated through the 
Bligh and Dyer method of protein/lipid extraction with 1:2 of chloroform and methanol (268). 
The protein fraction was harvested at the biphasic interphase and reconstituted in PBS. The lipid 
fraction was either dried by speed vacuum centrifugation or further separated through a lipid 
polarity extraction technique (269). Lipid extract was passed through a silicic acid (Sigma-
Aldrich) column (1 mg silicic acid per 1 µl vol lipid extract). The pass through was collected as a 
sample. Bed layer volumes of chloroform, acetone, and then methanol were passed in sequential 
and separate fashion to elute off potential neutral lipids, glycolipids/sulpholipids, and 
phospholipids respectively. Samples were harvested from each elute, dried with speed vacuum 
centrifugation, and stored at -20°C. 
Generating cell homogenate - Ten million J774A.1 were washed twice in PBS, pelleted 
and resuspended in homogenization buffer (100 mM KCl, 25 mM NaCl, 2 mM MgSO4, 12 mM 
sodium-citrate, 10 mM glucose, 25 mM HEPES [N-2-hydroxyehylpiperazine-N’-2-
ethanesulfonic acid], 5 mM ATP, 0.35% BSA [pH 7.0]) supplemented with protease inhibitor 
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mixture (Sigma-Aldrich). Cells were lysed through four cycles of freeze-thawing and 
homogenized with 30 strokes within a tight-fitting dounce homogenizer. The homogenate was 
then ultracentrifugated at 100,000 x g for 1 h at 4°C. Resulting pellets were resuspended in 500 
µl PBS, and then homogenized with 10 passes through a 27 gauge needle. Samples were used 
immediately or stored at -20°C. 
Measuring activation of treated BMDM - BMDM (wild-type [WT] or knock-out derived 
where indicated) were harvested following differentiation and plated at 1 x 106 cells/ml in 
IMDM complete (unless described differently) in petri dishes. Inhibitors where indicated were 
applied for at least 30 min prior to exposure to MV or other compounds, and were maintained 
throughout the experiment. Supernatants were tested for TNF-α ELISA (eBioscience, San Diego, 
CA), IL-12p70 ELISA (eBioscience), or IL-23 ELISA (eBioscience) according to 
manufacturers’ protocols.  
For flow cytometry studies to determine viability and expression of activation markers, 
cells were blocked with 1.5% normal goat serum diluted in 0.1% BSA in PBS for 20 min then 
stained with allophycocyanin anti-CD80 (BD Biosciences, San Jose, CA), PE anti-CD83 (BD 
Biosciences), FITC anti-CD86 (BD Biosciences), allophycocyanin anti-CD86 (BD Biosciences), 
or PE anti-I-Ab (BD Biosciences) Abs for 40 min. Cells were stained with 1 µg/ml DAPI 
(Sigma-Aldrich) viability dye. Flow cytometry was performed with a BD Biosciences LSR II 
and results analyzed using FlowJo software. MFI and population percentages of FITC, PE, 
and/or allophycocyanin were calculated for DAPI negative cell populations (i.e., living cells), 
which were >85% of the total cell population for all results and treatments shown in this work. 
  
65 
RAW264.7 NF-κB reporter assay - RAW264.7 macrophages stably transfected with pNF-
κB-MetLuc Vector (BD Clontech) under G418 selection were plated as 1 x 106 cells/ml of 
DMEM complete for each treatment. Supernatant following treatment was centrifuged at 10,000 
x g for 10 min and was then stored at -20°C until used to assay for luciferase activity according 
to manufacturer’s protocol (BD Clontech). Luminescence readings from each sample were read 
with an Orion microplate luminometer (Berthold Detection Systems, Huntsville, AL) in 
duplicate and the average was taken using Simplicity version 2.1 software (Berthold Detection 
Systems). Average readings and SEM were calculated according to the ratio of fold change over 
non-treated cells at each respective time point of the time course. 
Western blotting - For whole-cell culture supernatant studies, 2 x 106 J774A.1 were 
plated in 1 ml of DMEM complete with or without 1 µg/ml of LPS for 4 h. Cells were washed 
once with serum-free DMEM with no additions, and treated with or without 3 mM ATP and 10 
µM A23187 for 30 min. Supernatants were centrifugated at 10,000 x g for 30 s and proteins were 
precipitated through a TCA/cholic acid procedure (265) before loading onto a 9% SDS-PAGE 
gel. SDS-PAGE and protein transfer to 0.45-µm polyvinylidene difluoride transfer membrane 
were performed as previously described (265).  
For Western blot analysis of whole-cell lysates for phosphorylated and total p38 
expression, 1 x 106 BMDM were plated with or without 1 µg/ml LPS or 25 µg protein 
equivalents/ml J774A.1 derived MV for 2, 10, 30, or 60 min. Following the time course, cells 
were washed once with PBS and then given 100 µl of 1% Triton X-100 lysis buffer in the 
presence of protease inhibition mixture (Sigma-Aldrich) and phosphatase inhibition (Sigma-
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Aldrich) for 15 min on ice. Lysates were collected and centrifuged at 10,000 x g for 10 min at 
4°C before addition of sample buffer and loading onto 11% SDS-PAGE gels. 
Western blot was performed using the SNAP-ID according to manufacturer’s procedures 
(Millipore, Billerica, MA). Abs for Western blotting included 0.5 µg/ml mouse anti-HMGB1 Ab 
(Abcam, Cambridge, MA), 0.1 µg/ml rabbit anti-phospho-p38 (Thr180/Try182 epitope) 
(Millipore), 1:2,000 diluted rabbit anti-p38 (Poly6224; BioLegend, San Diego, CA), 1/1666.7 
diluted HRP-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology; Santa Cruz, CA), and 
1/1666.7 diluted HRP-conjugated donkey anti-rabbit IgG (BioLegend). Signals were developed 
using Western blotting luminol reagent (Santa Cruz Biotechnology). Imaging was performed 
with KODAK Image Station 4000MM and its accompanying KODAK MI SE Software Informer 
(Carestream Molecular Imaging, New Haven, CT). In some instances, the membrane was 
stripped for Western blot reprobing with Restore Western blot stripping buffer (Thermo Fisher 
Scientific), according to manufacturer’s protocols. 
Biotinylation and Cy5 labeling of MV and uptake by BMDM - MV were labeled with 
biotin or Cy5 using EZ-Link Sulfo-NHS-SS-Biotin reagent (Thermo Scientific) or monoreactive 
Cy5 dye (GE Healthcare, Piscataway, NJ), respectively for 1 h in the 500 µl PBS reconstitution 
using the protocols supplied by the manufacturers. An additional wash with PBS followed by 
ultracentrifugation at 100,000 x g for 1 h at 4°C was used to remove non-conjugated biotin or 
Cy5 reagent. Sizing of MV was performed with BD Biosciences FACSAria with various sized 
YG beads (Polysciences, Warrington, PA). 
For assessing MV association with recipient BMDM, 1 x 106 BMDM were plated on 12-
mm poly(d-lysine)-coated coverslips in petri dishes. Cells were allowed to adhere for at least 4 h. 
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Indicated amounts of Cy5-labeled or biotinylated MV were given to the BMDM for varying 
times. Cells not associated to the coverslips were harvested and processed for FACS analysis of 
CD86 and biotin/Cy5 label. For some experiments, coverslip associated cells were further 
stained with 5-chloromethylfluorescein diacetate (CMFDA) as a cytoplasmic counterstain 
(Invitrogen) and LysoTracker Red to label lysosomal compartments (Invitrogen), according to 
manufacturer’s protocols. Coverslips were then washed, 2% paraformaldehyde (PFA) fixed, then 
permeabilized and blocked with 0.5% saponin, 1.5% normal goat serum, and 1% BSA in PBS 
for 30 min. Alexa647 conjugated streptavidin (Invitrogen) and FITC-anti-CD86 (BD 
Biosciences) were used at 1/100 dilution for 1 h to visualize biotin and CD86 expression 
respectively. After successive washes, the coverslips were stained for nuclei with 1 µg/ml DAPI 
and then mounted with gelvatol. Confocal microscopy images were taken with an Olympus 
Fluoview 1000 (Inverted) and accompanying software (Olympus America Inc., Center Valley, 
PA). Laser excitations and emissions were performed sequentially for DAPI, Cy5/Alexa647, 
LysoTracker Red, and FITC/CMFDA and background noise was minimized. Differential 
interference contrast microscopy images for each field of view were also taken. Final images 
were then directly exported to Adobe Photoshop CS2 (Adobe, San Jose, CA). 
Liposomes – Artificial liposomes mixtures were generated as follows: Control liposomes 
(Con. Lipo) with 20% cholesterol (chol.) (Sigma-Aldrich), 10% phosphatidylserine (PS) (Cat.# 
840032C; Avanti Polar Lipids, Alabaster, AL), 35% phosphatidylcholine (PC) (Cat.# 840051C; 
Avanti Polar Lipids), and 35% phosphatidyletholamine (PE) (Cat.# 84118C; Avanti Polar 
Lipids); lysophosphatidylcholine (LPC)-loaded liposomes (LPC-Lipo) with 20% chol., 10% PS, 
22.5% PC, 22.5% PE, and 25% LPC (Cat.# 855476P; Avanti Polar Lipids); phosphatidic acid 
(PA)-loaded liposomes with 20% chol., 10% PS, 22.5% PC, 22.5% PE, and 25% PA (Cat.# 
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P3591; Sigma-Aldrich); 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)-loaded 
liposomes with 20% chol., 10% PS, 22.5% PC, 22.5% PE, and 25% POPC (Cat.# 850457P; 
Avanti Polar Lipids). Lipid formulations were prepared in chloroform, dried under nitrogen gas, 
then resuspended in PBS for 4 mg lipids/ml. Liposomes were kept at 37°C for 1 h then 
freeze/thawed five times. Lipososomes were stored at -80°C until used in applications. 
Determining the amount of protein within non-surface-derived MV and depleting surface-
derived MV – 500 µl streptavidin-coated magnetic 1 µM sized beads (Invitrogen) were washed 
and handled according to manufacturer’s protocol. Harvested MV from biotinylated J774A.1 
were quantified for their protein content by Bradford assay. For each separation, 75 µg protein 
equivalents were added to the washed beads within 100 µl PBS for 30 min. The negative fraction 
following application of a magnet was removed and quantified for its protein content by 
Bradford assay. 
Statistical analyses - Unpaired Student’s t test or one-way ANOVA analyses were 
performed using Graph Pad Prism (GraphPad Software, La Jolla, CA). Values of p were 
calculated where indicated, and for all statistical studies p<0.05 was considered as significant.  
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2.5  RESULTS 
 
2.5.1  P2X7-induced MV drive de novo TNF-α secretion and upregulate co-stimulatory ligand 
surface expression in macrophages 
 
J774A.1, a murine macrophage cell line that expresses P2X7 (249) was used to produce MV in 
response to ATP plus calcium ionophore. Whereas 3 mM ATP alone was sufficient for 
generating detectable levels of MV, the addition of 10 μM calcium ionophore A23187 produced 
greater quantities of MV as judged by Bradford assay of collected material (data not shown). 
A23187 alone did not induce MV release. These results suggested that MV release is P2X7 
dependent, and enhanced by A23187. To test this, J774A.1 cells were treated with P2X7 inhibitor 
A 740003 or A 438079 prior to generating MV. To confirm that the inhibitors blocked P2X7 
activity, I measured Yo-Pro-1 uptake, a common measure of P2X7-induced pore formation (270). 
Whereas treatment with 3 mM ATP alone was sufficient to induce Yo-Pro-1 uptake, co-
treatment with 10 µM A23187 and 3 mM ATP greatly increased the signal (Figure 2-1A). 
Furthermore, Yo-Pro-1 uptake by cells exposed either to 3 mM ATP or to 3 mM ATP plus 10 
µM A23187 was blocked by pretreatment with A 740003 inhibitor. Both P2X7 inhibitors either 
completely abolished or significantly decreased MV shedding, as determined through protein 
concentration determination by Bradford assay (Figure 2-1B). These results demonstrate that MV 
shedding induced by ATP is dependent on P2X7 activity, as others have shown (211, 245, 252, 
259).  
MV isolated from culture supernatants by ultracentrifugation were analyzed by flow 
cytometry and range in size from 0.5 to 1 µm (Figure 2-2). These sizes were confirmed by 
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electron microscopy (data not shown). The 0.5 to 1 µm size is consistent with plasma membrane 
derived MV and not exosomes or apoptotic blebs (246). 
 
 
Figure 2-1: P2X7 induces MV shedding.  
A, J774A.1 were treated with or without 100 µM A 740003 and then given further indicated treatment for 30 min. 
Cells were analyzed for Yo-Pro-1 association by flow cytometry. The histogram indicates median fluorescent 
intensities means ± SEM of n = 3. Statistical comparisons are made to non-treated J774A.1, except where indicated 
with the inclusion bars. B, J774A.1 were treated with or without 100 µM A 740003 or 10 µM A 438079 for 15 min 
prior to MV generation. Harvested MV were quantified for their protein concentration by Bradford assay. The 
histogram indicates protein concentration means ± SEM of n = 3. Statistical comparisons are made to MV harvested 
from non-drug-treated J774A.1. ND indicates that the protein concentration was lower than the lower limit of 
detection, which is marked with the dotted line. **p<0.01; ***p<0.001; n.s., not significant. 
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Figure 2-2: MV range in size between 0.5-1 µm.  
Under “Size Determination”, Cy5-labeled MV (blue) were analyzed for forward scatter (FSC-A) via FACS. 0.2 
(black), 0.5 (green), and 1 µm (red) sized YG fluorescent beads were included to estimate MV size under the size 
determination diagram. Mean forward scatter for each are indicated in the adjacent table. MV and bead signals were 
gated based on fluorescence and size. For “FITC Expression” histograms, green curve indicates a negative control 
population whereas the red curve indicates the identified population mentioned. Forward scatter is representative of 
3 different Cy5-labeled MV preparations. 
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To study the effect of MV on macrophage function, purified MV were incubated with 
BMDM for 18 h and supernatants were analyzed by ELISA for TNF-α. MV induced TNF-α 
secretion in a dose-dependent fashion, with the highest dose of MV (75 µg protein equivalents) 
stimulating more TNF-α secretion than LPS (Figure 2-3A and B). Importantly, an equivalent 
amount of cell homogenate from J774A.1 cells did not induce TNF-α secretion at significant 
levels. MV-depleted ultracentrifugation supernatant from MV preparations also did not induce 
TNF-α at significant levels. 
Next I examined the effects of MV on co-stimulatory ligand CD86 expression. CD86 
surface expression was upregulated in a dose-dependent fashion following exposure to MV 
(Figure 2-3C). Importantly, cell homogenates and MV-depleted supernatants did not increase 
CD86 levels compared to non-treated control BMDM (Figure 2-3C). To exclude the possibility 
that CD86 upregulation reflected a passive uptake of the protein from MV, BMDM were pre-
treated with brefeldin A (BFA). This significantly diminished CD86 upregulation induced by 
MV, suggesting that the observed increase of CD86 was due to transport of endogenously 
synthesized CD86 to the cell surface (Figure 2-3D).  Similar results of CD86 upregulation were 
also observed for BMDM treated with MV generated from BMDM, human monocyte cell line 
THP-1, the murine splenic dendritic cell line D2SC-1, and the murine fetal skin derived dendritic 
cell line FSDC (Figure 2-3E). 
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Figure 2-3: P2X7-induced MV promote TNF-α secretion and upregulation of CD86.  
A, BMDM were treated with 1 µg/ml LPS or 75 µg protein equivalents of MV, or were left non-treated for 18 h. 
The histogram indicates TNF-α means ± SEM of n = 3. The statistical comparison is made to non-treated BMDM. 
B, BMDM were treated with 0.25, 2.5, or 25 µg protein equivalents of MV; 25 µg protein equivalents of cell 
homogenate; the volume equivalent of 25 µg protein equivalent from ultracentrifugate following generation of MV 
pellets; or 1 µg/ml LPS; or were left non-treated for 18 h. The histogram indicates TNF-α means ± SEM of n = 3. 
The statistical comparison is made to non-treated BMDM. C, BMDM from B were analyzed for surface CD86 MFI 
means ± SEM of n = 3. The statistical comparison is made to non-treated BMDM. D, BMDM were treated with 1 
µg/ml LPS or 25 µg protein equivalents of MV, or were left non-treated with or without 10 µg/ml brefeldin A for 18 
h. The histogram indicates surface CD86 MFI means ± SEM of n = 3. E, MV harvested from PMA-differentiated 
THP-1, FSDC, BMDM, or D2SC-1 (25 µg protein equivalents) were incubated with 1 x 106 BMDM for 18 h. CD86 
expression induced by MV from each indicated cell (solid line) is compared with CD86 expression induced by an 
equivalent amount of J774A.1 MV (dotted line) and with non-treated BMDM (black filled). Each flow cytometry 
histogram is representative of n = 2. *p<0.05; **p<0.01; ***p<0.001. BFA, brefeldin A; Hom., homogenate; n.s., 
not significant; NT, non-treated; Sup., supernatant. 
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Exposure of cells to MV also upregulated the expression of other markers of activation, 
specifically CD80, CD83, and I-Ab (Figure 2-4A). I next characterized the potential for MV to 
elicit the production of cytokines known to have roles in polarizing Th1 and Th17 responses. In 
contrast to TNF-α, however, no increase in IL-12p70 or IL-23 was observed following MV 
treatment (Figure 2-4B). These data demonstrate that P2X7-induced MV can activate 
macrophages through a stimulatory activity that is not present in equivalent amounts of 
homogenates of the cells from which the MV derive.  
 
     
Figure 2-4: MV upregulate multiple activation markers, but do not induce IL-12p70 or IL-23 secretion.  
A, BMDM were treated with 1 µg/ml LPS (solid line) or 25 µg protein equivalents of MV (dotted line), or were left 
non-treated (gray filled) for 18 h. Cells were analyzed for CD80, CD83, and CD86 or I-Ab surface expression. 
Isotype control is shown filled in black. Data are representative of multiple experiments. B, BMDM were treated 
with 1 µg/ml LPS or 25 µg protein equivalents of MV, or were left non-treated for 18 h. The histogram indicates IL-
12p70 or IL-23 means ± SEM of n = 3. The statistical comparison is made to non-treated BMDM. The dotted line 
indicates the bottom limit of detection for each respective ELISA. ***p<0.001; n.s., not significant; NT, non-treated. 
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2.5.2  MV bind to BMDM and are largely retained at the plasma membrane before inducing 
TNF-α secretion and CD86 upregulation 
 
To examine their interaction with BMDM, MV were first biotinylated. After washing and 
repelleting, biotinylated MV were incubated for varying times with BMDM. Alexa647-labeled 
streptavidin was then added to visualize the interaction. When added to BMDM, MV bound to 
the cell surface within 30 min, with little increase seen after that (Figure 2-5A, 2-5B). In contrast, 
CD86 expression increased steadily, reaching an observed maximum at 18 h. Similar kinetics 
were seen with TNF-α secretion (Figure 2-5C). Confocal microscopy demonstrated that CD86 
and MV were not colocalized at the cell surface. By 4 h some MV congregated within 
lysosomes, whereas most of the MV remained at the plasma membrane (Figure 2-5D). 
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Figure 2-5: Differential kinetics of TNF-α and CD86 expression relative to surface binding of MV to BMDM.  
A, 5 x 105 BMDM were left untreated or treated with 75 µg protein equivalents of MV for 4, 10, or 18 h. The 
histogram indicates means ± SEM of TNF-α released into the supernatant of n = 3. B, BMDM were left untreated or 
exposed to 25 µg biotinylated MV for 4, 10, or 18 h. Surface CD86 and biotin MFI changes over time are shown. 
The histogram indicates MFI means ± SEM of n = 3. C, BMDM were incubated with 25 µg biotinylated MV for 0.5 
or 18 h. Cells were analyzed for nucleus (blue), CD86 (green), and biotin (red), and expression by confocal 
microscopy. Differential interference contrast image is also shown. Overlay of three fluorescent signals and 
differential interference contrast is shown in the far right image on the panel. Images are representative of 10 
random fields of view from two separate experiments. Scale bar, 10 µm. *p<0.05. DIC, differential interference 
contrast; NT, non-treated. D, Cytosolic dye CMFDA label (green) and lysosomal dye LysoTrackerRed (red) labeled 
BMDM were incubated with 50 µg of biotinylated MV for 4 h. Cell-associated biotin is in (blue). Overlay of three 
fluorescent signals with a DIC image is shown in the panel on the far right. Bar = 10 µm. 
D 
TNF-α [pg/ml] 
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2.5.3  MV-induced activation is partially TLR4-dependent and is independent of MyD88  
 
Damaged cells can release a number of mediators (such as damage associated molecular 
patterns) that can activate immune cells through TLR engagement. In particular, HMGB1 (38), 
hyaluronic acid (271) and S100A8/S100A9 complex (272), among others, bind TLR4 for cellular 
activation. To examine whether MV also act through a TLR4-dependent pathway, BMDM were 
generated from WT and TLR4-/- mice. TNF-α induction by MV was reduced in TLR4-/- BMDM, 
which produced 35-81% less TNF-α than WT BMDM; however, the decrease was not 
statistically significant (Figure 2-6A). TLR4-/- BMDM were significantly impaired in CD86 
upregulation when treated with MV with WT BMDM (Figure 2-6B). In contrast, CD86 
upregulation induced by the TLR4 agonist monophosphoryl lipid A (MPLA) was completely 
dependent on TLR4, whereas poly(I:C) stimulation was TLR4-independent, as expected. These 
data suggest that MV contain a stimulatory component that activates BMDM via TLR4, but that 
additional means of activation that are not dependent on TLR4 may also be present. 
 MyD88 and TRIF are the primary adaptor proteins downstream of TLR signaling. TLR4 
pathways initiate both MyD88 and TRIF pathways. Thus macrophages derived from MyD88-/- 
mice were treated with MV, Pam3CSK4, or poly(I:C). Pam3CSK4, a TLR2 and MyD88-
dependent agonist, was able to upregulate the secretion of TNF-α (Figure 2-7A) and IL-6 (Figure 
2-7B) from WT, but not MyD88-/- BMDM, and failed to upregulate CD86 on either WT or 
MyD88-/- BMDM. Poly(I:C), a TLR3 and MyD88-independent agonist, and MV were able to 
upregulate TNF-α (Figure 2-7A), IL-6 (Figure 2-7B), and CD86 (Figure 2-7C) from WT and 
MyD88-/- BMDM; MyD88-/- BMDM express more basal CD86 than WT. These results would 
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suggest that MV-induced activation shares similar signal transduction pathways to poly(I:C), 
including acting through MyD88-independent mechanisms. 
 
 
                   
 
Figure 2-6: Partial TLR4 dependence of MV-induced BMDM activation.  
A, 5 x 105 WT or TLR4-/- BMDM were treated with 10 µg/ml poly(I:C), 5 µg/ml MPLA, or 75 µg protein 
equivalents of MV, or were left untreated for 18 h. The histogram indicates TNF-α means ± SEM of n = 3. B, WT or 
TLR4-/- BMDM were treated with 10 µg/ml poly(I:C), 5 µg/ml MPLA, or 25 µg protein equivalents of MV, or were 
left untreated for 18 h. Surface CD86 MFI means ± SEM of n = 3 are shown. ***p<0.001. n.s., not significant; NT, 
non-treated. 
B 
TNF-α [pg/ml] 
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Figure 2-7: MyD88 is not required for TNF-α, IL-6, or CD86 production in response to MV. 
BMDM were non-treated or treated with 10 µg/ml Pam3CSK4, 10 µg/ml poly(I:C), or 25 µg/ml MV for 18 h. 
Supernatants were evaluated for TNF-α (A) or IL-6 (B). The histogram indicates TNF-α or IL-6 means ± SEM of n 
= 3. The dotted line indicates the lower limit of detection for the assay. C, BMDM were evaluated for surface 
expression of CD86. Surface CD86 MFI means ± SEM of n = 3 are shown. **p<0.01; ***p<0.001. n.s., not 
significant; N.D., none detected; NT, non-treated; KO, MyD88-/-. Dashed line indicates the lower limit of detection 
for the assay. 
B 
C 
A 
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2.5.4  MV-induced activation is independent of HMGB1 and RAGE 
 
Given the partial TLR4 response from macrophage derived MV, HMGB1 could mediate MV-
induced activation. HMGB1 can activate monocytes and macrophages (273) through TLR2, 
TLR4, and RAGE (38). Also, HMGB1 can be released from activated monocytes and 
macrophage (274) or necrotic cells (275) and is expressed within secretory lysosomes that are 
released from monocytes following stimulation with ATP (154). Furthermore, unlike hyaluronic 
acid and S100A8/S100A9 complexes, which require prior priming through agents like IFN-γ or 
LPS for their expression (276-278), HMGB1 can be passively released through cellular damage 
without the need for priming (279). Indeed, HMGB1 was detected in the supernatants of 
ATP/A23187-treated J774A.1 cells and also in purified MV, but not in supernatants from 
untreated or LPS-treated cells (Figure 2-8A, B). LPS treatment before exposure to ATP/A23187 
increased secretion of HMGB1 (Figure 2-8A). 
In addition to TLR4, HMGB1 can act through RAGE. To assess whether MV-induced 
activation requires RAGE, BMDM from RAGE-deficient mice were generated. I determined that 
there were no significant differences in TNF-α release between MV-treated WT and RAGE-/- 
BMDM (Figure 2-8C) following stimulation with either LPS or MV. To determine more broadly 
whether HMGB1 is a stimulatory agent in MV-induced activation, BMDM were incubated with 
MV in the presence of soluble RAGE, which should block the binding of HMGB1 to all of its 
potential receptors. Soluble RAGE did not diminish MV-mediated TNF-α release (Figure 2-8C). 
Additionally, there were no significant differences in CD86 upregulation between WT and 
RAGE-/- BMDM, demonstrating that RAGE does not participate in MV-induced activation 
(Figure 2-8D). Furthermore, soluble RAGE did not block MV-induced CD86 upregulation even 
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at high concentrations, suggesting that HMGB1 does not mediate the effects of MV (Figure 2-
8E). 
 
Figure 2-8: MV contain HMGB1, but CD86 upregulation is HMGB1 independent.  
A, J774A.1 cells were primed with 1 µg/ml LPS or left unprimed for 4 h, and were treated with 3 mM ATP and 10 
µM A23187 for 30 min or untreated. Supernatants were analyzed for HMGB1 by Western blot. Data are 
representative of repeat experiments. B, 25 µg protein equivalents from a reference lysate or 25 µg protein 
equivalents of MV were compared for HMGB1 expression via Western blot. C, 5 x 105 WT or RAGE-/- BMDM 
were treated with 1 µg/ml LPS or 75 µg protein equivalents of MV with or without 30-min preincubation with 1 
µg/ml soluble RAGE, or were left non-treated for 18 h. The histogram shows TNF-α means ± SEM of n = 3. 
Statistical comparison is to WT BMDM treated with 25 µg MV. D, WT or RAGE-/- BMDM were treated with 1 
µg/ml LPS or 25 µg protein equivalents of MV, or were untreated for 18 h. The histogram indicates surface CD86 
MFI means ± SEM of n = 3. E, 25 µg protein equivalents of MV were pretreated with 100, 500, or 1000 ng/ml 
soluble RAGE for 30 min prior to addition to BMDM. NT, LPS, and 25 µg protein equivalents of MV were 
included. Surface CD86 MFI ± SEM of n = 3 are shown. The statistical comparison is to 25 µg MV-alone. *p<0.05; 
**p<0.01; ***p<0.001. n.s., not significant; NT, non-treated. 
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2.5.5  Characterizing MV-induced signaling pathways 
 
NF-κB and p38 MAPK activation pathways are commonly initiated through TLR engagement 
(27). Indeed, in BMDM, p38 phosphorylation was induced within minutes of exposure to MV, 
and then declined over time, similar to the response to LPS (Figure 2-9A). To address whether 
p38 MAPK blockade was sufficient to diminish MV mediated CD86 upregulation, BMDM were 
pre-incubated with a titration of the p38 inhibitor SB203580 before exposure to MV. In the 
presence of the drug, CD86 upregulation was strongly inhibited, supporting a role for p38 
MAPK in MV-mediated activation (Figure 2-9B). In contrast, LPS-induced CD86 expression 
actually increased in the presence of 1 and 10 µM inhibitor, with significant inhibition only 
observed at 50 µM, suggesting differences in the two signaling pathways (data not shown).   
I also tested whether MV were able to activate NF-κB, using a RAW264.7 reporter cell 
line (Figure 2-9C). The kinetics of the response induced by MV were similar to LPS, with 
activation evident after 4 and 18 h but not after 1 h. The magnitude of the response was less with 
MV than with LPS however, and declined by 18 h post-treatment. 
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Figure 2-9: MV activate p38 MAPK and NF-κB pathways.  
A, BMDM were left non-treated or were treated with 1 µg/ml LPS or 25 µg protein equivalents of MV for 2, 10, 30, 
or 60 min. Expression of phosphorylated p38 (p-p38) and total p38 (p38) was evaluated via Western blot. Data are 
representative of repeat experiments. B, BMDM were treated with 25 µg protein equivalents of MV with or without 
additional treatment of the phosphorylated p38 inhibitor SB203580 at either 1, 10, or 50 µM, or were left non-
treated for 18 h. The histogram indicates surface CD86 MFI means ± SEM of n = 3. The statistical comparison is 
made to 25 µg MV-alone–treated BMDM. C, RAW264.7 macrophages expressing luciferase under control of a NF-
κB promoter were treated with 1 µg/ml LPS or 2.5, 25, or 75 µg protein equivalents of MV for 1, 4, or 18 h. The 
fold change over non-treated cells is shown. The histogram indicates fold change means ± SEM of n = 3. The 
statistical comparison is made to the 1-h fold change value for each respective treatment. *p<0.05; **p<0.01; ***p< 
0.001; n.s., not significant; NT, non-treated. 
 
Protein kinase A (PKA) and protein kinase C (PKC) can both influence p38 and NF-κB 
in immune cells (27). PKC is modulated by intracellular calcium and/or diacylglycerol (55) 
whereas PKA is cAMP-controlled (54). To indirectly inhibit calcium sensitive isoforms of PKC, 
BMDM were treated with 30 µM BAPTA/AM to chelate intracellular calcium. Treatment did 
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not impair CD86 upregulation in response to MV or LPS (Figure 2-10A). Direct PKC inhibition, 
through use of 50 µM Bisindolylmaleimide I HCl (BIM), significantly decreased MV mediated 
CD86 upregulation (Figure 2-10B). In contrast, PKC inhibition enhanced LPS-mediated CD86 
upregulation. MDL-12330A was used to inhibit adenylate cyclase, which generates cAMP, 
resulting in a significant decrease in expression from MV, but not LPS, treated BMDM (Figure 
2-10C). Inhibition of PKA using 10 µM H-89 HCl also resulted in a significant decrease (Figure 
2-10D). These results support the idea that MV mediated activation requires PKA and PKC 
pathways, which is in contrast to the activation response induced by LPS.  
 
Figure 2-10: CD86 upregulation is cAMP, PKA, and PKC dependent, but Ca2+ independent.  
BMDM were left non-treated or treated with 1 µg/ml LPS or 25 µg MV with or without additional treatment of 10 
µM intracellular calcium chelator BAPTA/AM in A, 50 µM PKC inhibitor BIM in B, 10 µM adenylate cyclase 
inhibitor MDL-12330A in C, or 10 µM PKA inhibitor H-89 in D, for 18 h. Surface CD86 MFI ± SEM of n = 3 are 
shown. *p<0.05; **p<0.01; ***p<0.001. n.s., not significant; NT, non-treated. 
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2.5.6  The stimulatory activity from MV consists of one or more phospholipids 
 
To characterize the stimulatory agent(s) from MV, biochemical fractionation was used to 
separate lipids and proteins as described in Materials and Methods. Only the lipid fraction, but 
not the protein fraction, significantly activated BMDM, as measured by CD86 upregulation 
(Figure 2-11A). Lipids were further separated according to polarity. The phospholipid fraction 
provided significant upregulation of CD86 as compared to non-treated control. Only minimal 
activity was recovered from the flow-through, the neutral lipids fraction, or the 
glycolipid/sulpholipid fraction (Figure 2-11B). Mock elution from the column for a phospholipid 
fraction also did not recover any stimulatory material, demonstrating that the columns 
themselves did not contain contaminants that could activate BMDM.  
To test the TLR4 dependence of the phospholipid-containing fraction of MV, TLR4-/- or 
WT BMDM were given equal amounts of phospholipid fraction. In agreement with the partial 
TLR4 dependence for MV mediated activation described in Figure 2-6, the phospholipid fraction 
from MV had a significant difference in activation between the TLR4-/- and WT BMDM. 
Additionally, phospholipid fraction activation of TLR4-/- BMDM did not significantly differ 
from non-treated BMDM. This at least partially confirms that the TLR4 agonist from the MV 
came in the form of a phospholipid.   
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Figure 2-11: The phospholipid but not protein fraction from MV activates BMDM.  
A, Lipids and protein were isolated from 25 µg protein equivalents of MV and applied to BMDM for 18 h. No 
treatment and non-fractionated 25 µg protein equivalents of MV were included as controls. Surface CD86 MFI 
means ± SEM of n = 3 are shown. The statistical comparison is made to non-treated BMDM. B, Total lipid fractions 
from 225 µg protein equivalents of MV were isolated and were further fractionated as follows: column flow-
through, neutral lipids, glycolipids and sulpholipids, and phospholipids. Mock methanol elution of the column 
without any loaded material was included as a control. Fractions were incubated with BMDM for 18 h. Non-treated 
BMDM and incubation of the phospholipid fraction with TLR4-/- BMDM are also shown. Surface CD86 MFI means 
± SEM of n = 3 are shown. The statistical comparison is made to non-treated BMDM, except where indicated. 
*p<0.05; **p<0.01; ***p<0.001. FT, column flow-through; GL/SL, glycolipid and sulpholipid; NL, neutral lipid; 
n.s., not significant; NT, non-treated; PL, phospholipid. 
 
2.5.7  Lipid-modifying enzymes play a role in generating MV capable of activating BMDM 
 
The above results led me to hypothesize that purinergic receptor activation in MV producer cells 
exposed to ATP might generate stimulatory phospholipids that are packaged into MV. This could 
explain why MV activated BMDM more strongly than the equivalent amount of cell lysate, as 
described earlier. P2X7 activation, which is required for generating ATP-induced MV, can 
activate lipid-modifying enzymes such as calcium-independent phospholipase A2 (iPLA2) (155), 
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phospholipase D (PLD) (156), and calcium dependent phospholipase A2 (cPLA2) (155). To test 
whether PLD, iPLA2, or cPLA2 were required to generate stimulatory MV, producer cells were 
treated with either PLD inhibitors (50 µM CAY10593 for PLD1 and 50 µM CAY10594 for 
PLD2), iPLA2 inhibitor (10 µM bromoenol lactone [BEL]), or cPLA2 inhibitor (10 µM 
AACOCF3) prior to, and during, ATP/A23187-elicited MV induction. When equivalent amounts 
of these MV populations were applied to recipient BMDM, MV from PLD1- and PLD2-inhibited 
J774A.1 producer cells were unable to stimulate CD86 upregulation (Figure 2-12A). PLD 
inhibitors did not directly impact MV-mediated CD86 upregulation of recipient BMDM, as 
inclusion of MV from PLD1- and PLD2-inhibited J774A.1 with MV from mock treated J774A.1 
did not result in any significant differences from BMDM treatment with MV from mock treated 
J774A.1 (Figure 2-12B). Furthermore, MV from mock or from PLD1- or PLD2-inhibited cells 
did not decrease phosphatidic acid levels of treated J774A.1, relative to non-treated J774A.1 
(data not shown). By contrast, inhibition of iPLA2 (Figure 2-12C) or cPLA2 (Figure 2-12D) in 
MV producer cells did not decrease the stimulatory capacity of the MV generated, which were at 
least as potent as those from producer cells not pretreated with inhibitors. It should be noted that 
MV were obtained from producer cells treated with these inhibitors in amounts approximately 
equal to mock-treated producer cells, suggesting that the stimulatory phospholipid is not required 
for MV structural integrity or secretion from cells. Furthermore, PLD1, PLD2, iPLA2, and 
cPLA2 inhibitors were not toxic at the concentrations used since cell viability was >85% in all 
cases (data not shown). 
I lastly considered whether lysophosphatidic acid (LPA) might be a potential stimulatory 
phospholipid from the MV. LPA is a product of P2X7 activity (280) and it can activate 
macrophages to promote cytokine production (281) and cAMP synthesis (282). Pretreatment of 
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BMDM with Ki16425, an inhibitor selective for LPA receptors LPAR1 and LPAR3, did not 
diminish CD86 upregulation by MV (Figure 2-12E). This suggests that LPA does not participate 
in MV-induced activation of macrophages, although it does not exclude the possibility that LPA 
could mediate effects through other receptors. 
 
Figure 2-12: Activities of lipid-modifying enzymes PLD1 and PLD2, but not iPLA2 or cPLA2, are required for 
generating stimulatory MV that can induce CD86 expression. 
J774A.1 were pretreated with 50 µM PLD1 inhibitor CAY10593 or 50 µM PLD2 inhibitor CAY10594 in A, and B, 
10 µM iPLA2 inhibitor BEL; in C, 10 µM AACOCF3; or in D, DMSO vehicle control for 30 min prior to and during 
MV generation. A total of 25 µg protein equivalents from the generated MV was incubated with BMDM for 18 h. B, 
25 µg protein equivalents from MV from mock-treated J774A.1 were incubated with or without 25 µg protein 
equivalents from MV from PLD1- or PLD2-inhibited J774A.1. E, BMDM were treated with or without 10 µM 
Ki16425 prior to MV treatment. Non-treated BMDM are included as controls. Surface CD86 MFI means ± SEM of 
n = 3 are shown. The statistical comparison is made to mock MV-treated BMDM. *p<0.05; **p<0.01; ***p<0.001. 
n.s., not significant; NT, non-treated. 
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2.5.8  Stimulatory MV are not derived from intracellular sources 
 
In order to better characterize the type of MV that elicit macrophage activation, I considered the 
source of the stimulatory MV. MV can originate from intracellular sources such as 
multivesicular bodies (MVB) or from the plasma membrane. In order to differentiate these 
origins, I first biotinylated proteins outwardly expressed on the plasma membrane prior to 
administration of ATP/A23187 for MV generation. Following harvest, protein equivalent 
amounts were incubated with streptavidin-coated magnetic beads. In this manner, extracellularly 
exposed protein containing MV can be removed upon magnetic selection; MV that do not 
contain a large surplus of extracellularly exposed proteins are negatively selected. Most of the 
MV are derived from the plasma membrane, as 82% of protein content from 75 µg protein 
equivalents of MV were apparently removed by addition of streptavidin-coated magnetic beads 
(data not shown) and (Figure 2-13A). BMDM were treated with 10 µg protein equivalents of 
biotinylated MV (prior to streptavidin-coated magnetic bead incubation), 10 µg protein 
equivalents of negatively selected MV (following streptavidin-coated magnetic bead incubation), 
or 10 µg protein equivalents of non-biotinylated MV. Biotinylated MV (prior to streptavidin-
coated magnetic bead selection) induced CD86 upregulation of BMDM similar to non-
biotinylated MV (Figure 2-13B). In contrast, an equal protein equivalent amount of biotinylated 
MV following streptavidin-coated magnetic bead selection display significantly diminished 
ability to activate BMDM as non-biotinylated MV (Figure 2-13B). The lack of retention of the 
biotin label at the plasma membrane of recipient BMDM from negatively selected biotinylated 
MV compared to biotinylated MV prior to selection was confirmed by flow cytometry (Figure 2-
13C). 
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Figure 2-13: Intracellular MV are unable to activate BMDM. 
A, 1 µg of protein equivalents of MV from surface biotinylated J774A.1 prior (1) to and after (2) streptavidin 
magnetic bead depletion are evaluate for biotin label and β-actin expression by Western blot. Data is representative 
of repeated experiments. B and C, 10 µg of protein equivalents of MV from surface biotinylate J774A.1 prior to and 
after streptavidin magnetic bead depletion or non-biotinylated J774A.1 derived MV are given to BMDM for 18 h 
and evaluated for surface CD86 (B) and biotin label (C) by flow cytometry. Surface CD86 MFI means ± SEM of n = 
2 are shown. The statistical comparison is made to non-biotinylated MV-treated BMDM. *p<0.05;.n.s., not 
significant; NT, non-treated. 
 
2.5.9  Phosphatidic acid loaded liposomes weakly stimulate CD86 expression on BMDM 
 
Since PLD enables the generation of stimulatory MV, I considered the potential stimulatory 
capabilities of phosphatidic acid (PA) loaded liposomes. Liposomes were created with non-
specialized lipids (Lipo Ctrl), phosphatidic acid (PA)-loaded liposomes (PA-Lipo), 
A 
B 
C 
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lysophosphatidic acid (LPC)-loaded liposomes (LPC-Lipo), and phosphatidylcholine (POPC-
Lipo) loaded liposomes (POPC-Lipo). PA-Lipo alone displayed ability to upregulate CD86 on 
BMDM (Figure 2-14).  
  
 
Figure 2-14: BMDM are activated by PA-loaded liposomes. 
BMDM were non-treated or treated with 1 µg/ml LPS, 25 µg protein equivalents of MV, 25 µg or 200 µg lipid 
equivalents of indicated liposomes (components detailed in the Materials and Methods) for 18 h and evaluated for 
surface CD86 by flow cytometry. Surface CD86 MFI means ± SEM of n = 3 are shown. The statistical comparison 
is made to non-treated BMDM. *p<0.05; ***p<0.001. n.s., not significant; NT, non-treated. 
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2.6  DISCUSSION 
 
MV released by cells can potently influence immune responses in a number of ways. Many cell 
types release exosomes constitutively and, depending on the cell of origin, may transfer antigens 
or other cargo to DCs that can initiate immune responses. A specialized type of MV release 
exists for myeloid cells that express P2X7 receptors, which, when exposed to receptor agonists 
such as ATP, shed MV from the cell surface and release them from intracellular stores. 
Characterizing MV generation induced by P2X7 activation on macrophages is important for 
understanding inflammatory processes, because tissue damage has been shown to release 
intracellular constituents like ATP into an environment containing large numbers of these cells 
(283-286).  
When macrophages are primed by exposure to TLR agonists, cytokines including IL-1β 
and TNF-α, are synthesized and may be released from the cell following appropriate stimulation 
by a secondary signal (34). For IL-1β release, P2X7 engagement is followed by cleavage of pro-
IL-1β into the bioactive form by caspase-1 in a NLRP3-dependent process. MV have been 
demonstrated to contain mature IL-1β and were first characterized as surface derived vesicles 
(217, 245), but later as exosomes (211). TNF-α-containing exosomes have been reported to be 
secreted from human melanoma cells (287). I have detected TNF-α within P2X7-induced MV 
from primed macrophages; however, TNF-α was also detected from cell culture supernatants 
devoid of MV (data not shown). Nevertheless, only primed macrophages would release pro-
inflammatory cytokines, whose synthesis primarily depends on NF-κB activation (27), whether 
in MV or as soluble proteins. 
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My study instead focused on characterizing the biological effects of MV released by non-
primed, primary macrophages, a condition that may be seen during sterile inflammation. As 
reported by others, MV are released following P2X7 engagement on non-primed macrophages 
(259), yet to the best of my knowledge, have not been studied for their ability to activate 
macrophages. Whereas 3 mM ATP alone is sufficient for P2X7 activation, I observed enhanced 
P2X7 activity when co-administering 10 µM A23187 with 3 mM ATP. A23187 with 0.3 mM 
ATP was not able to induce P2X7 activity; thus in this manner, A23187 is serving in some other 
function than for the autocrine release of endogenously stored ATP for P2X7 activation. I found 
that P2X7-induced MV from non-primed myeloid cells can induce expression of CD86, CD80, 
CD83, and MHC class II (Figure 2-4A), and also induce secretion of TNF-α from primary 
macrophages (Figure 2-3A, B). I further characterized the contents of these MV and found that 
phospholipids were responsible for stimulating macrophage activation in a TLR4-dependent 
process (Figure 2-6B). As separated phospholipids from MV activate macrophages, I can exclude 
a requirement for direct interaction of intact MV in this process. That being said, MV-mediated 
activation was only partially TLR4 dependent, thus MV must contain components in addition to 
phospholipids that activate macrophages independently of TLR4 and these activities may be 
contingent upon delivery of intact MV into intracellular departments. 
Stimulation of primed macrophages by P2X7 yields MV that are heterogeneous, 
consisting of exosomes (211, 259) and surface-derived vesicles (217, 245), and possibly 
including secreted lysosomes (256-258). The MV described in my study are predominantly 0.5-
1.0 µm in diameter (Figure 2-2), distinguishing them from larger 1-4 µm apoptotic blebs (246). I 
observed relatively few smaller MV that would be characteristic of exosomes as analyzed by 
electron microscopy (data not shown), and believe that my preparations were devoid of them for 
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several reasons. Whereas my MV were obtained from ultracentrifugation at 100,000 x g, I also 
found that material obtained from 10,000 x g centrifugation exerts equivalent ability to activate 
macrophages (data not shown). Exosomes do not pellet at the low speed as they are only 50-100 
nm in diameter. Thus, MV-induced macrophage activation seems to be exosome independent. 
Furthermore, the release of MHC class II-containing exosomes from macrophages requires 
apoptosis-associated speck-like protein containing a CARD (ASC)/NLRP3 inflammasome (259). 
Non-primed myeloid cells, such as I have used, typically do not express high levels of NLRP3 
(288), and thus, would not be expected to release MHC class II+ exosomes efficiently. In 
addition, I have purified MV from D2SC-1 cells, a murine splenic DC-derived cell line that lacks 
ASC (data not shown), and found that these MV are potent stimulators of macrophage activation 
(Figure 2-3E). In this way, D2SC-1 cells act similarly to RAW264.7, which also lack ASC (249) 
yet also shed MV in response to P2X7 stimulation (250). These results support the conclusion 
that MV distinct from previously characterized MHC class II+ exosomes are shed by myeloid 
cells and stimulate primary macrophages through a TLR4-dependent process involving 
recognition of phospholipids contained within MV. 
Endogenous phospholipids can activate macrophages through TLR4. Recently, it was 
demonstrated that oxidized low density lipoprotein (oxLDL), which binds to the scavenger 
receptor B family member CD36, can promote sterile inflammation through activation of 
TLR4/6 heterodimer on macrophages (41). Both cell death (289, 290) and foam-cell formation 
(291) have also been shown to be induced by oxidized LDL through TLR4 in macrophages. 
Furthermore, oxidized phospholipids from minimally modified low density lipoprotein 
(mmLDL), which contains essentially the same phospholipids as oxLDL, stimulate macrophage 
ROS generation (292), ERK activation (293), membrane spreading (294), and inhibition of 
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phagocytic uptake of apoptotic bodies (294), through a partially TLR4-dependent pathway. 
Whether phospholipids in P2X7-induced MV are structurally similar to those in oxLDL or 
mmLDL will be addressed in future studies. My study suggests that the stimulatory phospholipid 
is not lysophosphatidic acid (Figure 2-12E). Commercially available LPA, phosphatidic acid or 
phosphatidylserine were also unable to activate BMDM (data not shown). Phosphatidic acid 
loading into liposomes did however show some potential for upregulating surface CD86 (Figure 
2-14). It is possible that phosphatidic acid may alter membrane topology or composition through 
applied negative curvature to expose novel lipids that induce macrophage activation. 
Importantly, P2X7-induced MV from PLD1- and PLD2-inhibited MV producer cells 
were unable to activate macrophages (Figure 2-12A), although MV yields were equivalent 
between drug treated and non-drug treated cells (data not shown). This dissociates MV formation 
from incorporation of the stimulatory phospholipid into vesicles, and suggests that de novo 
generation of a bioactive phospholipid results from P2X7 activation leading to downstream PLD 
activation. Whereas PLD (156), iPLA2, and cPLA2 (155) are activated following P2X7 activation 
(data not shown), blocking PLD activity, but not iPLA2 or cPLA2, impaired the MV-activating 
capacity (Figure 2-12). These results may explain why cell homogenates of producer cells were 
unable to stimulate macrophage activation (Figure 2-3B, C), i.e., because PLD was not activated. 
Activated PLD produces phosphatidic acid to coordinate ADP-ribosylation factor-6, a known 
regulator of exocytosis, to sites of potential exocytosis (295). Future studies will understand the 
specific PLD activities that enable stimulatory phospholipid loading into P2X7-induced MV.   
It has been suggested that host cell-derived stimulators of TLR activity might contain 
microbial contaminants introduced during biochemical purification, a hypothesis described in 
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detail recently in a thought-provoking review (22). Based on this, I considered whether MV 
preparations might contain endotoxin. When tested by Limulus amebocyte lysate assay, 
endotoxin was present within stimulatory MV preparations at low levels, typically ~0.25 EU/ml 
(data not shown). However, the same amount of endotoxin is observed in non-stimulatory MV 
from PLD-inhibited cells (data not shown), indicating that these low levels cannot explain the 
stimulation I observe. Furthermore, treatment of BMDM with equivalent amounts of LPS to that 
found in MV (~50 pg/ml LPS for 25 µg protein equivalents of MV) did not induce significant 
TNF-α release or CD86 upregulation (data not shown). It should also be noted that in addition to 
testing non-stimulatory MV, I observed that cell homogenates, non-surface derived MV, and 
ultracentrifugation supernatants were also devoid of BMDM-stimulating activity.  
My study suggests that MV derived from macrophages in an environment where there is 
tissue damage without infection could have potent biological activities that may further drive 
inflammation. In tumors and other settings with significant necrosis, infiltrating macrophages 
expressing P2X7 would be exposed to elevated levels of extracellular ATP, as previously shown 
in tumors (162, 296, 297). Macrophage-produced MV would then bind to adjacent cells, 
including macrophages and DCs, leading to their activation and resulting in secretion of TNF-α 
and potentially other pro-inflammatory mediators. The most novel aspect of this work, 
implicating phospholipids from MV as the stimulatory component, is consistent with recent work 
implicating phospholipids in inflammation present in atherosclerotic lesions, as discussed above. 
In cancer and in atherosclerosis, as well as potentially in other pathological settings, there are 
strong indications that sterile inflammation plays a role in disease processes through largely 
unknown mechanisms. Innate responses by macrophages in inflammatory diseases may in part 
be explained by release of stimulatory phospholipids in MV at sites of tissue damage. 
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3.0   ATP PROMOTES THE RELEASE OF MATURE CATHEPSIN D IN A DYNAMIN-
DEPENDENT MANNER 
 
3.1   AUTHORS AND THEIR CONTRIBUTIONS 
 
L. Michael Thomas (Graduate Program in Immunology, University of Pittsburgh School of 
Medicine) designed and performed the experiments and prepared the manuscript; his funding 
was supported by an NIH training grant T32CA082084. Russell D. Salter (Department of 
Immunology, University of Pittsburgh School of Medicine) designed the scope of the study and 
edited the manuscript; his funding was supported by NIH funds R01AI072083 and 
P01CA073743. Chengqun Sun engineered the HEK293 cell line to express human P2X7 and the 
FSDC cell line to express dynamin-GFP or dynamin (K44A)-GFP, which were used in this 
study. Various contributors provided reagents including murine bone marrow and cell lines, 
which are discussed and acknowledged within the Materials and Methods. 
  
98 
3.2   ABSTRACT 
 
ATP engagement of purinergic receptors can promote the displacement and secretion of several 
intracellular inflammatory components from PAMP-primed and non-primed myeloid cells. 
Moreover, ATP can elicit the release of lysosomal hydrolases, which can have potent effects on 
the surrounding extracellular matrix that contribute to tissue structure. In this study, I sought to 
understand how lysosomal components such as cathepsin D are released from ATP-treated, non-
primed, myeloid cells. I found that ATP-induced microvesicles contained both endosomal and 
lysosomal forms of cathepsin D. Prior to microvesicle generation, ATP displaced cathepsin D 
from within main cell bodies to the periphery of cells. The release of the mature form of 
cathepsin D was dependent upon P2X7. The cathepsin D released in response to ATP was 
biologically active. Additionally, the secretion of mature cathepsin D was partially blocked by 
dynasore, a specific inhibitor of dynamin. Dynasore also decreased the peripheral expression of 
cathepsin D from the main cell body of myeloid cells. At the same time, stable expression of 
dynamin-2 dominant negative (K44A) did not result in decreased mature cathepsin D secretion. 
This work illustrates the potential for dynamin to regulate lysosomal component exocytosis, 
which may prove to have roles in diseases provoked by released hydrolases such as cathepsins.  
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3.3 INTRODUCTION 
 
ATP can promote the modification of proteins and lipids. This includes the ability to initiate 
biochemical alterations of these materials (e.g., cleavage of caspase-1) (78) and the redistribution 
of these materials from one location of the cell to another (e.g., exocytosis of IL-1β) (248). ATP 
engages a set of plasma membrane expressed ATP binding receptors called purinergic receptors 
(130). All together, purinergic receptors can shape the functions of cells including immune cells 
(37). 
 One critical aspect of intracellular trafficking is endocytosis, which is mechanistically 
carried out in several different ways. Most often depicted is clathrin-mediated endocytosis 
although there are several other endocytotic pathways, including caveolin-mediated, 
CLIC/GEEC-mediated, and flotillin-mediated endocytosis processes (298). Clathrin-mediated 
endocytosis is characterized by clathrin-coated pits that invaginate from the plasma membrane to 
allow the internalization of materials from outside the cell to inside the cell. This invagination 
process is in part governed by dynamin, a plasma membrane localized GTPase that can constrict 
the plasma membrane in a turn-style fashion. Eventually, dynamin induced constriction results in 
the pinching off of these invaginations to form endosomes. Caveolin and flotillin act differently 
where invaginated membrane form caveolae. Similar to clathrin, dynamin is required for 
caveolin-mediated endocytosis (299). Flotillin-mediated endocytosis is dynamin-independent 
(300). CLIC/GEEC-mediated endocytosis through glycosylphosphatidylinositol-anchored 
proteins (GPI-APs) is independent of dynamin (301) . ATP engagement of purinergic receptors 
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have been shown to regulate clathrin-mediated endocytosis (302) and phagocytosis by 
macrophages (174, 303).  
Secretory granule (SG) exocytosis is a coordinated process that involves aspects of 
intracellular trafficking and for certain SG, such as secreted lysosome related organelles (LRO), 
this can involve endocytosis (194). Upon outside-in signaling, conventional SG are first 
trafficked from the Golgi to the plasma membrane. After docking and fusing with the plasma 
membrane, SG release their harbored content. An immunological example of a conventional SG 
would be the degranulation of mast cells for the release of histamine. SG release does not 
necessarily require endocytosis pathways. 
By contrast, LRO traffic differently. Premature components of LRO are sent from the 
Golgi apparatus to the plasma membrane following homeostatic cues. From the plasma 
membrane, immature LRO are endocytosed back into the cell, where they can eventually fuse 
with pre-existing multi-vesicular bodies (MVB) to form mature LRO, which are held in check 
until calcium-driven signals promote their movement to the plasma membrane. LRO are 
trafficked to the plasma membrane through calcium-independent polymerizing microtubules. At 
the plasma membrane, calcium-dependent fusion by SNARE proteins and synaptotagmins 
enables the release of LRO components into the extracellular environment. 
ATP engagement of purinergic receptors found on myeloid cells have prompted the loss 
of cellular materials including the release of plasma membrane derived microvesicles (MV) 
(217, 245), exosomes from MVB (211, 259), and LRO (154). The manner in which ATP 
mechanistically performs these activities is not clear. Plasma membrane-derived MV shedding 
following ATP ligation of purinergic receptors is described to occur in a calcium-dependent 
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manner (217). These particular MV can be shed from either non-primed or PAMP-primed 
myeloid cells (249, 259). In contrast, purinergic receptor initiation for exosome exocytosis is 
described to require PAMP priming for the expression of the inflammasome component NLRP3, 
which promotes exosome exocytosis (259). The release of LRO is described from PAMP-
activated myeloid cells (258); however, the group that conducted this study did not elaborate on 
the need for PAMP priming. 
In this study, I describe a mechanism for LRO component (cathepsin D) exocytosis from 
non-primed myeloid cells. In response to 3 mM ATP, FSDC, a model cell line for murine 
immature dendritic cells, and murine bone marrow derived macrophages (BMDM) demonstrated 
abilities to shed 0.5-1 µm sized MV that contain both intermediate (endosomal) and mature 
(lysosomal) forms of cathepsin D. By 15 min, ATP promoted the displacement of lysosomal 
components away from the main cell bodies of cells. This displacement was dampened by 
inclusion of dynasore, a dynamin inhibitor. Furthermore, dynasore significantly decreased the 
secretion of mature, but not intermediate, cathepsin D. Dynamin itself was redistributed away 
from the main bodies of cells. In contrast to the effects of dynasore, however, I did not observe a 
significant decrease of cathepsin D secretion from FSDC that stably expressed a dominant 
negative form of dynamin-2. Regardless, this study suggests the possibly that dynamin may 
regulate the eventual secretion of ATP-induced release of LRO. 
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3.4 MATERIALS AND METHODS 
 
Cell culture and reagents - FSDC, an immortalized murine immature dendritic cell line via 
retroviral transduction of a vector carrying an envAKR-mycMH2 fusion gene (304), (gift from P. 
Ricciardi-Castagnoli, Singapore Immunology Network, Singapore) was maintained in IMDM 
(Lonza, Basel, Switzerland) supplemented with 10% fetal bovine serum (FBS) (Gemini Bio-
Products, West Sacramento, CA), 1% additional L-glutamine (Lonza), and 1% penicillin and 
streptomycin (Lonza). This IMDM supplemented media will hereafter be referred to as IMDM 
complete. Murine bone marrow derived macrophages (BMDM) were derived from bone marrow 
precursors (gift from L. Borghesi, University of Pittsburgh) differentiated with L-cell 
supplemented media as described previously (265). HEK293 cells tranduced to express human 
P2X7 or control vector (305) are maintained in DMEM (Mediatech, Manassas, VA) complete 
with 10% FBS, 1% additional L-glutamine, 1% penicillin and streptomycin, and 500 µg/ml 
G418. For some experiments, 1 μg/ml of lipopolysacharides (LPS) from Escherichia coli 026:B6 
(Sigma-Aldrich, St. Louis, MO) was used to prime the cells where indicated. Other regents 
include ATP (Thermo Fisher Scientific, Waltham, MA), A23187 (Sigma-Aldrich), latrunculin A 
(Invitrogen, San Diego, CA), and dynasore (EMD Chemicals, Gibbstown, NJ). 
MV generation and harvest - 60 million FSDC or BMDM were plated in culture within 
T225 cm2 flasks per treatment. Following 4 h to allow cells to adhere (or to also become LPS 
primed as described above), the cells were washed twice with 25 ml PBS. Cells were then treated 
with no treatment or 3 mM ATP treatment within 40 ml serum-free IMDM with no additions for 
30 min at 37°C. Following the 30 min of treatment, supernatant was harvested off and 
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centrifuged at 309.1 x g for 10 min to pellet potential non-adherent cells. The supernatant 
following the 309.1 x g centrifugation was further separated with 100,000 x g ultracentrifugation 
for 1 h. The pellet fraction from the 100,000 x g ultracentrifugation was resuspended within 15 
μl 4 x sample buffer to be subsequently run on an SDS-PAGE for western blotting. 
In some instances, 800 nM latrunculin A was given in IMDM with no additions for 30 
min prior to 3 mM ATP administration. 3 mM ATP was administered in the presence of 800 nM 
latrunculin A. MV generation and harvest proceeded as described above. 
Biologically active cathepsin D studies - 2 million FSDC were plated within 6-well plates 
with IMDM complete then non-treated or 3 mM ATP treated for 30 min. Supernatant was 
collected following treatment then centrifuged at 1200 x g to pellet potential cells. The 
subsequent supernatant following the centrifugation was then stored at -80°C until utilized in the 
fluorimetric SensoLyte 520 Cathepsin D Assay Kit (AnaSpec, Fremont, CA). Determination of 
biologically active cathepsin D was performed following the manufacturer’s protocol. 
Western blotting - For whole supernatant experiments, 2 million cells were plated within 
6-well plates with IMDM complete. Cells were washed twice with serum-free IMDM with no 
additions then given treatment where indicated. Some studies included a 30 min dynasore 
treatment prior to 3 mM ATP addition in the presence of dynasore. HEK293 studies included 
samples treated with 10 μM A23187 alone, 6 mM ATP alone, or 10 μM A23187 plus 6 mM 
ATP. Following treatment, the entire cell culture supernatant was centrifugated at 10,000 x g for 
30 s and then the resulting centrifugation supernatant was concentrated via trichloroactetic acid 
and 10% cholic acid as described in (265) and loaded with 4 x sample buffer onto a 9% SDS-
PAGE gel for protein electrophoresis. For HEK293 studies, cell lysates were prepared in 1% NP-
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40 lysis buffer as described in (265). Protein from HEK293 cell lysates were quantified by 
Bradford assay and 20 µg of protein were loaded along-side concentrated supernatants on a 9% 
SDS-PAGE gel. Protocols for electrophoresis, subsequent protein transfer, and western blotting 
are described in (265). Western blot was performed using the SNAP-ID according to 
manufacturer’s procedures (Millipore, Billerica, MA). Western blotting for cathepsin D was 
performed with 1/66.7 diluted goat anti-cathepsin D (Santa Cruz Biotechnology, Santa Cruz, 
CA) then subsequent with 1/1666.7 diluted HRP-conjugated donkey anti-goat IgG (Santa Cruz 
Biotechnology). In other studies, western blotting was performed with 1/1000 diluted rabbit anti-
dynamin-2 (Santa Cruz Biotechnology), 1/1000 diluted mouse anti-GFP (Millipore), 1/1000 
diluted mouse anti-β-actin (Sigma-Aldrich), 1/1666.7 diluted HRP-conjugated donkey anti-rabbit 
IgG (Biolegend, San Diego, CA), and 1/1666.7 diluted HRP-conjugated goat anti-mouse IgG 
(Santa Cruz Biotechnology). Signals were developed using Western blotting luminol reagent 
(Santa Cruz Biotechnology). Imaging and densitometry was performed with KODAK Image 
Station 4000MM and its accompanying KODAK MI SE Software Informer (Carestream 
Molecular Imaging, New Haven, CT). Densitometry readings are reported as relative percentages 
calculated for a band net intensity divided by the sum of the net intensities of similar molecular 
weight bands for all analyzed samples. 
Microscopy - For confocal microscopy studies, 200,000 FSDC or BMDM were plated on 
poly(d-lysine)-coated coverslips within 24-well plates. Cells were allowed to adhere for at least 4 
h. 4 h LPS priming (as described above) was performed for BMDM where indicated. Following 
the 4 h, cells were washed once with PBS then given treatments where indicated. After 
treatment, supernatant was discarded and the cells were washed once with PBS. 2% 
paraformaldehyde fixative was applied for 15 min at room temperature.  
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For antibody labeling experiments, after the fixation step, fixative was removed and 
replaced with 50 mM glycine for 5 min, then blocked and permeabilized with 1.5% BSA and 
0.5% saponin in PBS for 30 min at room temperature. Coverslips were washed once with PBS 
then given primary antibody of 1/100 diluted rat anti-Lamp-1 (eBioscience, San Diego, CA), 
1/500 diluted Alexa-488 conjugated rat anti-Lamp-1 (Biolegend, San Diego, CA), and/or 1/50 
diluted rabbit anti-cathepsin D (Santa Cruz Biotechnology) where indicated at room temperature 
for 1 h. Coverslips were washed three times with 0.5% saponin in PBS then given 1/100 diluted 
Alexa-647 conjugated goat anti-rabbit IgG (Invitrogen) or 1/100 diluted Cy5 conjugated goat 
anti-rat IgG (Jackson Laboratories) along with 400 nM rhodamine phalloidin (Sigma-Aldrich) 
where indicated at room temperature for 1 h. Coverslips were washed three times with 0.5% 
saponin in PBS then given 1 μg/ml DAPI (Sigma-Aldrich) for 30 s. Coverslips were washed 
three times with PBS before mounting onto a glass slide with gelvatol (gift from CBI).  
To track cathepsin D without permeabilizing cells, prior to ATP treatment, cells were 
given 10 µM BODIPY-pepstatin-A (Invitrogen) for 30 min. Following treatment, cells were 
fixed as described above, washed three times with PBS, then mounted with gelvatol on a glass 
slide for confocal microscopy. 
  Confocal microscopy images were taken with an Olympus Fluoview 1000 (Inverted) 
(Olympus America, Inc., Center Valley, PA). Live cell microscopy images were taken from 
Nikon A1 Confocal Live Cell System (Nikon Instruments Inc., Melville, N.Y.). Laser excitations 
were collected sequentially and background noise was minimized. Confocal microscopy 
included DIC microscopy. Live cell microscopy was conducted without delayed exposures; ATP 
was added after one minute of starting the 20 min time course. Final images were taken from 
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each microscope and cropped using Adobe Photoshop CS2 (Adobe, San Jose, CA). Analysis of 
live cell microscopy was performed with NIS Elements Viewer (Nikon Instruments Inc.)  
 For obtaining counts of percentage of cells with budding cathepsin D, 10 random fields 
of view were collected respective for each treatment. Each field of view had at least 10 cells with 
determinable localization of cathepsin D. Averages and SEM were obtained from 3 separate 
experiments. Cells were considered positive for peripheral cathepsin D if cathepsin D was 
observed outside of the main cell body as determined with BODIPY-pepstatin-A overlaid with 
DIC microscopy. An example of a cell that was counted as positive or negative is in Figure 3-5. 
Dynamin-GFP and Dynamin K44A-GFP – Dynamin 2-GFP plasmid (K44K) and 
dynamin 2-(K44A)-GFP (dominant negative) plasmid were gifts from L. Traub (University of 
Pittsburgh). Rat dynamin 2-GFP (K44K) and dynamin 2-dominant negative-GFP (K44A) 
fragments were amplified from the plasmids containing rat dynamin 2-GFP (K44K) and dynamin 
2-dominant negative-GFP (K44A) by PCR, respectively. The primers with Not I or EcoR I sites 
were as follows: forward primer, 5’- TTATTGCGGCCGCCTCAAGCTTGGCACCATGG -3’; 
reverse primer, 5’- AGTCTTAAGGAATTCATCACTTGTACAGCTCGTCCAT -3’. The 
Expand high fidelity PCR system (Roche Applied Science, Indianapolis, IN) was used for PCR 
reactions. The PCR amplicons were then cloned into the retroviral pFB/neo vector with 
neomycin-resistant gene using Not I and EcoR I restriction enzymes and the Rapid DNA 
Ligation Kit (Roche Applied Science). The corresponding sequences subcloned into vectors were 
verified by DNA sequencing. 
For making retroviruses, retroviral packaging gp293 cells were plated in six-well plates 1 
day before and co-transfected with retroviral constructs containing dynamin 2-GFP (K44K) or 
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dynamin 2-dominant negative-GFP (K44A) and with VSV-G vector using LipofectamineTM LTX 
Reagent. 4 μg retroviral constructs, 2 μg VSV-G vector, 5 μl PlusTM reagent, and 10 μl 
LipofectamineTM LTX Reagent in 500 μl of Opti-MEM® I Reduced Serum Medium were used 
per well with 2 ml media. Then the plates were incubated at 37oC, 5% CO2 for 4 h, and replaced 
with 3 ml fresh media and continue to incubate for 2-3 d. The media which contain retroviruses 
were harvested and filtered. The filtered media were aliquot and stored at -80°C for transduction. 
For transduction, 30,000-40,000 cells of FSDC cells were plated in 12-well plates a day 
before and infected by replacing their media with 1 ml retroviral preparation containing 3 μg 
polybrene and incubated for 1 d, then replaced with media containing with 1 mg/ml G418 for 3-5 
weeks to generate stably expressing cell lines and maintained in 500 µg/ml G418. 
LDL-endocytosis assays – One million native FSDC and dynamin K44A FSDC were 
given 10 µg/ml LDL conjugated to Alexa594 (Invitrogen) in 1 ml IMDM complete for 1 h. Flow 
cytometry was performed with a BD Biosciences LSR II and results analyzed using FlowJo 
software (Tree Star, Inc., Ashland, OR). 
Statistical analyses - Unpaired Student’s t test was performed using Graph Pad Prism 
(GraphPad Software, La Jolla, CA). Values of p were calculated where indicated, and for all 
statistical studies p<0.05 was considered as significant. 
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3.5   RESULTS 
 
3.5.1 ATP promotes the release of MV that contain mature cathepsin D 
 
Microvesicle shedding has previously been acknowledged as a function of ATP acting on the 
P2X7 purinergic receptor (211, 217, 236, 245, 259). Given the reports of cathepsin secretion 
following P2X7 stimulation of macrophages (186) and P2X7-mediated exocytosis of LRO (154), 
I examined whether cathepsin D would be enriched within MV fractions. MV harvested from 3 
mM ATP treated BMDM (Fig. 3-1, top panel) and FSDC (Figure 3-1, bottom panel) expressed 
both immature cathepsin D (46 kDa) and mature cathepsin D (33 kDa). LPS priming of BMDM 
was not a requirement for the expression of cathepsin D within harvested MV. Latrunculin A, an 
actin polymerization inhibitor, decreased the expression of cathepsin D observed within 
harvested MV from ATP treated FSDC (Figure 3-1, bottom panel). In agreement with ATP 
induced secretion of cathepsin D (as detected by western blot), ATP induced the secretion of 
biologically active cathepsin D secreted from FSDC (Figure 3-2). 
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Figure 3-1: ATP-induced MV contain intermediate and mature forms of cathepsin D regardless of initial LPS 
priming. 
BMDM (top panel) and FSDC (bottom) panel were treated with 1 µg/ml LPS or non-treated for 4 h. For FSDC, 
some samples were also given 800 nM latrunculin A (Lat. A) given for the final 30 min of the LPS treatment. 
Following the 4 h, cells were non-treated or treated with 3 mM ATP for 30 min. Supernatants were processed for 
MV harvest. The resulting pellet fractions following 100,000 x g ultracentrifugation were processed for western blot 
determination of intermediate cathepsin D (46 kDa) and mature cathepsin D (33 kDa). Brackets indicate individual 
western blots. The blots shown here are representative of repeated experiments. 
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Figure 3-2: ATP promotes the release of biologically active cathepsin D. 
FSDC were treated with or without 3 mM ATP for 30 min. Biologically active cathepsin D was measured and 
determined according to manufacturer’s protocol. The histogram shows means of determined biologically active 
cathepsin D ± SEM of n = 3. **p<0.01. 
 
3.5.2 P2X7 is an ATP-activating receptor for mature cathepsin D release 
 
To confirm that P2X7 was the activating receptor for the release of mature cathepsin D, I utilized 
native HEK293 cells, which do not express P2X7, or HEK293 cells that express human P2X7 
(HEK293-P2X7) (305). Only HEK293-P2X7 released mature cathepsin D in response to ATP 
(Figure 3-3). To validate that the mechanism was specifically due to a novel function of P2X7 
and was not just due to an influx of calcium, I also treated cells with the calcium ionophore 
A23187, which alone failed to produce mature cathepsin D from either HEK293 cell type 
(Figure 3-3). However, A23187 in combination with 6 mM ATP though released even more 
mature cathepsin D than ATP alone from HEK293-P2X7. This is in agreement with our previous 
findings that A23187 potentiates P2X7 function (236). 
** 
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Figure 3-3: P2X7 expression promotes mature cathepsin D secretion. 
HEK293 (mock transduced) or HEK293 (expressing human P2X7) were treated with no treatment (NT), 6 mM ATP, 
10 µM A23187, or 6 mM ATP plus 10 µM A23187 for 30 min. Supernatants and lysates were evaluated for their 
expression of intermediate and mature forms of cathepsin D by western blot. The western blot shown is 
representative of repeated experiments.  
 
3.5.3 ATP promotes the displacement of lysosomal components towards the periphery of treated 
cells 
 
P2X7 activity can promote LRO exocytosis (154). To characterize the potential for LRO 
exocytosis, localization of Lamp-1 and cathepsin D were determined between non-treated 
BMDM (Figure 3-4A) and 3 mM ATP-treated BMDM (Figure 3-4B). ATP treated BMDM 
displayed a peripheral (to the main cell body) localization of Lamp-1 and cathepsin D. Similar to 
direct antibody labeling of cathepsin D, BODIPY-pepstatin A signal (to label cathepsin D) was 
significantly localized  to the periphery of 3 mM ATP treated FSDC (Figure 3-5).  
Intermediate Cat. D (46 kDa) 
Mature Cat. D (33 kDa) 
Intermediate Cat. D (46 kDa) 
Mature Cat. D (33 kDa) 
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Figure 3-4: ATP promotes the displacement of cathepsin D and lamp-1 to the periphery of cells away from 
the main cell body of BMDM. 
BMDM were left untreated (A) or treated with 3 mM ATP (B) for 15 min. Cells were stained for nuclei (gray, top 
left), lamp-1 (green, top middle), F-actin (red, top right), and cathepsin D (blue, bottom left). DIC microscopy 
(bottom middle) and overlay of all of the stains and DIC are included (bottom right). White arrows indicate 
peripheral expression. Images are representative of repeated experiments. Scale bar, 10 µm. 
A 
B 
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Figure 3-5: ATP promotes the displacement of cathepsin D to the periphery, away from the main cell bodies 
of FSDC.  
FSDC were incubated with 10 µM BODIPY-pepstatin A for 30 min. Cells were cultured with or without 3 mM ATP 
for 15 min. BODIPY-pepstatin A signal (green) was analyzed by confocal microscopy. Individual cells were 
determined to be “positive” or “negative” for having BODIPY-pepstatin A signal away from their main cell bodies 
towards the periphery. Examples of positive and negative cells are included on the right half of the figure. The blue 
lines with the example images are included for clarity of the main cell bodies, which are clear with the original DIC 
images. White arrows indicate peripheral expression. The histogram shows the mean number of cells with displaced 
BODIPY-pepstatin A ± SEM of n = 3. Scale bar, 10 µm. **p<0.01. 
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3.5.4 Dynasore inhibits mature, but not intermediate, cathepsin D secretion from ATP treated 
cells 
 
Dynamin activity can be involved in the release of lytic granules (306, 307), the release of 
insulin granules (308), and catecholamines release from chromaffin cells (309). Furthermore, 
dynamin is a regulator of topological changes of the plasma membrane for exocytosis of 
secretory granules following their fusion with the plasma membrane (310). Given the similarity 
of these secreted compartments to secretory lysosomes, I then asked if dynamin was involved for 
cathepsin D exocytosis from myeloid cells. Pre-treatment of dynasore, an inhibitor of dynamin-1 
and dynamin-2 (311), prior to ATP administration was able to significantly decrease the 
secretion of mature but not intermediate cathepsin D (Figure 3-6A-C). 100 µM dynasore 
significantly decreased mature cathepsin D expression as compared to 3 mM ATP treatment 
alone. Dynasore was not toxic to treated FSDC (data not shown), it does not decrease cathepsin 
D expression within cell lysates (data not shown), and it functioned to block LDL receptor-
mediated endocytosis (data not shown), which occurs in a clathrin-dependent manner (312). 
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Figure 3-6: Dynasore treatment significantly decreases mature, but not intermediate, cathepsin D secretion. 
FSDC were treated with various doses of dynasore (Dyna) for 30 min. Following dynasore treatment, cells were 
non-treated or treated with 3 mM ATP for 30 min. Supernatants were analyzed for expression of the intermediate 
and mature forms of cathepsin D by western blot. A representative blot is shown in A. Densitometry analysis 
indicates means of relative abundance of intermediate (B) and mature (C) forms of cathepsin ± SEM of n = 3. 
**p<0.01. 
 
A 
B C Intermediate Cathepsin D 
Expression 
Mature Cathepsin D 
Expression 
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 To further evaluate the effects of dynasore treatment prior to ATP-mediated cathepsin D 
secretion, I considered that dynasore may affect the amount of cathepsin D observed at the 
periphery. Dynamin is primarily localized at the plasma membrane for its function in endosomal 
recycling, but it has been proposed to play roles in other intracellular trafficking events (298). 
Dynasore pretreatment resulted in decreased amounts of cathepsin D in the cell periphery, in 
response to 3 mM ATP (15 min); however, the decrease was not significant from three 
experiments (Figure 3-7). 
 
Figure 3-7: Dynasore decreases the peripheral expression of cathepsin D away from the main cell body 
following ATP treatment. 
FSDC were were incubated with 10 µM BODIPY-pepstatin A for 30 min. Cells were non-treated or treated with 100 
µM dynasore for 30 min. Cells were non-treated or treated with 3 mM ATP for 15 min. BODIPY signal and analysis 
was determined as described in Figure 3-5. The histogram indicates mean number of cells with displaced BODIPY-
pepstatin A ± SEM of n = 3. 
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3.5.5 Over-expressed dynamin-2 localizes to the periphery upon ATP treatment 
 
Given its involvement in potentiating mature cathepsin D secretion across the plasma membrane 
of ATP treated cells (Figure 3-6), I hypothesized that dynamin itself may be localized to the 
periphery of ATP treated cells, away from cellular main bodies. To test this hypothesis, I 
expressed dynamin-2 fused to GFP within FSDC. Without ATP treatment, dynamin-2-GFP 
signal was mainly retained within main cell bodies (Figure 3-8A) with strong expression at the 
plasma membrane. Upon 3 mM ATP treatment, dynamin-2-GFP was redistributed to the 
periphery with a noticeable loss from the main cell bodies within seconds (Figure 3-8B, C, D). 
This rapid loss was not observed for non-treated cells (Figure 3-8D); the loss over the longer 
course of time of non-treated and ATP-treated cells may have been due to instability of the GFP 
fluorochrome under the constant laser excitation employed in these experiments. 
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Figure 3-8: ATP promotes the displacement of dynamin to the periphery of cells away from the main cell 
bodies. 
FSDC expressing dynamin-GFP were left untreated or treated with 3 mM ATP. In A and B, following 15 min of 
treatment, cells were fixed and stained for confocal microscopy. Cells were stained for nuclei (blue, top left), F-actin 
(red, top right), and lamp-1 (yellow, bottom left). Dynamin-GFP (green, top middle) and DIC microscopy (bottom 
middle) were also analyzed. Overlay of all of the signals, including the DIC, are included (bottom right). White 
arrows indicate peripheral expression. Images are representative of multiple experiments. Scale bar, 10 µm. In C, 
cells were tracked over time (min:s) following 3 mM ATP treatment. ATP was given after the first min of live cell 
microscopy (indicated with black arrow in D). In D, non-treated and 3 mM ATP treated cells were tracked for 
peripheral expression of dynamin-GFP and main cell body expression of dynamin-GFP. Examples of the gating 
strategy for the periphery and main cell bodies of cells in included as an inset in D.  
A 
C 
Time (seconds) 
B 
D 
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3.5.6 Dynamin-GFP (K44A) does not decrease cathepsin D secretion from ATP treated FSDC 
 
To evaluate dynamin other than by inhibition with dynasore, I stably expressed dynamin-2 
dominant negative (K44A) within FSDC to decrease the function of endogenous dynamin-2 
(313). Expression of dynamin-2 (K44A) fused to GFP was determined both by flow cytometry 
(analysis of GFP expression in Figure 3-9A) and western blot (analysis of GFP blot and 
dynamin-2 blot in Figure 3-9B). Expression of dynamin-2-GFP was assessed as well (Figure 3-
9A, B). Functionality of the dominant negative activity of dynamin-2 (K44A)-GFP was 
confirmed by observing a decrease in LDL endocytosis (Figure 3-9C, D). Upon 3 mM ATP 
challenge for 30 min though, there were no detectable differences in mature cathepsin D 
secretion between dynamin-2 (K44A)-GFP, dynamin-2-GFP, and native FSDC (Figure 3-10). 
This was in contrast to dynasore-mediated inhibition of dynamin as dynasore significantly 
decreased mature cathepsin D secretion (Figure 3-6A-C, Figure 3-10). 
  
120 
 
   
Figure 3-9: Dynamin (K44A)-GFP FSDC exhibit decreased LDL endocytosis  
In A, neomycin control (red), dynamin-GFP (green), and dynamin (K44A)-GFP (blue) were evaluated for GFP 
expression by flow cytometry. In B, native, dynamin-GFP, and dynamin (K44A)-GFP FSDC cell lysates were 
evaluated for GFP and dynamin-2 expression by western blotting. In C, dynamin (K44A)-GFP FSDC were non-
treated (red) or given 10 µg/ml of Alexa594-LDL (green) for 1 h.  In D, native FSDC were non-treated (red) or 
given 10 µg/ml of Alexa594-LDL (green); dynamin (K44A)-GFP FSDC were given 10 µg/ml Alexa594-LDL 
(blue). C and D were conducted by flow cytometry.  
C D 
B 
A 
Dynamin
-GFP 
Endogenous 
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Figure 3-10: Dynamin (K44A)-GFP FSDC fail to demonstrate a decrease in mature cathepsin D secretion 
upon ATP treatment. 
Neomycin control, dynamin-GFP, and dynamin (K44A)-GFP FSDC were non-treated or given 100 µM dynasore for 
30 min. Cells were then non-treated (-) or treated with 3 mM ATP (+) for 30 min. Supernatants were analyzed for 
their expression of intermediate and mature forms of cathepsin D by western blot. A representative blot is shown. 
Intermediate 
Cat. D (46 kDa) 
Mature Cat. D 
(33 kDa) 
  
122 
3.6 DISCUSSION 
 
ATP administration can promote the release of lysosomal components (186); however, the 
mechanism of how this occurs has yet to be elucidated. This study demonstrates that P2X7 
induces rapid lysosomal component dissemination. Membrane blebbing has consistently been 
observed in numerous studies and it has been implicated in the shedding of MV (217, 252); 
however, this is the first study to verify cathepsin D exocytosis within MV and to invoke 
dynamin in mature cathepsin D secretion. Intermediate (endosomal) cathepsin D and mature 
(lysosomal) cathepsin D forms are released following ATP-induced activation of P2X7 (Figure 3-
3) within MV (Figure 3-1) but they are released through distinct mechanisms (Figure 3-6) as 
mature cathepsin D secretion was selectively decreased in cells pretreated with the dynamin-
inhibitor dynasore (Figure 3-6). 
Dynamin-2 is classically described for its role with clathrin-mediated endocytosis (298); 
however, there have been reports suggesting its participation in exocytic processes (306, 308-
310). Most of these reports have implicated its participation through dynamin inhibition but the 
localization of dynamin in these studies relative to secretory lysosomes had not been closely 
examined microscopically. With myeloid cells following ATP treatment, I observed a 
relocalization of dynamin to the periphery (Figure 3-8). As dynamin-2 was preferentially re-
localized away from the main cell body, this would suggest its involvement in the periphery. 
While dynasore treatment decreased mature cathepsin D secretion (Figure 3-6) and re-
distribution to the periphery (Figure 3-7) and dynamin-2 was localized at the periphery (Figure 
3-8), the dominant negative dynamin-2 (K44A)-GFP construct did not decrease mature cathepsin 
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D secretion (Figure 3-10). This was despite the ability of dynamin-2 (K44A)-GFP construct to 
inhibit LDL receptor mediated endocytosis (Figure 3-9C, D). 
There are several reasonable explanations for the differences observed between the 
dynasore and dominant negative dynamin-2 (K44A) results. Dynasore and dynamin-2 (K44A) 
both block the GTPase function of dynamin, preventing coated vesicle formation during clathrin-
mediated endocytosis (311); however, the difference is unlikely due to differences in inhibition 
mechanism. There are not any observed or reported discrepancies between these modes of 
dynamin inhibition, and both are allegedly specific for dynamin (311). One difference with how I 
employed them in this study is that dynasore was transiently administered whereas dynamin-2 
(K44A) was stably expressed by retrovirus transduction. Stable selection favors cells that adapt 
survival strategies; it is very possible that these cells evolved some abnormal function to enable 
endocytosis of some vital materials as endocytosis is a crucial component for cellular survival. It 
is also possible that dynasore was more efficient at inhibiting this partial role for dynamin than 
the K44A dominant negative. In my study, 100 µM dynasore inhibited about 50% of the secreted 
mature cathepsin D in response to 3 mM ATP (Figure 3-6); if the dominant negative was not as 
effective, this partial inhibition may not be observed. 
If dynamin is legitimately partially mediating the preferential secretion of mature but not 
intermediate cathepsin D from ATP treated myeloid cells, the mechanism has yet to be 
elaborated. A predicted outcome would an absence of peripheral cathepsin D expressed away 
from main cell bodies following dynasore treatment of ATP treated cells. While it is not 
significant, there is a trend towards a decrease of cells with cathepsin D in the periphery away 
from main cell bodies in the presence of dynasore (Figure 3-7); since I know that dynasore also 
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decreases the amount of secreted mature cathepsin D (Figure 3-6) while not decreasing the 
intracellular amount of cathepsin D (data not shown), cathepsin D is largely sequestered within 
the main cell body in response to dynasore.  
How might dynamin lead to the loading of cathepsin D into MV? ATP ligation of P2X7 
promotes the shedding of several types of MV, including plasma membrane-derived MV (246). 
The topology of dynamin necessitates its function to act to invaginate vesicles into cells; 
however, if these various studies are correct in implicating dynamin in secretory granule 
exocytosis, there may be a role for vesicle excision away from the cell. Axelrod’s group 
determined through polarized total internal reflection fluorescence microscopy (TIRFM) images 
of the plasma membrane–cytosol interface of chromaffin cells that dynamin plays a role in 
altering membrane topology during secretory granule exocytosis (310). If dynamin acts to pinch 
off vesicles into the periphery of ATP-treated myeloid cells, this may lead to the selective 
loading of materials (including lysosomal components like mature cathepsin D) into shedding 
MV. 
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4.0   P2X7 ELICTS THE DE NOVO PRODUCTION OF F-ACTIN ENRICHED STRUCTURES 
FOR DISSEMINATION OF LIPIDS AND PLASMA MEMBRANE 
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4.2  ABSTRACT 
 
P2X7 is capable of inducing a number of cytoskeletal modifications, including zeiotic blebbing, 
shedding of plasma membrane, and release of microvesicles. In this study, I discovered that 
P2X7 initiates de novo actin-nucleation, leading to the production of F-actin enriched structures, 
resembling the morphology of filopodia. Furthermore, these extended arms displayed a twisting 
phenotype to the extent that they formed a beaded appearance. Calcium ionophore alone did not 
mimic the activities of P2X7, although it did enhance P2X7 activity for filopodia formation. 
P2X7-induced filopodia required the activities of phospholipase D, calcium-dependent 
phospholipase A2, N-WASP, and Rho-associated kinase. While the response has not been 
defined mechanistically, lipids and actin nucleation machinery were displaced to the periphery of 
main cell bodies within the de novo produced filopodia. I hypothesize that ATP induced 
filopodia upon fragmentation could serve as a source of materials that stimulate inflammation. 
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4.3 INTRODUCTION 
 
Actin nucleation is a highly coordinated activity (314). Several stimuli can promote actin 
nucleation for various purposes. For example, chemotactic agents can initiate actin redistribution 
and the de novo production of actin filaments to extend out leading edge lamellipodia towards 
the chemotactic gradient. Actin nucleation is also important for secretory granule release; for 
instance, activated cytolytic immune cells promote Arp2/3-mediated actin nucleation to polarize 
their immunological synapases to target cells (315). Formin family actin nucleators can also 
coordinate microtubule processes, which are required for the exocytosis of lytic machinery (316). 
Arp2/3 actin nucleation results in the canonical 70° branching of actin filaments within 
lamellipodia (314). Formin family members such as mammalian diaphanous-2 have roles in 
stress fiber formation and the formation of filopodia, which, unlike the sheet-like appearance of 
lamellipodia, form mostly straight structures extending out from the main cell bodies of cells 
(314). 
ATP-mediated activation of purinergic receptors can result in several morphological 
changes in various cells. Several purinergic receptors including A1 (37), A3 (131), P2Y2 (131, 
141, 142), P2Y11 (37), and P2Y12 (37, 136) can promote chemotactic movements of immune 
cells. Chemotaxis in this manner is largely the results of the coordinated activities of G proteins, 
leading to actin-based alterations in which the leading edge of lamellipodia is extended towards 
the chemotactic gradient (314).  
P2X7 is a purinergic receptor implicated in several cytoskeletal rearrangements (246). 
Most of these rearrangements have been described as membrane blebs. This blebbing starts 
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within minutes of P2X7 activation in myeloid cell types and can continue over several minutes 
(317). Characteristically, these blebs resemble those observed during apoptosis including the 
externalization of phosphatidylserine (217); however, unlike apoptosis, the blebbing can subside 
and cells regain a healthy phenotype upon removal of the P2X7 agonist (280). The exact purpose 
of the blebbing has been a bit elusive but some have argued that it is not involved in P2X7-
induced secretion of IL-1β (247) and that it is distinct from the shedding of microvesicles (252). 
P2X7 can modify lipids that influence the actin cytoskeleton directly or indirectly. P2X7 
activates several phospholipases, including phospholipase D (PLD), calcium-dependent (cPLA2) 
and independent phospholipase A2 (iPLA2), phospholipase C (PLC), and sphingomyelinase 
(SMase) (183). PLD is a particularly interesting case as the PLD product phosphatidic acid (PA) 
can directly result in the recruitment of proteins to the plasma membrane or can be converted to 
other biologically active lipids (178). PA can be converted to diacylglycerol for the promotion of 
protein kinase C or the generation of phosphatidylinositol 4, 5-bisphosphate (PIP2) by activating 
phosphatidylinositol 4-phosphate 5-kinase, which can recruit proteins that express PH domains. 
These recruited proteins include actin nucleators such as Arp2/3, that once recruited to the 
plasma membrane, are activated to induce actin polymerization (318).  
In this study, I identified a new property of P2X7, specifically that P2X7 engages actin 
nucleation machinery to promote the formation of F-actin enriched structures that resemble 
filopodia. This activity is dependent on a P2X7-driven mechanism that is not solely driven 
through calcium-promoted pathways. I further know that some of these pathways include PLD 
and cPLA2. These filopodia disperse the substrate and products of PLD indicating a potential 
mechanism for P2X7-induced spreading of pro-inflammatory mediators. 
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4.4 MATERIALS AND METHODS 
 
Cell culture and reagents - FSDC, an adherent immortalized murine immature dendritic 
cell line via retroviral transduction of a vector carrying an envAKR-mycMH2 fusion gene 
(Girolomoni et al., 1995), (gift from P. Ricciardi-Castagnoli, Singapore Immunology Network, 
Singapore) was maintained in IMDM (Lonza, Basel, Switzerland) supplemented with 10% fetal 
bovine serum (FBS) (Gemini Bio-Products, West Sacramento, CA), 1% additional L-glutamine 
(Lonza), and 1% penicillin and streptomycin (Lonza). This IMDM supplemented media will 
hereafter be referred to as IMDM complete. Murine bone marrow derived macrophages 
(BMDM) were derived from bone marrow precursors (gift from L. Borghesi, University of 
Pittsburgh) differentiated with L-cell supplemented media as described previously (265). P2X7-/- 
mouse bone marrow is a gift from G. Dubyak (Case Western Reserve University School of 
Medicine); they were on the C57BL/6 background. For some experiments, 1 µg/ml of 
lipopolysacharides (LPS) from Escherichia coli 026:B6 (Sigma-Aldrich, St. Louis, MO) was 
used to prime the cells where indicated.  
Other regents include ATP (Thermo Fisher Scientific, Waltham, MA), BzATP (Sigma-
Aldrich), KN-62 (Sigma-Aldrich), A23187 (Sigma-Aldrich), cytochalasin D (Sigma-Aldrich), 
latrunculin A (Invitrogen, San Diego, CA), colchicine (Sigma-Aldrich), UTP (Sigma-Aldrich), 
CAY10593 (Enzo Life Sciences, Farmingdale, NY), CAY10594 (Enzo Life Sciences), A 740003 
(Tocris Bioscience; Ellisville, MO), 187-1 (Tocris Bioscience), HA-1077 (Enzo Life Sciences), 
Y-27632 (Enzo Life Sciences), AACOCF3 (Enzo Life Sciences), H-89 (Cayman Chemical, Ann 
Arbor, MI), Ki16425 (Cayman Chemical), SB203580 (EMD Chemicals, Gibbstown, NJ), U0126 
(EMD Chemicals). 
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Microscopy - For filopodia quantification studies, 200,000 FSDC or BMDM were plated 
within 12 or 24-well plates with IMDM complete. Cells were allowed to adhere for at least 4 h. 
LPS priming (as described above) was performed for BMDM where indicated. Following the 4 
h, cells were washed once with PBS then given treatments where indicated. Where indicated, 
cells were treated with inhibitor for 30 min prior to ATP administration. After treatment, 
supernatant was discarded and the cells were washed once with PBS. 2% paraformadehyde 
fixative was applied for 15 min at room temperature after which the fix was removed being 
replaced with Coomassie Blue (Thermo Fisher Scientific) for at least 1 h. Coomassie Blue was 
removed and the cells were washed three or more times with PBS. Counts were performed under 
a standard light microscope for at least 100 counted cells per treatment taken from at least 10 
randomly chosen fields of view over 3 separate experiments. 
For confocal microscopy studies, 200,000 FSDC or BMDM were plated on poly(d-
lysine)-coated coverslips within 24-well plates. Cells were allowed to adhere for at least 4 h. LPS 
priming (as described above) was performed for BMDM where indicated. Following the 4 h, 
cells were washed once with PBS then given treatments where indicated. Where indicated, cells 
were treated with inhibitor for 30 min prior to ATP administration or treated with 10 μM 
BODIPY-phosphatidylcholine (Invitrogen). After treatment, supernatant was discarded and the 
cells were washed once with PBS. 2% paraformaldehyde fixative was applied for 15 min. After 
the fixation step, fixative was removed being replaced with 50 mM glycine for 5 min, then 
blocked and permeabilized with 1.5% BSA and 0.5% saponin in 1xPBS for 30 min at room 
temperature. Coverslips were then washed once with PBS then given primary antibody of 1/100 
diluted anti-N-WASP (Santa Cruz Biotechnology; Santa Cruz, CA) where indicated at room 
temperature. Coverslips were then washed three times with 0.5% saponin in PBS then given 
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1/100 diluted Alexa-647 conjugated goat anti-mouse IgG (Invitrogen) along with 400 nM 
rhodamine phalloidin (Sigma-Aldrich) or DiI (Invitrogen) where indicated at room temperature. 
Coverslips were then washed 3 times with 0.5% saponin in PBS then given 1 µg/ml DAPI 
(Sigma-Aldrich) for 30 s. Coverslips were then washed 3 times with PBS before mounting onto a 
glass slide with gelvatol (gift from CBI).  
Confocal microscopy images were taken with an Olympus Fluoview 1000 (Inverted) 
(Olympus America, Inc., Center Valley, PA). Laser excitations were collected sequentially and 
background noise was minimized. Confocal microscopy included DIC microscopy for observing 
the cellular cytoskeleton. Images were then consistently digitally enhanced (if modified at all) for 
signal with Adobe Photoshop CS2 (Adobe, San Jose, CA). Where necessary, counts were 
performed from obtained images for at least 100 counted cells per treatment taken from at least 
10 randomly chosen fields of view over 3 separate experiments. 
Live cell imaging was performed using a Nikon TI inverted microscope with a 60X 1.49 
NA oil immersion optic, a NikonPiezo driven XYZ stage, a Prairie Sweptfield confocal head and 
Prairie Technology (Madison, WI) laser bench. Images were collected using a QuantEM 
backthinned 512B camera (Photometrics, Tucson AZ). Cells were maintained at 37oC in the 
microscope with a Tokai Hit Environmental Stage (Tokyo Japan). Software control of the 
microscope was with Elements (Nikon, Melville NY).  
Statistics - Student’s T-test was utilized for studies invoking statistical analysis. Values of 
p were calculated where indicated, and for all statistical studies p<0.05 was considered as 
significant. 
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4.5  RESULTS 
 
4.5.1   ATP induces de novo filopodial arm formation that is distinctly different from steady-state 
filopodia and ATP-induced membrane blebs 
 
ATP has been known to produce several morphological changes in myeloid cells. Most often 
cited is the zeiotic blebbing phenomenon (246). The zeiotic blebbing appear as if the cells were 
boiling. This boiling ends with the cells rounding up and the loss of actin-enriched podosomes 
(data not shown). I also observe zeiotic blebbing within 5 min of live cell microscopy of 3 mM 
ATP treated FSDC (Figure 4-1); however, after the blebbing subsided, there was a progressive 
production of growing F-actin enriched filopodia with characteristics that differ from the resting 
state filopodia (Figure 4-1, 4-2). These filopodia following ATP administration had a rotating 
movement and were noticeably curved to form beaded structures along the filopodial arms 
(Figure 4-3). Kinetically, these de novo produced filopodia were observed from 5 min and 
continued to extend at 15 min (Figure 4-4). These filopodia differed morphologically and 
kinetically from membrane blebbing. Lower doses of ATP (0.1-0.6 mM ATP) were able to 
increase the percentage of FSDC with membrane blebs whereas filopodia formation required at 
least 1 mM ATP (Figure 4-5). Interestingly, at 1 mM ATP, whereas the production of de novo 
filopodia increased, the production of membrane blebbing actually decreased as compared to 
lower ATP doses.  
  
133 
 
Figure 4-1: ATP induces several morphological alterations. 
FSDC were treated with 3 mM ATP. Above is an illustration of some of the ensuing morphological alterations that 
occur over time following ATP treatment. The left image shows quiescent cells prior to ATP treatment. The middle 
image shows zeiotic blebbing that occurred between 2-4 min of ATP treatment. The right image shows the extension 
of novel filopodia that were distinctly different from filopodia of non-treated cells following 5-20 min of ATP 
treatment.  
 
Figure 4-2: ATP treatment produces extensions enriched with F-actin. 
FSDC were non-treated (left) or treated with 3 mM ATP (right) for 15 min. Cells were fixed and stained for nuclei 
(blue) and F-actin (red). Images were taken by confocal and overlaid with DIC microscopy. The images are 
representative of over 10 separate experiments. 
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Figure 4-3: ATP treatment produces beaded filaments. 
FSDC were treated with 3 mM ATP with analysis by live cell microscopy. From left to right, the arrow indicates the 
growth, movement, and beaded appearance of these filaments. Time is indicated in the lower right portion of each 
micrograph. 
 
Figure 4-4: ATP induces novel filopodia development over time. 
FSDC were non-treated (0), 0.5, 1, 2.5, 5, 7.5, 10, and 15 min. Cells were fixed and quantitated as being positive or 
negative for novel filopodia formation. The histogram is representative of repeated experiments of cells that were 
positive for filopodia formation. 
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Figure 4-5: ATP concentration and calcium flux dictates blebbing and filopodia generation. 
In A and B, FSDC were non-treated (0.0), 0.15, 0.3, 0.6, 1.0, and 3.0 mM ATP for 15 min. In A, cells were 
compared for blebbing (black) and novel filopodia (gray) generation. In B, cells were co-treated with (gray) or 
without (black) 10 µM A23187 along with the indicated dose of ATP then analyzed for novel filopodia formation. 
For A and B, the histograms indicate means of cells with the respective morphology ± SEM of n = 3. The statistical 
comparison is made to non-treated FSDC for the respective morphology. **p<0.01; n.s., not significant. For C, 
FSDC were treated with indicated treatments for 15 min then fixed for confocal microscopy. Cells were stained for 
nuclei (blue) and F-actin (red). Images were overlaid with DIC microscopy and are representative of repeated 
experiments. 
C 
  
136 
4.5.2 Elevated intracellular calcium potentiates ATP-induced de novo filopodia but it is not 
sufficient by itself to drive the de novo filopodial response 
 
Intracellular calcium is essential for many different signal transduction pathways, and actin 
polymerization and cytoskeletal rearrangements can be regulated through calcium influx (314). 
One way to trigger a powerful calcium-driven response is to treat cells with a calcium ionophore.  
In order to test the role of calcium in my observed filopodial response, I tested calcium 
ionophore either alone or co-administered with varying amounts of ATP. Calcium ionophore 
A23187 in combination with at least 0.3 mM ATP, but not A23187 by itself or in combination 
with 0.1 mM ATP, was able to elicit the filopodial response (Figure 4-5B). In addition to 
potentiating the ability for lower concentrations of ATP to produce de novo filopodia, A23187 in 
combination with concentrations of ATP equal to or greater than 0.3 mM elevated the over-all 
percentage of cells positive for novel filopodia. This is in agreement with our previous finding 
that A23187 can potentiate P2X7 activities of large pore formation and MV shedding (236). 
 
4.5.3 ATP-induced de novo synthesis of filopodia is actin-based and does not depend on 
microtubule polymerizing processes 
 
Since ATP treatment induced altered F-actin structures, I tested the possibility of de novo actin 
nucleation. Actin-based processes downstream of purinergic receptor engagement (such as P2X7 
activation) have been well documented for membrane blebbing. At the same time, it was possible 
that my observed cytoskeletal rearrangements could be mediated by microtubules. While 
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microtubule polymerization processes are distinct from actin polymerization processes, 
microtubules can influence the structure of the cytoskeleton so thus theoretically also alter the 
arrangement of actin. Furthermore, others have noted that ATP (through P2X7) can induce 
microtubule polymerization in microglia cells (319). In contrast, I observed that P2X7 induced 
altered cytoskeleton for novel filopodia was an actin polymerization phenomenon, as 
cytochalasin D and latrunculin A were able to inhibit the response, whereas the microtubule 
polymerization inhibitor colchicine was not able to significantly decrease the response (Figure 4-
6A). 
 
4.5.4 P2X7 is the ATP activating receptor for the de novo filopodial response 
 
The concentrations of ATP applied to these cells thus far are certainly high enough within the 
range for P2X7 activation (37); however, it was possible that ATP was activating other 
purinergic receptor(s). To test this, I tried various purinergic receptor agonists and antagonists. 
BzATP, a P2X1 (320), P2X7 (130), and P2Y11 (321) agonist, was able to activate the filopodial 
response with FSDC whereas UTP, a P2Y agonist (130), was not (Figure 4-6B). KN-62, a 
specific inhibitor of P2X7 relative to inhibiting other purinergic receptors (322), was able to 
ablate ATP’s ability to stimulate the response (Figure 4-6C). P2X7 knock-out BMDM were 
unable to produce the de novo filopodia, as compared to the wild-type BMDM (Figure 4-6D). 
Lastly, another inhibitor of P2X7, A 740003, was able to block novel filopodia generation 
(Figure 4-6F). 
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Figure 4-6: Filopodia formation is dependent on P2X7 and actin polymerization. 
For each panel, inhibitors are given for 30 min prior to 15 min treatment with agonists where indicated. In A, FSDC 
were non-treated or treated with 3 mM ATP. Where indicated, cells were pretreated with 800 nM latrunculin A 
(actin polymerization inhibitor), 10 µM colchicine (microtubule polymerization inhibitor), or 10 µM cytochalasin D 
(actin polymerization inhibitor). In B, FSDC were non-treated, 3 mM ATP, 0.3 mM ATP plus 10 µM A23187, 0.3 
mM BzATP, or 3 mM UTP. In C, FSDC were non-treated or 0.3 mM ATP plus 10 µM A23187. Where indicated, 
cells were pretreated with 10 µM KN-62 (P2X7 inhibitor). In D, wild-type (WT) or P2X7-/- BMDM were non-treated 
or treated with 3 mM ATP. In E, FSDC were non-treated or treated with 3 mM ATP. Histogram indicates means of 
cells positive for novel filopodia formation ± SEM of n = 3. Unless indicated by brackets, statistical comparisons are 
made to 3 mM ATP treated cells. **p<0.01; ***p<0.001. n.s., not significant; NT, non-treated; N.D., none detected. 
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4.5.5 Phospholipase D, calcium-dependent phospholipase A2, N-WASP, and Rho-associated 
kinase inhibition block the de novo filopodial response 
 
To understand further what might be regulating filopodia formation, I considered various 
pathways that have the potential to regulate actin rearrangements including phospholipases and 
regulators of actin nucleation such as Arp2/3 actin nucleation (e.g., through N-WASP) or formin-
mediated actin nucleation (e.g., through Rho-associated kinases). 
Phospholipase D (PLD) is a phospholipase that induces the cleavage of 
phosphatidylcholine to phosphatidic acid (PA) and choline (178). PA is incorporated in the 
plasma membrane as a biologically active cleavage product; choline is thought to be relatively 
inert. PA can promote recruitment of proteins to the plasma membrane (178), initiate 
phosphatidylinositol 4, 5-bisphosphate (PIP2) synthesis pathways by activating type I 
phosphatidylinositol 5-kinases (323), or be modified to other biologically active materials 
including diacylglycerol (178). In this manner, PA can modulate the actin cytoskeleton of cells 
(324) including the activation of actin nucleation machinery through PIP2 (318). PA itself can 
also contort the plasma membrane by incorporating negative charges within the lipid bilayer of 
membranes (178). PLD comes in two isoforms: PLD1 and PLD2. PLD1 is thought to act 
primarily at the Golgi apparatus whereas PLD2 is thought to act at the plasma membrane. 
However, upon activation, both of these PLD isoforms can act at the plasma membrane. 
Inhibition of both PLD1 and PLD2 resulted in significantly decreased amounts of cells positive 
for de novo filopodia formation (Figure 4-7A, Figure 4-8). Interestingly, inclusion of a stable 
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analog of PA (C8PA) was unable to elicit the filopodia response by itself; C8PA did however 
affect the cytoskeleton as C8PA was able to expand the lamellipodia of FSDC cells (data not 
shown). 
 Given the phospholipase involvement with PLD, P2X7-dependence, and the potentiation 
observed with the inclusion of A23187 with ATP, I also considered a role for calcium-dependent 
phospholipase A2 (cPLA2). P2X7 activates cPLA2 for the secretion (but not the cleavage) of IL-
1β from PAMP-stimulated human monocytes (257). PLD and cPLA2 can coordinate together for 
the cleavage of substrates; for instance, PLD can cleave phosphatidylcholine to PA and choline, 
then cPLA2 can cleave PA to lysophosphatidic acid (LPA). LPA is then secreted from cells, 
allowing it to engage LPA receptors (LPAR) in an autocrine or paracrine fashion. LPAR act as G 
protein coupled receptors to initiate G protein signal transduction. This is the case following 
P2X7 activation of osteoblasts where released LPA was then able to bind to LPAR to initiate 
Rho-associated kinase for membrane blebbing (280). Inhibition of cPLA2 through a specific 
cPLA2 inhibitor, AACOCF3, significantly reduced the amount of cells positive for the filopodial 
response (Figure 4-7B, Figure 4-8). Blockade of LPAR1 and LPAR3, two LPAR expressed on 
myeloid cells, with Ki16425, however, did not significantly reduce the response (Figure 4-7B). 
Furthermore, exogenous administration of LPA alone did not produce de novo filopodia or 
potentiate filopodia production together with limiting amounts of ATP (data not shown). 
 As P2X7 promotes the production of F-actin-enriched structures, actin nucleation is likely 
a required event for these newly formed filopodia. Actin nucleation is mediated through a couple 
of different actin nucleators including Arp2/3, formins, and spire proteins (314). Each type of 
actin nucleator can induce different types of actin-based structures. They can also coordinate 
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together to create various actin-based structures. For instance, Arp2/3 actin nucleation results in 
a predictable 70° branching of F-actin; this pattern is consistent through newly produced sheets 
of lamellipodia surrounding cells. This lamellipodia platform can serve as a launching pad for 
formin-based actin nucleation, leading to elongated actin structures such as filopodia (325). In 
this manner, filopodia are both a function of Arp2/3 and formin family members. Inhibition of 
Arp2/3 associated protein N-WASP resulted in a near complete abrogation of filopodia 
formation (Figure 4-7B, Figure 4-8). Inhibition of Rho-associated kinase with Y-27632 but not 
HA-1077 resulted in a significant decrease in ATP-induced filopodia (Figure 4-7B, Figure 4-8). 
Rho has also been associated with MAPK and PKA pathways. Inhibition of p38 MAPK, 
MEK1/2, or PKA did not result in any reduction of filopodia production (Figure 4-7B). 
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Figure 4-7: Filopodia formation is dependent on P2X7, PLD, cPLA2, N-WASP, and ROK. 
For each panel, inhibitors are given for 30 min prior to 15 min treatment with agonists where indicated. In E, FSDC 
were non-treated or treated with 3 mM ATP. Where indicated, cells were pretreated with 50 µM CAY10593 (PLD1 
inhibitor) or 50 µM CAY10594 (PLD2 inhibitor). In F, cells were non-treated or 3 mM ATP treated. Where 
indicated cells were pretreated with 50 µM 187-1 (N-WASP inhibitor), 100 µM A 740003 (P2X7 inhibitor), 50 µM 
HA-1077 (ROK inhibitor), 50 µM Y-27632 (ROK inhibitor), 10 µM AACOCF3 (cPLA2 inhibitor), 10 µM Ki16425 
(lysophosphatidic acid receptor 1, 3 inhibitor), 10 µM H-89 (PKA inhibitor), 50 µM SB203580 (p38 MAPK 
inhibitor), or 50 µM U0126 (MEK 1/2 inhibitor). Histogram indicates means of cells positive for novel filopodia 
formation ± SEM of n = 3. Unless indicated by brackets, statistical comparisons are made to 3 mM ATP treated 
cells. **p<0.01; ***p<0.001. n.s., not significant; NT, non-treated; N.D., none detected.  
  
143 
 
Figure 4-8: Inhibition of P2X7, PLD, cPLA2, N-WASP, and ROK prior to ATP treatment display an absence 
of filopodia. 
For each panel, inhibitors are given for 30 min prior to 15 min treatment with agonists where indicated. Cells were 
treated similar to Figure 4-7 but were fixed and stained for nuclei (blue) and F-actin (red) for confocal microscopy. 
Image was overlaid with DIC microscopy (except for HA-1077 sample) and is representative of repeated 
experiments. 
 
4.5.6 P2X7-induced filopodia serve as locales for displaced actin nucleation components and 
lipids including phosphatidylcholine 
 
Since I had identified N-WASP as a critical regulator of ATP-induced filopodia, I wanted to 
evaluate the localization of Arp2/3-related machinery respective to the filopodia. As these 
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filopodia have an oddly shaped curved morphology, N-WASP may be present within the curves 
of the filopodia. Alternatively, perhaps N-WASP is present at the base of the filopodia along the 
main cell bodies. N-WASP localized largely within the main cell body; however, N-WASP 
expression was found within ATP-induced filopodia (Figure 4-9A, B) as over 75% of the cells 
expressing noticeable ATP-induced filopodia had N-WASP expression within at least one of 
their arms of filopodia (Figure 4-9B). 
 PLD was identified as a regulator of filopodia production (Figure 4-7A, Figure 4-8). The 
main substrate is phosphatidylcholine (178). To monitor the substrates and products of PLD, 
BODIPY-phosphatidylcholine was incubated with cells then given ATP. At 15 min, BODIPY 
signal was displaced from the main cell body to the periphery, to and within the newly produced 
filopodia (Figure 4-9A, B). Over 75% of cells expressing ATP-induced filopodia had BODIPY 
expression within at least one of their arms of filopodia (Figure 4-9B). Furthermore, ATP 
promotes the peripheral displacement of BODIPY signal significantly away from main cell 
bodies as compared to non-treated cells (Figure 4-10A, B).  
  
145 
 
 
 
 
Figure 4-9: De novo generated filopodia contain phosphatidylcholine and N-WASP. 
FSDC were given 10 µM BODIPY-phosphatidylcholine (PC) for 1 h prior to further treatment. Cells were non-
treated (left in A) or treated with 3 mM ATP for 15 min (right in A) then fixed and stained for nuclei (gray), lipids 
(red), or N-WASP (blue) prior to confocal microscopy (A). Images were overlaid with DIC microscopy (bottom 
right) and are representative of repeated experiments. White arrows indicate positive expression of respective 
phenotype in filopodia. Scale bar, 10 µm. In B, means of cells positive for the indicated phenotype ± SEM of n = 3. 
A 
B 
No treatment 3 mM ATP 
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Figure 4-10: ATP promotes the peripheral displacement of BODIPY-phosphatidylcholine away from main 
cell bodies of FSDC. 
FSDC were given 10 µM BODIPY-phosphatidylcholine for 1 h prior to further treatment. Cells were non-treated 
(top micrograph) or treated with 3 mM ATP for 15 min (bottom micrograph) then analyzed by confocal microscopy. 
In A, FSDC are shown with BODIPY (green) overlay with DIC microscopy. The red markings highlight the outline 
of the main cell bodies of cells, which was clearer with the original DIC micrographs. Black arrows indicate 
negative cells whereas blue arrows indicate positive cells for displaced BODIPY away from the main cell bodies of 
cells. Scale bar, 10 µm. In B, means of cells positive for the peripheral expression of BODIPY signal (PC) ± SEM of 
10 fields of view that contain at least 10 cells each. ***p<0.001. NT, non-treated. 
 
 
 
 
 
A B 
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4.6  DISCUSSION 
 
Understanding the mechanisms of how inflammatory materials are released from cells is 
important as these explanations ultimately come to the core of immunological processes that are 
relevant for inflammation and disease. As others have described, ATP administration can 
activate the purinergic ion channel P2X7 for the induction of membrane blebbing and shedding 
of MV (246). Membrane blebbing has been observed in numerous studies and it was once 
implicated in the shedding of MV (217); however, this is the first study to identify a novel actin-
based filopodia formation response following P2X7-induced membrane blebbing. 
 This response to P2X7 is a novel activity with broad cytoskeletal ramifications. P2X7 
induction starts with zeiotic blebbing, but after 5 min, there is a rapid extension of F-actin-based 
structures that we classify as filopodia. Formation of these filopodia requires activities of N-
WASP, PLD, cPLA2, and ROK2 (Figure 4-7, Figure 4-8). Whereas calcium ionophore alone was 
insufficient for inducing de novo filopodia, calcium ionophore synergized with minimal amounts 
of ATP (Figure 4-5). Given the sequence of zeiotic blebbing then filopodia formation (Figure 4-
1) and the known requirements for zeiotic blebbing (including phospholipase A2 and PLD) (280), 
it is possible that the blebbing primes P2X7-activated cells for eventual filopodia production. The 
exact actin nucleation events have yet to be fully disclosed; however, given the requirement for 
ROK2 and N-WASP (Figure 4-7, Figure 4-8) and the structural phenotype of the F-actin 
structures (Figure 4-2), it is likely that this actin nucleation is at least in part mediated by formin 
proteins – possibly mammalian diaphanous-2 (mDia2). mDia2 induces stress fiber formation 
(314) for formation of elongated F-actin structures in a variety of mammalian cell types. 
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 The exact purpose of the P2X7-induced filopodia is an interesting question. P2X7-induced 
filopodia promoted the displacement of BODIPY-phosphatidylcholine (Figure 4-9 and Figure 4-
10). The BODIPY adduct would be retained with released PA (as opposed to choline) signifying 
that the BODIPY signal may possibly show PA localization. PA is a signaling macromolecule 
but it may also demonstrate how P2X7 initiates the dissemination of lipid and protein mediators. 
P2X7 promoted the twisting of de novo filopodia into a beaded-like appearance (Figure 4-3). 
Could these beads be a precursor to shed MV? Cellular requirements for filopodia formation and 
MV shedding were distinct, as shown in chapters 2 and 4 of this thesis. In this manner, P2X7-
induced filopodia may represent a subset of released MV. P2X7-induced filopodia break off very 
readily and at later time points, the filopodia appear to be shorter; however, there is no direct 
evidence that filopodia and MV have a precursor-product relationship. Live cell high speed 
confocal microscopy is required to visualize the possibility of this relationship. 
 P2X7 has been shown to promote inflammation in several settings; however, the cellular 
mechanisms have been lacking. It is noted that P2X7 activation can redistribute cellular 
cytoskeleton into membrane blebs and MV but this is the first report for a novel actin 
redistribution into extending arms of filopodia. It is the goal of this study to further characterize 
these cytoskeletal rearrangements to reveal how inflammatory stimuli are released from P2X7-
activated myeloid cells. While these filopodia may not be the sole mechanism for inflammatory 
stimuli release, it can serve as one of the mechanisms. An intriguing possibility may exist in the 
physiological context of tissues in vivo. As these filopodia can extend over long distances 
(greater than the main cell body itself), it is quite possible upon ATP ligation of P2X7 on myeloid 
cells, there is the potential for contact with multiple adjacent cells, perhaps distributing pro-
inflammatory signals to cells following filopodial breakage. 
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5.0   OVERALL SUMMARY AND INTERPRETATIONS OF THESIS 
 
5.1 PROPOSED MODEL AND THERAPEUTIC IMPLICATIONS 
 
The work described within this dissertation reveals a provocative role of P2X7-induced MV in 
modulating immunity. More specifically, these MV contain inflammatory materials. 
Phospholipids from MV are able to upregulate co-stimulatory molecules required for antigen 
presentation and induce the secretion of pro-inflammatory cytokines from macrophages. 
Lysosomal materials such as biologically active cathepsins are released within P2X7-induced 
MV. Lipids and lysosomal materials are displaced from the main cell bodies of ATP-treated 
myeloid cells for their potential loading into MV. These studies further elucidate the role of P2X7 
in coordinating release of pro-inflammatory materials from myeloid cells. In a larger sense, this 
work describes how P2X7 initiates cellular responses for release of pro-inflammatory materials in 
the absence of the inflammasome and moreover in the absence of infection. 
Chapter 2 of this thesis provides a mechanistic understanding of how inflammatory 
phospholipids are associated with MV and how they mediate macrophage activation. 
Phospholipids and shed MV have been implicated in macrophage activation but their generation 
has not yet been explained. This work details a role for P2X7-induced PLD in generating 
stimulatory MV. This may be due in part to PLD-generated PA, as PA-loaded liposomes were 
capable of stimulating significant macrophage activation. PLD also has a role in enabling the 
displacement of phospholipids into P2X7-induced filopodia; I hypothesize that P2X7-induced 
filopodia may provide material for shed MV. The phospholipids from P2X7-induced MV were 
able to activate macrophages in a TLR4-dependent manner. More work is necessary to 
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understand how these phospholipids are capable of activating TLR4; however, it is hypothesized 
that P2X7-induction results in membrane asymmetry for the exposure of several phospholipids to 
engage pattern recognition receptors (Figure 5-1). My thesis work has shown that P2X7 greatly 
modifies the cellular cytoskeleton and the studies of others have established P2X7 induction of 
PS flip (157). It is possible that this exposure reveals phospholipids to oxidative environments 
during diseases such as cancer, arthritis, and atherosclerosis (326, 327). P2X7 itself can also 
generate free radicals (188, 328-331) that could oxidize phospholipids such that they can induce 
immune responses. Furthermore, oxidation of phospholipids, such as PC, results in oxidized-PC; 
oxidized-PC is capable of activating TLR4 (41, 293). Preliminary data from our lab suggest a 
role for oxidized phospholipids capable of macrophage activation. 
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Figure 5-1: Proposed mechanism for MV-induced inflammation.  
(1) ATP engages P2X7 for activation of pore formation and ion flux – calcium (Ca2+) and sodium (Na+) influx and 
potassium (K+) efflux. (2) Ion flux induces several changes within cells including cytoskeletal changes and 
recruitment of stimulatory materials (e.g., cathepsins) (orange) to the plasma membrane; this activity is modified in 
some instances by phospholipase D. Oxidation (red) may also modify phospholipids (green) as alterations of 
membrane topology are occurring at the plasma membrane. (3) The altered cytoskeleton (along with other 
mechanisms such as actin polymerization and calcium signaling) results in the shedding of MV. (4a) Shed MV can 
remobilize to distal sites for the timed release of components including cathepsins; these cathepsins can cleavage 
substrates such as extracellular matrix (ECM). (4b) Alternatively, shed MV could present modified phospholipids 
(perhaps oxidized) to macrophages that can engage a variety of pattern recognition receptors (PRR) including TLR4. 
Signal transduction pathways involving p38 MAPK, NF-κB, protein kinase C (PKC), and protein kinase A (PKA) 
enable the release of pro-inflammatory cytokines (e.g., TNF-α and IL-6) and upregulation of co-stimulatory ligands 
(e.g., CD80 and CD86) and MHC class II at the plasma membrane. 
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It is possible that P2X7-induced MV also promote lipid dissemination. By nature, some 
lipids such as phospholipids are highly amphipathic with polar and non-polar chemical 
components; in this manner, phospholipids need to be associated with other lipids and/or proteins 
to disperse in aqueous environments. As they are comprised primarily of lipid bi-layer 
membranes, MV are capable of dispersing lipid mediators (210). Some novel components, 
including specific lipids, are trafficked into MV such as exosomes; lipids (e.g., 
lysobisphosphatidic acid) can be sorted through directional cues to multi-vesicular bodies 
(MVB), the organelle for exosome biogenesis (251). For plasma membrane-derived MV, 
phospholipase A2 promotes lysophosphatidic acid formation and loading into shed MV (332). 
The formation of MV has been hypothesized to occur in several ways but most commonly 
through membrane curvature and detachment (333). Various plasma membrane components, 
including lipids (e.g., phosphatidic acid) and cholesterol, can impart this required membrane 
curvature (334). Since these components result in the membrane curvature responsible for the 
budding off of MV, they would thus be enriched within the MV. Formation of MV also involves 
membrane asymmetry. Phosphatidylserine flip outward occurs during MV formation (231). Thus 
MV contain not only an enrichment of novel lipids, but they can also contain unique topologies 
of lipids such that normally cytofacial lipids are exofacial facing outward towards the 
extracellular environment.  
Lipid-mediated modulation of the immune system has been recognized for a long time 
and it is possible that P2X7-induced MV participate in these processes. From my work, 
phospholipids from P2X7-induced MV are capable of promoting macrophage activation. It is 
interesting to consider phospholipid-mediated immune cell activation in the setting of 
inflammatory diseases. P2X7-induced MV themselves expose phosphatidylserine (PS) and have 
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thrombotic activities associated with atherosclerosis progression (190, 250). MV (described in 
relevant literature as microparticles) promote coagulant activities in atherosclerosis through their 
exposure of negatively charged phospholipids, especially PS (335). Another potential property of 
PS found on MV is its ability to activate the scavenger receptor CD36, which promotes 
atherogenesis and thrombosis (336). It is not just PS that promotes disease. In cancer, 
sphingomyelin from MV act with VEGF to promote angiogenesis (337, 338).  
Another class of potential immune modulators described from this work are cathepsins. 
Cathepsins are capable of restructuring extracellular matrices (ECM) within tissue; ECM 
degradation following inflammatory situations can develop for diseases such as arthritis, cancer, 
or neurodegeneration (209). In the context of cancer, oncogenic materials including cancerous 
cells can be disseminated for metastasis (339). During preparation of this work, another group 
described that P2X7 stimulated myeloid cells can release biologically active cathepsins in the 
absence of initial PAMP priming (186). We, however, provide a more thorough mechanistic 
understanding. This work describes intermediate and mature cathepsin D presence within P2X7-
induced MV and I reveal some of the cellular machinery for mature cathepsin D release. 
Cathepsin D is displaced towards the periphery of cells, where it is in close proximity to 
dynamin. Dynamin inhibition by dynasore resulted in significantly less mature cathepsin D 
secretion from ATP treated cells. Upon close evaluation, lysosomal components cathepsin D and 
lamp-1 were localized to the periphery within F-actin enriched filopodia. Whether or not these 
filopodia serve as conduits for lysosomal component release is not yet clear; however, actin 
polymerization inhibition did result in decreased mature cathepsin D within harvested P2X7-
induced MV. Given the role of dynamin for cathepsin D release from my work and a recent 
report of dynamin in mediating actin filament elongation (340), de novo produced filopodia may 
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serve as a release point for dynamin-mediated cathepsin D release. Much more work would be 
necessary to establish this potential function of dynamin and how it would coordinate with these 
actin structures, let alone with lysosomal compartments or machinery. However, dynamin 
associated exocytosis of materials is an established concept (306, 308-310). A related small 
GTPase to dynamin, ARF6, along with phospholipase D have also been associated with the 
pinching off of MV from the plasma membrane (341); these authors suggest a role for dynamin 
as well (333). Whether cathepsin D-loaded MV are the same as the MV that contain stimulatory 
phospholipids is not yet clear, but it is understood that there is a diversity of types of shed MV 
from P2X7-stimulated myeloid cells (246). 
Cathepsins within harvested MV have been documented; however, it is interesting to 
consider why the delivery of cathepsins within MV would be beneficial or how they could be 
functional. An enticing possibility is the selective delivery of cathepsins across tissues for 
extracellular matrix degradation; the mechanisms by which macrophages promote protease-
mediated ECM degradation have not been fully characterized. MV can serve to preserve cargo; 
in this sense, cathepsins may act at some more distal site to be released from MV at later time 
points. MV also express receptors that could result in the selective targeting to preferred sites. 
Such receptors include integrins, which can promote the attachment of MV to certain materials, 
including ECM. Upon MV degradation, MV contents, including their contained cathepsins, 
could leak out to the local environment. Thus MV may be an effective means for cathepsin-
mediated degradation of the ECM within tissue. Another interesting angle comes from the 
potential for MV generation following P2X7-mediated filopodia production. Macrophages and 
dendritic cells reside primarily in selective niches within tissue. Upon P2X7 induction, these 
newly developed filopodia could extend far into tissue where cellular passage is not generally 
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possible. Thus these filopodia may promote the delivery of MV across tissue barriers. Even 
without the need for filopodia-mediated MV shedding, the detachment of filopodia could 
selectively deliver cathepsins to certain ECM. This would have large implications in disease 
biology as cathepsin-mediated break-down of the ECM can result in angiogenesis, atherogenesis, 
and other diseases. 
Whereas a large focus of the work described here has been to mechanistically understand 
what P2X7-induced MV contain and how they can activate macrophages, there is potential for 
their therapeutic application – in particular with vaccination strategies. P2X7-induced MV greatly 
upregulate the antigen-presenting machinery of macrophages while also promoting pro-
inflammatory cytokine secretion. Since these stimulatory MV are largely derived from the 
plasma membrane of cells, it is certainly possible for the MV to contain a diversity of plasma 
membrane materials. Thus P2X7-induced MV could contain antigens or intact MHC + peptides 
along with stimulatory activities necessary for efficient cross-priming of cytolytic CD8+ T cells, 
which enables effective adaptive immune responses. In some circumstances, professional antigen 
presenting cells (APC) can cross-present extracellular antigen epitopes on MHC class I (10). 
Once mature (or activated), these APC can in certain circumstances cross-prime naïve CD8+ T 
cells to become efficiently activated cytolytic T cells capable of killing specific antigen-cognate 
target cells. In this manner, it is possible to engineer myeloid cells with desired antigen 
expression at the plasma membrane. Upon P2X7 stimulation, MV are shed with antigen and 
stimulatory phospholipids and possibly other stimulatory materials. These MV can be 
administered in a vaccination regimen. Alternatively, once enough mechanistic understanding is 
obtained, artificial liposomes could be generated with stimulatory phospholipids and the 
antigen(s) of interest.  
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5.2 TRANSITIONING IN VITRO RESULTS TO IN VIVO MECHANISMS 
 
MV are not just artifacts from cell culture. MV can be harvested from in vivo sources including 
peripheral blood, urine, and ascitic fluids (333). Greater levels of MV have been harvested from 
the blood of cancer patients than healthy individuals. MV also have relevance in promoting 
diseases such as atherosclerosis (342). Given their presence and influence in disease, 
understanding how MV are generated in vivo and how they act in vivo are very important. 
Transitioning in vitro cell biology observations to in vivo mechanisms that naturally 
occur is not a simple task. Observing MV shedding in vivo has been very circumstantial (210). In 
large part, this comes from the difficulties in obtaining indisputable in vivo imaging evidence and 
separating biologically shed MV from artifacts. Harvesting MV from in vivo sources is daunting 
given the potential for artifacts such as fragmented cellular components from damaged tissue.  
Most of the potential for in vivo understanding, though, will come from modulating 
molecular mechanisms understood from in vitro studies. Such mechanisms include blockade of 
ATP and P2X7 in addition to other molecular targets associated with stimulatory MV generation, 
such as PLD. Attempting to observe MV shedding should not be the primary focus for in vivo 
MV relevance. Rather, biological outcomes from molecular target blockade should be the 
ultimate goal in conjunction with attempts to visualize MV in vivo.  
Our understanding of the in vivo function of ATP and purinergic receptors has greatly 
improved over the past few years. Several studies have implicated P2X7 in inflammatory 
activities from abrogating immunosuppressive regulatory T cells (165) to promoting neutrophil 
recruitment (40) to promoting inflammatory disease (37, 161, 162, 189, 283, 284, 343). 
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Furthermore, the concept that ATP is physiologically able to promote the activation of purinergic 
receptors in vivo is now generally accepted. ATP activity through P2X7 can result in graft-versus 
host disease (187), initiate contact hypersensitivity (161), and engage the immune response to 
ameliorate cancer (162) in vivo. Various groups have directly observed relevant amounts of 
physiologically released ATP from damaged cells in vivo and have determined ATP’s role in 
modulating disease in vivo. An interesting approach utilizes implanted cells expressing an 
exofacial expressed luciferase protein chimera; in the presence of injected luciferin and ATP 
released from damaged cells, bioluminescence is produced (148, 161, 187). Individuals with 
hyperactive P2X7 activity progressively develop inflammatory diseases such as Alzheimer’s 
disease (189). Additionally, individuals with loss-of-function P2X7 polymorphisms exhibit 
decreased ability to clear mycobacterial infections, which is a function of P2X7 (173). 
In this work, I have uncovered several cell biological phenomena that have 
immunological implications in vitro; in order to move forward in vivo studies are necessary. An 
intriguing concept presented within this summary section is the potential for P2X7-induced MV 
to disperse their cargo to selective sites. A highly relevant model would be trauma or more 
generalized tissue damage. Damaged tissue can result in the release of intracellular content 
including ATP. MV shedding and damaged tissue fragments are currently hard to visually 
discriminate; a better approach would be to selectively block known mechanisms for stimulatory 
MV generation.  
In this summary section, I discuss the potential for P2X7-induced MV to complicate 
inflammatory diseases. As mentioned, P2X7-induced MV expose PS, which has pro-coagulant 
properties that can exacerbate diseases such as atherosclerosis (190, 250). An important question 
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resides in whether P2X7-induced MV can direct inflammatory disease progression. One approach 
would be to inhibit P2X7 and stimulatory MV generation processes in an inflammatory disease 
model (e.g., ApoE-/- mouse model of atherosclerosis). Specifically evaluating MV involvement, 
as opposed to soluble phospholipids, may be difficult; however, ex vivo characterization of the 
relevant cell populations (e.g., macrophage foam cells developed during atherogenesis) should 
reveal the passive acquisition of several MV-derived materials at their cell surface. I have 
observed that biotinylated proteins from MV can remain on the cell surface of recipient cells for 
several hours. MV-derived materials are very heterogeneous and can be unique; for instance 
otherwise healthy cells would not express markers such as PS on their plasma membrane. While 
it may be difficult to make definitive conclusions, these extracted cells could also be evaluated 
by electron microscopy for the presence of MV on the plasma membrane or within the 
phagosomes of these cells. 
Another practical aspect that emerges from my studies is the potential for MV to induce 
effective cross-priming. P2X7-induced MV could deliver materials for cross-presentation or 
incorporate materials at the plasma membrane for semi-direct antigen presentation (antigen 
“cross-dressing”). Further, these MV also promote APC maturation/activation. Demonstrating 
cross-priming in vivo is important, as cross-priming is thought to be necessary for effective 
CD8+ T cell responses and vaccination strategies. While injection of in vitro-generated P2X7-
induced MV (loaded with a model antigen) into mice is good first step to analyze potential in 
vivo immune responses, a more physiological approach would be to initiate tissue damage along 
with the model antigen. Deducing P2X7-induced MV relevance could partly be achieved by 
blocking P2X7 and MV generation pathways. Following induced tissue damage, antigen-cognate 
CD8+ T cells could be removed from local draining lymph nodes and analyzed for activation.  
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Another possible extension of my studies is the possibility for MV-derived cathepsins to 
mediate ECM degradation. Released cathepsins have displayed abilities to degrade ECM; 
however, MV induced dissemination of cathepsins for ECM degradation has not been reported. 
P2X7 activity has been linked to the release of cathepsins by the work of others (186) and from 
my own work. An intriguing disease model would be collagen-induced arthritis as blockade of 
P2X7 ameliorates arthritis development (184, 185). Deducing P2X7-induced MV relevance could 
also partly be achieved by blocking P2X7 and MV generation pathways. The integrity and 
composition of the affected ECM could be analyzed by histochemistry. Additionally, the 
deposition of MV-derived materials on the localized ECM could be evaluated by histochemistry. 
The task of developing in vivo relevance for P2X7-induced MV is difficult but it could 
ultimately answer disputed issues in immunology. An important question deals with antigen 
processing, presentation, and delivery for activating naïve CD8+ T cells in lymph nodes. In mice, 
lymph node resident CD8α+ dendritic cells are also thought to be the best APC for cross-
presenting antigen to CD8+ T cells (344). At the same time, though, in the context of presenting 
antigen from dying cells, migratory dendritic cells with the correct haplotype of MHC are also 
crucial for this priming, despite not being the primary cell type that engage CD8+ T cells (13). 
This sets up the hypothesis that such migratory dendritic cells are donating materials to the 
CD8α+ dendritic cells (12). How is this donation occurring? In order to efficiently cross-prime, 
the CD8α+ dendritic cells must be matured. How is this maturation occurring? Stimulatory 
materials from P2X7-induced MV may provide some insight for not only this question but could 
prove to be therapeutically beneficial in future vaccination strategies. 
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